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Abstract 
This thesis is mainly focused on the design, synthesis and DNA binding studies of 
aminobenzyl and guanidinium calix[4]arene dimers. The work consists of two parts. 
The first part of my Ph.D. work was focused on the synthesis and DNA binding studies of 
Dimer A and Dimer B. Structures of these molecules can be found on the next page. In order 
to broaden the scope of the investigation, the corresponding monomeric calixarenes 
(Monomer A and Monomer B) were also synthesized. Compared with anilino-calix[4]arenas 
(R. Zadmard, T. Schrader, Angew. Chem. Int. Ed. 2006, 45, 2703 –2706), these dimers and 
monomers are water-soluble, and bind to DNA with much higher affinity (binding constants: 
106–108 M-1 in 2 mM Hepes buffer with 150 mM NaCl). 
When investigating the properties of new DNA binding molecules, one initial goal is to 
establish their mode of binding to DNA. Because direct structure information from a crystal 
or NMR structure was not yet available in my work, several other biophysical experiments 
have been designed and performed between calixarenes and different nucleic acids with 
varying base composition and conformation. The following results from established binding 
assays strongly support a major groove binding mode:  
(1). The DAPI displacement assay indicates that the calixarene dimers and DAPI can 
simultaneously bind to poly (dAdT) – poly (dAdT). Because DAPI occupies the minor groove, 
the dimeric calixarenes should reside in the major groove.  
(2). Ethidium bromide displacement assays, fluorescence titrations, and circular dichroism 
measurements indicate that calixarene dimers strongly prefer nucleic acids with a wide, 
shallow or even major groove; while low affinities are observed for nucleic acids with a 
narrow, deep or rugged major groove, which must be widened before complexation occurs. 
This characteristic also implies that the accessible area for our ligands is on the major groove 
side, contrary to the well-known slim oligoamide binders, which target the minor groove. 
In line with these observations, it was noticed that changes in shape and width of the minor 
groove had no influence on the ligands’ affinities. 
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Unfortunately, Dimer A and Dimer B showed similar affinities for different DNA duplexes. 
Therefore, we planed to replace the simple alkyl bridge between both calixarenes by a 
fragment which should be able to bind specific sequences of DNA in the promoter region of 
each gene. Heterocyclic oligoamides were found out. They consist of N-methylpyrrole, 
3-hydroxypyrrole and N-methyl imidazole amino acid building blocks (P. B. Dervan, 
Bioorganic & Medicinal Chemistry 2001, 9, 2215–2235.). 
In the second part of my Ph.D. work, a calixarene dimer with a triimidazole bridge (Dimer C) 
was synthesized. 
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Dimer C 
Because in minor grooves, N-methylimidazoles of polyamides could recognize the positive 
electrostatic potential of amino groups of guanine bases via hydrogen bonds, it was assumed 
that Dimer C, which contained a triimidazole bridge, could prefer a major groove with large 
positive potentials. Moreover, because the triimidazole bridge is slim, it was also assumed that 
Dimer C should prefer a narrow major groove, which could offer the appropriate shape for the 
bridge’s recognition. In view of the above-mentioned assumptions, we found that the major 
groove of poly dG – poly dC fulfilled both requirements. Therefore, it was predicted that 
Dimer C should show the high affinity for poly dG – poly dC.  
Ethidium bromide displacement assays, fluorescence titrations, and circular dichroism 
measurements imply that Dimer C is a major groove binder. Furthermore, as we expected, 
these experiments indicate that Dimer C showed stronger preference for this specific DNA 
duplex: poly dG – poly dC. 
It was also observed that Dimer C frequently showed reduced affinity to other DNA duplexes. 
Probably, the decrease in affinity is related to their wider major grooves, in which the slim 
triimidazole bridge will not produce extensive close van der Waals contacts, and the whole 
ligand itself shows orientational disorder. Another explanation is the unfavorable electrostatic 
potentials, because these DNA duplexes have more neutral areas in major grooves than does 
poly dG – poly dC.
Herein, we present a proposed mechanism of DNA binding by Dimer C: the cationic moieties 
on the upper rim of the calixarenes form hydrogen bonds with nucleobases as well as 
phosphate groups of the nucleic acid, the butoxy tail is toward the free solution, and the 
triimidazole bridge binds along the major groove and recognizes the amino groups of 
nucleobases. 
 
  
 
Keywords: major groove binding, dimeric calixarene, polyamide, sequence selectivity, 
binding affinity, minor groove binding, DAPI, ethidium bromide, circular 
dichroism spectroscopy, fluorescence titration 
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1. Introduction 
Nucleic acids are biological polymers, which have essential roles in transmission, expression 
and conservation of genetic information. They are universal in living organisms and can be 
found in all cells. In nature, nucleic acids exist as deoxyribonucleic acid (DNA) and 
ribonucleic acid (RNA). The main role of DNA is storage and transmission of biological 
information, whereas RNA has a broader range of functions. Several different types of RNA 
have been found in cells. For example, messenger RNA (mRNA) is transcribed from DNA, 
and carries genetic information that will be translated in ribosomes to proteins [1]. During 
transcription, transcription factors perform their functions alone or with other proteins in a 
complex, by promoting (as an activator) or blocking (as a repressor) the recruitment of RNA 
polymerase to specific genes, and control the movement of genetic information from DNA to 
mRNA [2,3]. Consequently, a number of transcription factors unquestionably became the target 
sites in medicinal chemistry in the past [4,5]. With the completion of the Human Genome 
Project, the new challenge now is to develop new pharmaceutical interventions to regulate 
and manipulate genes and treat diseases at the DNA level [6,7,8,9,10]. The common method of 
this strategy is to identify pathogenicity genes and use artificial molecules to target them for 
silencing. This strategy was applied to my work: because the major groove is more 
informative than the minor groove, we planed to design and synthesize artificial major groove 
binders to target specific DNA sequences (for example, pathogenicity genes). They could 
block these sequences and perturb gene expression at the initiation of transcription.   
 
1.1 Introduction to Nucleic acids 
1.1.1 Composition of Nucleic acids 
Nucleic acids are made from repeating unites called nucleotides, each of which has three 
components [11]: a heterocyclic nitrogenous base, a 2'-deoxy-D-ribose (in DNA) or D-ribose 
(in RNA) sugar ring, and a phosphate group. The phosphate group connects two 
pentofuranose sugars to form a 3’→5’ phosphate diester bond (Figure 1.1). The nucleobases 
in DNA are represented by purines [adenine (Ade) and guanine (Gua)] and pyrimidines 
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[cytosine (Cyt) and thymine (Thy)]. For RNA, the pyrimidine Uracil (Ura) takes place of 
thymine (Figure 1.2). Purines are linked at N9 to the C1’ of the sugar and pyrimidines are 
linked at N1. The pentofuranose sugar and a heterocyclic aromatic nucleobase are attached 
through an N-glycosidic bond in β configuration to form a nucleoside. 
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Figure 1.1. General structures of nucleic acids. The nucleotides are connected by the 
3’→5’ phosphate diester linkage. The chain direction is from 5’ to 3’ end as shown by 
arrow. The pentofuranose sugar and phosphate form the backbone to which bases (Ade, 
Gua, Cyt and Thy / Ura) are attached. Compared with deoxyribonucleic acid (DNA), in 
ribonucleic acid (RNA), the hydrogen attached to C2’ is replaced by hydroxyl, and 
thymine by uracil. 
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Figure 1.2. Chemical structures of nucleobases. 
 
 
 
1.1.2 Structural and Conformational Properties of Nucleotides 
1.1.2.1 Bases and Base Pairs 
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Purines and pyrimidines can form base pairs via hydrogen bonds. There are several different 
types of base pairs, for example, Watson-Crick base pairs [12], Hoogsteen base pairs [13], 
reversed Hoogsteen base pairs [14], and Wobble base pairs [15] and so on (Figure 1.3). In the 
canonical Watson-Crick DNA base pairing, adenine forms a base pair with thymine and 
guanine with cytosine. In RNA, thymine is replaced by uracil. Hoogsteen base pairing allows 
the third strand to occupy the major groove of the DNA double helix which are assembled in 
the Watson-Crick pattern to form triple-stranded helices, such as poly(dA)•2poly(dT) and 
poly(dG)•poly(dC)•poly(dC)+  [16,17,18,19]. Hoogsteen base pairing also allows the formation of 
G-quadruplex, which is the secondary structure of single stranded G-rich DNA and RNA. A 
wobble base pair is a non-Watson-Crick DNA base pair between two nucleotides in RNA 
molecules. There are four main wobble base pairs: guanine-uracil, inosine-uracil, 
inosine-adenine, and inosine-cytosine (G-U, I-U, I-A and I-C). They are fundamental in RNA 
secondary structures and are critical for proper translation of genetic codes. A complete 
graphic list of different base pairs can be found on page 120 of the text book [20].  
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1.1.2.2 Sugar Conformations 
A planar conformation for the pentafuranose sugar moiety of a nucleotide is energetically 
unfavorable because in this arrangement, all the substituents attached to carbon atoms are 
fully eclipsed. To reduce the non-bonded interaction between these substituents, the furanose 
ring could adopt preferably either the C3'-endo and C2'-exo conformation (the North or 
N-type conformation) or the C2'-endo and C3'-exo conformation (the South or S-type 
conformation) (Figure 1.4). The conformations of the pentofuranose sugars are not static and 
in solution they are involved in a dynamic two-state North South equilibrium [21,22,23]. 
The deoxyribofuranosyl sugars of DNA are preferentially in the South-type form, whereas the 
ribofuranosyl sugars of RNA in the North-type form. 
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Figure 1.4 Definition of sugar puckering modes: North type (left) and South type (right) 
 
In fact, the primary structure of DNA and RNA has a high degree of similarity, but the 
presence of 2’-OH in the ribose sugar differentiates RNA from DNA, and makes RNA 
structurally and functionally different from DNA. For example, DNA is double stranded but 
RNA, in most case, is a single-stranded molecule and consists of many types of secondary 
structures, for instant, hairpin loops, bulges, internal loops, junctions and so on [24]; the 2'-OH 
group of RNA can provide a scaffold for solvent or protein interactions [25], can mediate 
catalysis [26], can make RNA less stable than DNA [27] and can also stabilize RNA tertiary 
structures [28] and so on. 
 
 
1.1.2.3 Phosphate Backbone Conformations 
The conformation of the sugar phosphate backbone can be defined by torsion angles α, β, δ, ε, 
 5
ζ (Figure 1.5). The sugar puckering mode is indicated by ζ: 74º to 95 º corresponding to 
C3’-endo (A-DNA, A-RNA), and 134 º to 158 º corresponding to C2’-endo (B-DNA, C-DNA 
and D-DNA) [20].  The typical range of phosphate backbone torsions for A and B families of 
DNA and RNA can be found on page 230, reference 20. The torsion angles of the 
pentofuranose sugar ring are indicated by νo to ν4. The torsion angle about a glycosidic bond 
is indicated by χ [O4’-C1’-N9-C4] for purines and [O4'-C1'-N1-C2] for pyrimidines. There 
are two main conformations: syn (-90º ≤ χ ≤ 90º) and anti (90º ≤ χ ≤ 180º). The anti 
conformation is usually more stable and more common, because there is no particular steric 
hindrance between the sugar and the nucleobase in the anti conformation. 
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Figure 1.5 The definition of torsion angles for one nucleotide. 
 
 
1.1.3 Helical Structures of Nucleic Acids 
There are several types of double helix structures for DNA and RNA, depending on the 
sequence, relative humidity and salt concentration. A-form, B-form and Z-form [29] are the 
main three types of double helical structures. Nucleic acids also exist in other forms of 
duplexes, for example, C-form, D-form, E-form and S-form and so on. A-form, B-form and 
C-form are right handed, and Z-form is left handed. The RNA helix exists predominantly in 
A-form [20,30], and the DNA-RNA duplex adopts an intermediate conformation between A and 
B but closer globally to A than the B form [31]. B-form is the dominant form for DNA [32]. 
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Table 1.1 Comparison of A form, B form and Z form of DNA [33,34,35,36] 
 A form B form Z form 
Helix sense Right handed Right handed Left handed 
Pitch (Å) 28.2 33.8 45 
Base pairs per helical turn 11 10 6 
Helix rise per base pair (Å) 2.56 3.38 3.7 
Turn angle per base pair (º) 32.7 36.0 -33.0 
Glycosidic bond conformation anti anti C: anti, G: syn 
Sugar pucker conformation C3'-endo C2'-endo C: C2'-endo, G: C2'-exo 
Diameter(Å) 26 20 18 
 
 
A-DNA B-DNA        Z-DNA 
Figure 1.6 Helical Structures of A-DNA, B-DNA and Z-DNA. 
In double helical structures, base pairs are usually not located at the center of the helix axis, 
but are displaced by distance D, and the two glycosidic bonds branch off from one side of the 
base pairs (figure 1.7a). The outer envelop of the double helix is not cylindrically smooth but 
can display two grooves of different widths and depths [20]. Any groove can be defined by two 
different regions [37]: the ‘bottom’ is formed by the edges of the nucleic base that faces into the 
groove, and the ‘walls’ are formed from the phosphate backbones of the nucleic acid. The 
minor groove is at the O2 (pyrimidine) or N3 (purine) side of the base pairs, and the major 
groove is on the opposite side. The pentafuranose sugar is on the minor groove side. 
Furthermore, A:T sequences produce steric hindrance within the major groove by the presence 
of the methyl group of thymine (figure 1.7b), and the minor groove of G:C is blocked by the 
guanine’s amino group (figure 1.7c). Generally speaking, B-DNA has a wide major groove 
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and a narrow minor groove; A-DNA or A-RNA has a shallow, wide minor groove and a 
narrow, deep major groove (Table 1.2). Table 1.3 lists the groove widths and groove depths of 
several selected nucleic acid sequences, which were studied in this work. 
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Figure 1.7 The major groove and the minor groove of double helical structures. 
Table 1.2 Groove parameters of different forms of nucleic acids [20,38] 
Structure type 
Groove width a (Å) Groove depth a (Å) 
major minor major minor 
A-DNA 2.7 11.0 13.5 2.8 
A-RNA 3.8 10.9 - - 
B-DNA 11.7 5.7 8.5 7.5 
C-DNA 10.5 4.8 7.5 7.9 
D-DNA 8.9 1.3 5.8 6.7 
Z-DNA 2.0 8.8 13.8 3.7 
a. Groove widths are defined to be the perpendicular separation of the two helices that 
connect the phosphorus atoms of each strand in least distance, reduced by 0.58 nm, the 
minimum diameter assumed for a phosphate group. Minor groove depth is defined as 
rP–rO2T+0.14 nm. Major groove depth is defined to be rP–rN6A +0.14 nm [reference 42, 20]. 
Table 1.3 Groove parameters of several nucleic acid sequences 
Nucleic acids 
Groove width(Å) Groove depth(Å) 
major minor major minor 
poly (dGdC) – poly (dGdC) [39] 13.5 9.5 10.0 7.2 
poly (dG) – poly (dC) [30] 8.1 9.5 - - 
poly (dAdT) - poly (dAdT) [40] 11.23 6.30 - - 
poly dA - poly dT [41] 11.4 3.3 - - 
poly dA - poly dU [42] 13.5 3.0 9.3 7.4 
poly A - poly U [38] 3.8 10.9 - - 
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1.2  Introduction to Regulation of Gene Expression 
Generally speaking, DNA stores genetic information. A segment of a DNA molecule that 
contains the information required for the synthesis of functional biological products, whether 
proteins or RNA, is referred to as a gene. After transcription and translation, genes can be 
expressed as proteins which are the physical manifestations of the abstract information 
recorded in the genes and help to carry out almost all biological activities. There are at least 
seven processes to control or regulate gene expression (Figure 1.8) [43]:  
 
Figure 1.8 Seven processes that affect the gene expression [43]. 
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(1). Transcription: Synthesis of the primary RNA transcript. (2). Posttranscriptional 
modification of mRNA. (3). mRNA degradation. (4). Translation: Protein synthesis. (5). 
Posttranslational modification of proteins. (6). Protein targeting and transport. (7). Protein 
degradation. Because in all biochemical processes, an efficient place for the regulation is at 
the beginning of the pathway, the initiation of transcription is probably the best place for gene 
regulation.  
Interestingly, the interactions between proteins and DNA are the key to the regulation of 
transcription initiation. RNA polymerase binds to DNA at promoters, and requires 
transcription factors to form an active transcription complex. Generally speaking, these 
transcription factors are proteins. They not only could bind to RNA polymerases, but also may 
recognize other factors, or recognize DNA. Transcription factors usually contain DNA 
binding domains (DBD) [44,45] and trans-activating domains (TAD), and sometimes also 
contain signal sensing domains (SSD). DNA binding domains are known to interact 
specifically with either the major or the minor grooves of DNA. For example, helix-turn-helix 
domains (THT) [46], basic leucine zipper domains (bZIP) [47] and zinc finger domains [48] 
recognize major grooves of DNA; TATA box binding proteins (TBP) [49], integration host 
factors (IHF) [50], and HMG-Box domains [51] recognize minor grooves [52]. Transcription 
factors play an important role in the long-term regulation of cell growth [53], differentiation [54], 
and programmed cell death (apoptosis) [55]. There is growing evidence that transcription 
factors are closely associated with the development and maintenance of the diseased state at 
the genetic level [56]. Therefore, transcription factors became pharmaceutical target sites. 
Several transcription factors have been used in the treatment of diseases [57]. 
Small molecules can also bind to DNA in the place of transcription initiation. In general, there 
are three different binding modes between guest molecules and host DNA [58,59]: (1). minor or 
major groove binding (2). intercalation (3). external binding. These molecules can modulate 
transcription by any means, and therefore provide potential opportunities for the rational 
design of drugs. These molecules will probably become novel pharmaceutical interventions in 
the future.
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1.3  Binding of Small Molecules to DNA 
1.3.1 Intercalation 
Intercalation is the reversible inclusion of a molecule (or a group) between two base pairs [60] 
(Figure 1.9). It is typically observed for cationic molecules having planar aromatic rings. The 
positive charge need not be part of the ring system, but rather could be on a substituent 
(Figure 1.10). Anthracyclines [61], berberine [62], ethidium bromide [63,64,65], proflavine [66], and 
thalidomide [67] etc. are typical intercalators. Some intercalators can inhibit DNA replication 
and have been used as antineoplastic agents. For example, doxorubicin [68] and daunorubicin 
[69] are used in the treatment of Hodgkin's lymphoma, and dactinomycin is used in the 
treatment of Wilm's tumour [70]. 
 
 
N
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Figure 1.9 The intercalative mode of binding within DNA 
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Figure 1.10 Several examples of intercalators 
In the classical model of intercalation, the binding process consists of three steps [71]: The first 
step is a thermally activated local opening of DNA, creating a binding site for an intercalating 
molecule. The second step is the insertion of the intercalator into the binding site (a 
hydrophobic transfer process). The third step is the formation of molecular interactions 
(hydrogen bonds between the intercalator and surrounding base pairs). The intercalated site is 
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then slightly smaller in size than the preintercalation site required to accommodate the first 
intercalator. The important driving forces for these steps are dipole-dipole interactions and π 
stacking interactions of the guest molecule with the aromatic nucleic bases. Compared with 
groove binding, interaction has a significant effect on DNA structures, because the DNA must 
unwind to enable the intercalators to fit between the two base pairs [37,58,72]. This unwinding 
leads to the lengthening of the helix, and can cause DNA cleavage.  
In addition, intercalators only show modest DNA sequence selectivity [73]. For example, the 
anthracycline drug daunomycin has been shown by footprinting studies that it prefers the 
triplet sequence 5’- pyrimidine - purine – purine [74,75]. A molecule which has site-specificity 
of three bases can only distinguish one out of 32 random sequences. In the context of the 
human genome, such a molecule will have ca. 100000000 unique binding sites [76]. Therefore, 
these agents cannot readily discriminate between different genes. Thus, their mode of action is 
inherently non-selective in terms of the genomes of normal versus abnormal cells [77].  
Therefore, some intercalators are high toxicity chemicals, and most of intercalative drugs 
have strong side effects.  
Interestingly, some intercalators (for instance, ethidium bromide, oxazole yellow [78], thiazole 
orange [79,80], etc.) have low fluorescence until they bind to DNA. They are used to detect 
DNA fragments. In addition, they can also be used for the high throughput fluorescent 
intercalator displacement (HT-FID) assay [81], which makes possible highly sensitive and even 
sequence specific detections of DNA. HT-FID assays are used to judge the DNA binding 
site-selectivities of low molecular weight molecules and other agents, and are also used for a 
single-stranded DNA molecule of interest to be screened against a large number of 
compounds to discover low molecular weight ligands with particular binding properties. 
Details of this part can be found in chapter 3.1 Ethidium Bromide Displacement Assay.
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1.3.2 Minor Groove Binding 
A minor groove binder (MGB) refers to a compound that binds selectively to the minor 
groove of B-DNA [82]. They typically contain aromatic rings and charged end groups. 
Compared with intercalation which requires a major deformation due to the formation of a 
binding cavity, minor groove binding does not require large conformational changes of DNA 
[83]. The interactions between MGB and DNA are the combination of ionic, hydrophobic, and 
hydrogen bond interactions [84,85]. Hydrogen bonding is very important, in that many MGBs 
can read DNA strand sequences through specific hydrogen bonds with those parts of DNA 
bases exposed at the ‘bottom’ of a minor groove (see below) [37]. The general mechanism of 
groove binding is shown in Figure 1.11 [71,86]. Conceptually, the binding process may be 
divided into at least two processes. First, the groove binder undergoes a hydrophobicity 
transfer from a solution into the DNA groove. If the groove binder is positively charged, this 
event will be accompanied by the release of condensed counter ions that surround the DNA 
(Figure 1.11a). Second, the groove binder will form specific molecular interactions with DNA, 
including van der Waals attractions and hydrogen bond interactions (Figure 1.11b). 
 
 
 
a b 
Figure 1.11 The mechanism of groove binding [71] 
1.3.2.1 Classification of MGBs 
There are three broad families of noncovalent minor groove binders that bind without a 
significant increase in the groove width from free DNA [87,88]. They are natural products or 
synthetic compounds based on natural products. The first family of the compounds is the 
analogues of the nature product, netropsin or distamycin (Figure 1.12a, b). The second family 
of the compounds is the analogues of CC-1065 and anthramycin (Figure 1.12c, d). They have 
more complex heterocyclic systems of cyclopropanopyrroles and pyrrolobenzodiazepines. 
The third family of the compounds is the benzheterocyclic-containing dyes, including  
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Figure 1.12 Different classes of MGBs 
benzimidazoles (for example, Hoechst-33258, Figure 1.12e; DAPI, Figure 1.12h), 
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benzofurans (Figure 1.12f), bisarylfurans (Figure 1.12g) and so on. Structural derivatives of 
these families have been exploited, including the introduction of longer and branched alkyl 
groups in place of the N-methyl group, the variation of N- and C-terminal groups and the 
introduction of other aromatic or heteroaromatic amino acids.  
Another type of the minor groove binder is the polyamide hairpin and related compounds 
(Figure 1.12i). They broaden minor grooves to accommodate side-by-side chains of the 
aromatic rings joined with amide bonds to give a high level of sequence selectivity [89]. 
 
1.3.2.2 Sequence Selectivity of MGBs 
Importantly, sequence selectivity of drug-DNA binding is generally higher for MGBs than for 
intercalators. These MGBs can bind specifically and selectively to a defined region of DNA 
with sufficient affinity to inhibit the normal functions of DNA, including replication, 
transcription and expression of specific genes. With the availability of the data in the Human 
Genome Project, it is possible to combine genomics and chemistry to develop specific disease 
agents that act at the DNA level. These MGBs have therapeutic potential in a wide range of 
applications, not least of which include anti-biotic, anti-viral and anti-cancer drugs.  
Majority of MGBs bind to DNA and show higher affinity for A:T-rich sequences [78,90,91]. 
There are two reasons. On the one hand, the minor groove with alternating A and T sequences 
is generally narrow (see table 1.3) and can be approximated by a single smooth curve, which 
allow favorable van der Waals interactions between the MGB and the DNA. Whereas, 
G:C-rich sequences have wider minor grooves, and also have the amino groups of guanine 
bases, which affect the groove geometry (Figure 1.13). These prevent groove-binding 
molecules from attaining the multiple close contacts with the floor in G:C sequences that are 
possible in the A:T regions [92]. Interestingly, a highly structured network of water molecules 
has been observed in A:T regions [93,94], so it is possible that displacement of water located in 
the minor groove (especially in A:T regions) by a minor groove binder contributes to the 
entropic changes [95] (see below: Chapter 3.5 ITC Experiment).  
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a b c 
Figure 1.13 DNA minor grooves and minor groove binders [78,91,96] 
a. The dodecanucleotide d(CGCAAATTTGCG) has a narrow A:T minor groove at the 
  center of the sequence. 
b. The sequence d(CCAGGCCTGG) has a wide G:C minor groove. 
c. The crystal structure of the netropsin complex with the dodecanucleotide  
  d(CGCGAATTCGCG) 
On the other hand, the distribution of electrostatic potential along a DNA sequence is also 
sequence-dependent. A:T base pairs have the greatest negative potential at the floor of the 
minor groove. But for G:C base pairs, they are not as negative as the A:T base pairs, due to 
the guanine 2-NH2 (δ+) in the minor groove of G:C base pairs (Figure 1.14) [97]. Almost all 
minor groove binders carry cationic charges and complement the potential in A:T regions.  
  
  
 H-bond acceptor
 H-bond donor
 ring H atom
 
Thymine Adenine Cytosine Guanine  
Figure 1.14 Donors & acceptors and electropotential surfaces in minor grooves [97] 
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In fact, hydrogen bonding to base edges in minor grooves provides the ability to discriminate 
between A:T and G:C base pairs, due to the differences in numbers of hydrogen bond donors 
and acceptors (Fig. 1.14).  
 
1.3.2.3 The Development of Sequence-Specific MGBs [78,90] 
In my opinion, the development of sequence-specific MGBs has gone through four stages: 
1). The crystal structures of a netropsin complex with the dodecanucleotide duplex sequence 
d(CGCGAATTCGCG) [96] and a distamycin complex [98] with the sequence d(CGCAAATTT 
GCG) provided detail pictures of the interactions between these MGBs and A:T base pairs. It 
also provided an explanation for it’s A:T selectivity and a paradigm for other MGBs in this 
class (Figure 1.15 a). In the crystal structures, (i). Netropsin and distamycin fit into the 
5’-AATT region of DNA. (ii). The walls of the minor groove are in close contact with pyrrole 
and amide groups. (iii). Hydrogen bonding to base edges provides selectivity for A:T base 
pair edges: each amide group forms a hydrogen bond to N3 of adenine or O2 of thymine, and 
the terminal guanidinium groups are also involved in hydrogen bonding to bases.  
2). Based on the facts mentioned above, it was assumed that a modification of netropsin to 
produce a N-methylimidazole group taking place of a pyrrole ring could result in recognition 
of the minor groove exocyclic N2 atom of guanine, i.e. active recognition of a G:C base pair. 
And then lexitropsins were synthesized [99]. Unfortunately, although they showed ability to 
recognize G:C base pairs, however, the A:T recognition was retained. In addition, they 
frequently show reduced affinity for the overall DNA [100,101].  
3). After that, a surprising discovery was shown by NMR [102.103] and crystal [104] studies: 
distamycin and DNA can form a 2:1 complex (Figure 1.15 b). In these structures, (i). Two 
distamycin molecules bind in a side by side manner to the A:T tract, with high orientational 
and sequence specificity. (ii). Each distamycin molecule binds to one strand. (iii). The DNA is 
overall in the B-form, but the minor groove is widened by 2 Å compared to canonical B-DNA. 
4). The 2:1 motif has led to a new and effective class of DNA sequence recognition molecules, 
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the polyamides (Figure 1.12 i). These molecules combined the precise hydrogen bonding to 
base pair edges shown by netropsin and distamycin (Figure 1.15a), with the enhanced groove 
width in G:C-containing sequences, which can accommodate dimeric molecules (Figure 
1.15b). The dimeric molecule (the polyamide) can ‘‘read’’ one DNA duplex at a time rather 
than the two in a 1: 1 complex. Therefore, the polyamide shows much higher affinity (at least 
tenfold) for DNA compared to the monomer. In addition, the enhanced affinity is usually 
accompanied by a corresponding increase in sequence specificity. 
a. The X-ray crystal structure of a 1:1 
complex of netropsin: DNA [105] 
b. The NMR structure of a 2:1 complex of 
distamycin:DNA [103] 
Figure 1.15 
 
 
1.3.2.4 Sequence Specificity of Polyamides and Pairing Rules for Minor Groove Recognition [89] 
For polyamides designed by Peter B Dervan, Im/Py recognizes G:C and disfavours C:G, A:T 
and T:A; Py/Im only favours C:G; Py/Py recognizes A:T and T:A; and Im/Im does not 
recognize any of the four, and thus is useful in correctly positioning a polyamide within a 
sequence (Figure 1.16). 
However, the defect of the pairing code mentioned above is that Py/Py can not distinguish 
between A:T and T:A base pairs. 3-hydroxypyrrole (Hp) was then introduced to the 
recognition motifs [106], in that the 3-hydroxy group can form a specific hydrogen bond with 
the O2 of thymine (Figure 1.17a), and the Hp-OH has a steric clash with the adenine of the 
T:A base pair (Figure 1.17b). The Hp/Py pair shows steric destabilization against T:A, but 
steric permissiveness at A:T. 
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Figure 1.16. The hydrogen-bonding model of the hairpin motif 
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Figure 1.17 Models for Py/Hp binding A:T, but not T:A 
Thus, four Watson–Crick base pairs can be unequivocally recognized by Hairpin-linked 
polyamides composed of Py, Im and Hp (table 1.4).  
Table 1.4 Pairing rules for minor groove recognition 
 C:G G:C T:A A:T 
Im/Py - + - - 
Py/Im + - - - 
Hp/Py - - + - 
Py/Hp - - - + 
Favored (+), disfavored (-)
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1.3.3 Major Groove Binding 
Because the minor groove is too narrow and backbones are on the minor groove side, 
relatively large molecules (for example, DNA binding proteins) often interact with the bases 
(the internal parts of the DNA molecule) on the major groove side [37]. In nature, most protein 
DNA contacts occur in major grooves. Because the base pairs contain genetic information, 
and in major grooves, the four base pairs present four different edge patterns to amino acids 
approaching (Figure 1.18), the major groove is therefore more informative than the minor 
groove (the minor groove only has two distinct patterns, Figure 1.14).  
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 methyl group
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Figure 1.18 Steric geometries and donors & acceptors in the major groove 
 
In a major groove, protein-nucleic acid interactions are sequence-specific recognition [107]. 
The sequence-specific recognition is closely related to the geometry (the shape) and the 
electrostatic potential of the major groove (Figure 1.18, Table 1.2 and Table 1.3). 
The electrostatic potential is a key point to understand intermolecular association [108]. For 
nucleic acids, the first contributor to different electrostatic potentials is the intrinsic base pair 
potential. In major grooves, G:C base pairs [C-4-NH2 (δ+), G-6-CO (δ-), and G-N7 (δ-)] have 
a larger electrostatic potential gradient than T:A base pairs [T-4-CO (δ-), A-6-NH2 (δ+), and 
A-N7 (δ-)]. For example, dG6-dC6 and dA6-dT6 have dramatic differences between the 
potentials in major grooves. For dG6-dC6, one side of the major groove is negative, and the 
other side is positive. For dA6-dT6, there are no negative potentials at all. The second main 
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contributor is a nearest-neighbor interaction, which can either reinforce the intrinsic base pair 
potentials or decrease these potentials. For example, in major grooves, d(CGCGCG)- 
d(CGCGCG) has more neutral areas than does dG6-dC6 because the neighboring base pair 
potentials  somewhat cancel each other. The electrostatic patterns of the major grooves of 
d(TATATA)-d(TATATA) and dA6-dT6 are more similar than those of d(CGCGCG)- 
d(CGCGCG) and dG6-dC6.  
From the examples mentioned above, we know that in major grooves, G:C base pairs are 
more special than A:T base pairs. That is indeed the case. Although some amino acid side 
chains (for example, Asn and Gln) have hydrogen bonding complementarity to the major 
groove site of adenine [109] and A:T pair hydrogen bonding interactions are sources of major 
groove specificity [110], however, G:C base pairs are more important in major grooves: G:C 
base pairs confer greater specificity, and nature likely takes advantage of the greater potential 
specificity of G:C base pairs [109]. For example [110,111], there are more than twice as many G:C 
as A:T pairs in the known recognition sequences of restriction endonucleases; and for a lot of 
restriction endonucleases, adenine can replace thymine in the recognition pattern, but guanine 
can replace cytosine. 
Zinc finger domains, helix-turn-helix domains and basic leucine zipper domains are typical 
major groove binders. They have been studied in detail and have been used to interpret 
sequence-specific recognition in major grooves between DNA binding proteins and 
double-stranded DNA (ds-DNA). 
(1). Zinc finger domains [112,113,114] 
This domain is common in eukaryotic DNA-binding proteins. It was originally found in the 
eukaryotic transcription factor TFIIIA. TFIIIA contains nine repeated modules. The general 
transcription factor Sp1 has a DNA-binding domain that consists of three zinc fingers, each of 
which contains two Cysteine and two Histidine residues. These four residues coordinate one 
Zn2+ ion. The C-terminal part of each finger forms α-helices that bind to the major groove of 
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DNA, and the N-terminal part forms β-sheets (Figure 1.19a). The three fingers line up in the 
same major groove of the DNA (Figure 1.19b). There are direct amino acid-base pair contacts 
as well as amino acid-DNA backbone contacts. The amino acids in the C-terminal side of 
each finger are responsible for recognizing specific target sites of DNA. The target bases all 
lie on one strand. Each finger interacts with three bases. In zinc finger domains, Arg (24, 18, 
46, 74, 80) contacts with guanine; His (49) intercalates between guanine and thymine, forms a 
hydrogen bond with N7 with the guanine, and has van der Waals interactions with thymine.  
 
a b c 
Figure 1.19 Zinc finger domains [114] 
(2). Helix-turn-helix domains [114,115,116] 
This motif was originally identified in bacterial proteins, and has been found in hundreds of 
DNA-binding proteins from both eucaryotes and prokaryotes. This motif has both the ability 
to bind DNA and to dimerize. It is constructed from two amphipathic α helices connected by a 
short extended chain of amino acids, which constitutes the "turn" (Figure 1.20a). HTH 
proteins can form both homodimers and heterodimers by means of interactions between the 
hydrophobic residues on the corresponding faces of the two helices. The dimer binds to DNA 
stronger than the monomer, and furthermore, by changing the relative positions of monomers, 
the dimer activity can be easily turned on and off. The carboxyl-terminal helix is called the 
recognition helix because it fits into the major groove of DNA. The amino acid side chains of 
the recognition helix are positioned to facilitate hydrogen bonding with the edges of base 
pairs in the specific DNA sequence to which the protein binds (Figure 1.20b).  
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a 
 
 b Helix turn helix motif of Cro repressor protein (phage Lambda) 
Figure 1.20 Helix-turn-helix domains [114] 
By analyzing several examples of the protein-DNA interactions, we can get some valuable 
conclusions: 
(1). The specificity of DNA-protein interactions depends upon certain amino acids in 
recognition domains that protrude into the groove of the DNA double helix and make specific 
contacts with functional groups of specific bases. Several studies proved that interactions 
between arginine-guanine, lysine-guanine and lysine-thymine in major grooves would be 
unusually strong. Ser also bind to guanine on the major groove side [115,20,110]. (Figure 1.21a-c) 
(2). Asn or Gln can interact with adenine (N6 and N7), guanine (O6 and N7), and backbones 
via hydrogen bonds [20]. (Figure 1.21 d-e) 
(3). The methyl groups of the some side chains (for example, Ala and Thr) can form a 
hydrophobic pocket to receive the methyl group of thymine. 
(4). Peptide backbone NH groups can form hydrogen bonds with the DNA phosphate groups. 
It is sequence unspecific interactions, but these interactions stabilize the appropriate DNA 
conformation and a large number of residues are distributed along the polypeptide chain. 
These unspecific interactions make the ’unit’ which is responsible for differential binding to 
different DNA regions become really a specific binding domain. (Figure 1.21 f-h) 
(5). These interactions are electrostatic and topographic complementarity [108]. 
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Figure 1.21 Examples of Protein-Nucleic Acid Interactions 
Beside DNA binding proteins, several small molecules also bind to major grooves of DNA. 
For example, methyl green [117] [poly(dAdT)-poly(dAdT) and poly dA-poly dT], methylene 
blue [118] [poly dA-poly dT], APF [poly(dGdC)-poly(dGdC), also intercalation], and Hoechst 
33258 [ 119 ] [poly(dGdC)-poly(dGdC), also intercalation]. Another major groove binder 
candidate, which was first synthesized and studied by the group Prof. Dr. Thomas Schrader, is 
the large calixarene dimer [120] . 
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1.4  Calixarene 
Calixarenes are a readily available and important class of macrocycles in supramolecular 
chemistry. Compared with traditional molecular chemistry, which is focused on the covalent 
bond, supramolecular chemistry pays more attention to noncovalent interactions between 
molecules [121]. These interactions are weaker and reversible [122]. The driving forces for the 
formation of supramolecular structures include hydrophobic interactions, electrostatic 
interactions, hydrogen bond interactions, van der Waals interactions, cation – π interactions, 
π-π stacking interactions and so on. The total intermolecular force acting between two 
molecules is the sum of all the forces they exert on each other. Supramolecules can form some 
special structures, for example, self-assembly, folding, mechanically interlocked molecular 
architectures. Supramolecular chemistry is often related to several research areas, for instance, 
molecular recognition, host – guest chemistry, dynamic covalent chemistry [123], etc. Because 
the noncovalent interactions are the basis of life, supramolecular chemistry becomes crucial to 
understanding, modeling and mimicking biological processes and biological systems, and it 
can broaden our horizons to develop new materials with special properties and functions.  
The design and synthesis of water-soluble synthetic macrocycles as artificial receptors and 
bio-mimetic models has been a major subject of supramolecular chemistry in recent years. 
Calixarenes are one of the most famous macrocyclic compounds. They were obtained by the 
oligomerization of phenol and formaldehyde, and consist of phenolic units arranged in cyclic 
arrays by the linking with methylene bridges ortho to the phenol groups [124]. They can be 
defined with upper and lower rims and a central annulus (Figure 1.22a). Compared with other 
macrocycles (for example, cyclodextrins, crown ethers, cryptands, etc.), calixarenes have 
several special properties and advantages [125], which can be involved in molecular recognition 
processes. 
(1). They have different forms due to the flexibility in the rotation of Ar – CH2 – Ar bonds [126]. 
For example, the calix[4]arene macrocycle is in one of its four possible conformations: ‘cone’, 
‘partial cone’, ‘1,2-alternate’, ‘1,3-alternate’ conformations (Figure 1.22). Calix[6]arenes can 
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exist in eight different ‘up-down’ conformations like calix[4]arenes. The core conformation is 
the most stable conformation amongst all the forms of calix[n]arenes. 
(2). The larger and conformationally more mobile calix[6]- and -[8]arenes can adapt their 
conformations to the stereochemical request of the multivalent receptor entity through 
induced fit [130]. 
(3). The cavity with a size is suitable for inclusion of ions and small molecules [127].  
 
Upper rim
Annulus
Lower rim 
a. Division of calixarene 
 
 
cone partial cone 1,2-alternate 1,3-alternate 
     
Figure 1.22 The division and four conformations of a calix[4]arene [128] 
(4). It is possible to create ligands with binding sites or functional groups at the upper or 
lower rims of the present compounds, for example, –CHO, –COOH, –NH2, –NCS, etc [129]. 
These modifications not only make calixarenes easily form complexes with a variety of guests, 
but also extend their use in the construction of large architectures, such as calixcrowns, 
calixcryptands, and calixspherands, calixcavitands, and calixcarcerands. Calixarenes can form 
dimers with the help of spacers. In this work, I exclusively focused attention on the calixarene 
dimers. 
Compared with a calixarene monomer, the corresponding calixarene dimer is bigger and 
contains more binding sites (or functional groups), which make them useful building blocks 
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and carrier molecules. Furthermore, they can use the internal dynamics to arrange multiple 
and interconnected components to minimize free energy [130]. In solution, they could form a 
tightly packed ball. Such intramolecular reorganizations may lead to shape and volume 
changes, the creation of internal microenvironments, the cooperative organization of the 
surface or inner functionalities, the concentration or the exclusion of substrates from the 
molecular “cavity” of calixarene dimers, and the formation of defined multimolecular 
assemblies.  
The first work about DNA recognition with large calixarene dimers was published by the 
group Professor Dr. Thomas Schrader in 2006 [120]. Two different calixarene dimers connected 
by either a flexible aliphatic linker or a rigid aromatic linker were synthesized (Figure 1.23).  
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Figure 1.23 Calix[4]arene dimers a/b based on trifunctional anilinium building blocks 
Because direct structure information from a crystal or NMR structure was not available, a 
number of DNA binding experiments were performed. The binding mode between the 
calixarene dimers and nucleic acids was established according to the following arguments: 
(1). The average size of these molecules is about 3 nm2. The dimension excludes intercalation 
and minor groove binding. 
(2). 1H NMR spectroscopy and fluorescence titrations indicate that there is no interaction 
between sugars and the dimers, and the binding of dimers with phosphate backbones is weak. 
These results exclude external binding. 
(3). The dimer showed efficient displacement of intercalated ethidium bromide, which can 
prove that the calixarene dimer does not attack the phosphodiester backbone by multiple salt 
bridges, but rather inserts into the groove. 
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(4). The UV absorption intensity strongly enhanced and the melting curves were inverted in 
the presence of the calixarene dimers. This is in perfect agreement with an insertion of the 
extended nonpolar calixarene dimer corpus into the groove accompanied by hydrogen 
bonding to the chromophores (nucleic bases) in Hoogsteen sites. 
(5). As A:T pairs present methyl groups into the major groove but G:C pairs do not, pure 
(GC)n DNA strands should be preferred for insertion into the calixarene dimer owing to 
additional hydrogen bond contacts. This sequence selectivity was indeed established with 
fluorescein-labeled dG12-dC12 and dA12-dT12 model DNA, which produced a pronounced 
difference in the KD value of one order of magnitude. This experiment proved the major 
groove binding mode. 
 
 
 
Figure 1.24 The mechanism of DNA binding by dimeric calixarenes. 
The mechanism of DNA binding by dimeric calixarenes was presented: the ammonium 
groups of the calixarene units were deeply buried within the major groove, and contact to 
various nucleic bases with hydrogen bonds. The butoxy tail is toward the free solution. The 
adipic acid linker binds along the major groove (Figure 1.24).
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After that, two different series of related compounds with varied bridging units were 
synthesized by the same group (Figure 1.25) [131]. In one series, the alkyl bridge between both 
calixarenes was varied in successive steps of C-2 ethylene units from 4 to 6 and 8 up to 10 
carbon atoms (Dimer 1-4). In a second series, they introduced two full positive charges 
directly into the bridging alkyl chain or alternatively into its close vicinity (Dimer 5-6). All 
the calixarene dimers were subjected to a wide range of DNA or RNA binding experiments. 
We can get some valuable results. 
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Figure 1.25 Calixarene dimers with different spacers 
(1). Dimer 1, Dimer 2, Dimer 3 and Dimer 4 (Figure 1.24 a) can not dissolve in water, and 
have similar equilibrium binding affinities for DNA. 
(2). Dimer 5 and Dimer 6 (Figure 1.25b, Figure 1.25c) exhibit higher equilibrium binding 
affinities (about one order of magnitude) for DNA, more efficient displacement of intercalated 
ethidium bromide, and significant stabilization in the DNA duplex.  
Unfortunately, the two additional charges can not render the whole calixarene dimers water 
soluble, and the affinity is only at the micromolar level. In order to block pathogenicity genes, 
it is necessary to synthesize new calixarene dimers, which not only should be water-soluble 
but also should show much higher affinities for DNA.
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1.5  Objectives 
Objective 1: To synthesize water-soluble dimeric aminobenzyl calixarene (Dimer A) and its 
guanidinium counterpart (Dimer B) (Figure 1.26), and to observe whether they bind DNA 
with higher affinity, and to prove whether they are major groove binders. 
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Figure 1.26 Structures of calixarene dimers 
The design of Dimer A and Dimer B was based on the following experimental results: 
(1). Previous experimental results have been implied that anilino-calixarenes (Figure 1.23, 
Figure 1.25) could be major groove binders [120]. 
(2). Compared with aniline analogues, benzylamine and its guanidinium counterpart have 
good solubility in water. 
(3). Benzylamine and its guanidinium counterpart have higher pKa values than aniline 
analogues (pKa ≈ 5). Thus at physiological pH (7.3-7.4), benzylamine (pKa ≈ 10) and its 
guanidinium counterpart (pKa ≈ 12) are easily protonated. They can exhibit high affinities for 
nucleobases and phosphate backbones via hydrogen bond interactions and electrostatic 
interactions. 
(4). Benzylamine and its guanidinium counterpart can mimic lysine and arginine to interact 
with nucleobases via hydrogen bond interactions on the major groove side or to interact with 
phosphate backbones via electrostatic interactions (Figure 1.21 a, b, g, h). 
(5). The amides of Dimer A and Dimer B could mimic NH groups of peptide backbones to  
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form hydrogen bonds with the phosphate groups or the nucleobases on the major groove side 
(Figure 1.21 d, e and f). 
In order to broaden the scope of the investigation, the corresponding monomeric calixarenes 
(Figure 1.27) were also synthesized. Because direct structure information from a crystal or 
NMR structure was not yet available in my work, several other biophysical experiments have 
been designed and performed between these calixarenes and different nucleic acids with 
varying base composition and conformation. These experiments include DAPI displacement 
assays, EtBr displacement assays, fluoresence titrations, CD measurements and so on. 
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Figure 1.27 Structures of calixarene monomers 
Although the experimental results indicate that they are water-soluble and they exhibit much 
high affinities for DNA, and the results also strongly support a major groove binding mode, 
however, these calixarenes (Dimer A, Dimer B, Monomer A and Monomer B) showed similar 
affinities for different DNA duplexes. Thus, it is urgent to design a new class of calixarene 
dimers, each of which can show stronger preference for only one specific DNA duplex. 
Objective 2: To synthesize calixarene dimers containing heterocyclic oligoamide bridges 
(Figure 1.28), and to prove whether they are major groove binders, and furthermore, to 
observe whether they can recognize specific DNA sequences. 
The heterocyclic oligoamides contain N-methylpyrrole, 3-hydroxypyrrole and N-methyl 
imidazole amino acid building blocks. In this part, I synthesized the calixarene dimer with a 
triimidazole bridge (Dimer C). 
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Dimer C 
Dimer D 
Dimer E 
The design of Dimer C-E was based on the following experimental results: 
(1). Dimer A and Monomer A are major groove binders. 
(2). The hydrogen bonding of polyamides [89] to base edges in minor grooves provides the 
ability to discriminate between A:T and G:C base pairs, due to the differences in numbers of 
hydrogen bond donors and acceptors (Figure 1.16 and Table 1.4).  
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(3). Dimer A or Monomer A binds DNA with higher affinity, which can drive the oligoamide 
bridge (probably a minor groove binder) from a minor groove to a major groove. 
(4). Because in major grooves, the four base pairs present four different edge patterns to 
amino acids approaching (Figure 1.18), the heterocyclic oligoamide bridges (amino acids) can 
specifically recognize different edge patterns in major grooves.  
At the same time, we also want to know, in vitro, whether these calixarene dimers or 
monomers have biological activities, whether they can regulate gene expression, and whether 
they really bind to the major groove of promoters and block pathogenicity genes. In this thesis, 
recent studies on these topics will be reported. 
1.6  Overview of the Thesis 
This thesis presents the design, synthesis and DNA binding studies of aminobenzyl and 
guanidinium calix[4]arene dimers. The present work consists of three parts. The first part 
describes the synthesis of dimeric calixarenes in Chapter 2. In the second part (Chapter 3, 4 
and 5) the bindings of these dimers with nucleic acids have been examined. Chapter 3 
highlights the methodology and the basic theories and the most important experimental 
techniques that were used throughout the work. Chapter 4 addresses the results of DNA 
binding experiments, and the mechanism of DNA binding by dimeric calixarenes is elucidated. 
Then, the focus is shifted towards the proliferation study of living cells. Chapter 5 focuses on 
the conclusions of previous studies and discusses the work in the future. The last part of the 
thesis (Chapter 6) provides the experimental procedures, the spectra of NMR and MS, and the 
data of fluorescence titration experiments. 
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2. Synthesis 
2.1 Synthesis of Monomeric Calixarenes  
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Figure 2.1 Synthesis of Monomer A (6) and Monomer B (14) 
 
2.1.1 Synthesis of Calix[4]arene 
Calixarenes are macrocyclic compounds, which are composed of phenolic units. The phenolic 
units are connected by methylene bridges to form a hydrophobic cavity. These molecules 
were generated from the base catalyzed reactions of p-alkylphenols with formaldehyde. It is 
necessary to use p-substituted phenols to avoid the formation of cross-linked networks when 
both ortho and para positions of phenols are available for condensation [132].  
Because the base catalyzed synthesis is the most convenient and reliable, the mechanism of 
these reactions was studied (Figure 2.2) [133]. The first step is a nucleophilic addition reaction 
of the ortho-position of a phenoxide ion to the carbonyl group of formaldehyde and forms a 
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hydroxymethyl phenol. The second step is the formation of a quinomethidine intermediate. 
Then, the quinomethidine intermediate reacts with another phenolate anion to produce a 
diphenylmethane derivative and even more complicated liner oligomers (precursors).  
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Figure 2.2 The mechanism of the base-induced condensation reaction 
 
There are more than 36 noncyclic components in precursors [132]. How the cyclic oligomers 
are produced from the mixture and why the different liner oligomers can form a specific 
cyclic oligomer remain to be clarified. But the experimental results are quite definite:  
(1). A mixture of p-tert-butylphenol (1 eq.), 37 % formaldehyde (1.25 eq.) and NaOH (0.045 
eq.) is heated for 2 hours at 100-120 °C to produce the “precursor”. The “precursor” is then 
refluxed in diphenyl ether for 3-4 hours, cooled and added ethyl acetate to get tetra(tert-butyl) 
-tetrahydroxy-calix[4]arene (1) in 61 % yield [134].  
(2). If this “precursor” is refluxed in xylene, the product collected is the octa(tert-butyl)- 
octahydroxy-calix[8]arene in 62-65 % yield [135]. 
(3). If the base is KOH (0.34 eq.), then reflux in xylene, the product is the hexa(tert-butyl)- 
hexahydroxy-calix[6]arene in 83-88 % yield [136]. 
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(4). The base (or the cation) has a significant effect on the final product. For example, NaOH 
tends to give high yields of the cyclic octamer, while LiOH gives low yields; the larger radii 
alkali metal cation (K+, Rb+ and Cs+) produces the cyclic hexamer in high yields [133,137]. 
Based on the observation and investigations of Gutsche and coworkers, it is suggested that the 
octamer is the kinetic controlled product, and the tetramer is the thermodynamic controlled 
product [133,137, 138 ]. It has been proven that after heating octa(tert-butyl)-octahydroxy- 
calix[8]arene in diphenyl ether, the product was identified as tetra(tert-butyl)-tetrahydroxy- 
calix[4]arene. It is thought that the cyclic octamer is generated in the beginning, and then 
undergoes some kind of transformation to yield the cyclic tetramer. There are two 
explanations. (1). The fragmentation recombination pathway [139]: the cyclic octamer is 
completely broken into single aryl units and subsequent recombination produces two cyclic 
tetramers. (2). The molecular mitosis mechanism: the cyclic octamer divides into two cyclic 
tetramers. More mechanisms remain to be studied. 
 
In order to introduce a functional group on the upper rim, it is necessary to remove the alkyl 
group (tert-butyl) by a retro Friedel-Craft alkylation reaction in the presence of a Lewis acid 
(for example, AlCl3) and an acceptor solvent such as phenol [140]. Thus, calix[4]arene (2) was 
synthesized in 61% yield. 
2.1.2 Lower Rim Etherifications of Calix[4]arene 
Calix[4]arenes contain free intraannular OH groups, and have four conformational isomers: 
cone, partial cone, 1,2-altemate, and 1,3-altemate because of the rotation of bonds of the 
Ar-CH2-Ar groups. All the aryl units of calix[4]arenes can rotate independently in a 'lower rim 
through the annulus' mode, but not in an 'upper rim through the annulus' mode. The latter 
mode can be found in the rotation of aryl units in the larger cyclic oligomers. The rotation 
effect is considerably more pronounced in polar solvents [133], such as acetone, acetonitrile and 
pyridine, than in non-polar solvents, such as chloroform and benzene. It may be explained in 
terms of the inversion barrier in which polar solvents are able to disrupt the intramolecular 
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hydrogen bonds that contribute in maintaining the calixarene in the cone conformation. 
Because of the 'lower rim through the annulus' pathway, it is possible for the calix[4]arene to 
be locked in one of the four conformations by etherifications of the hydroxy groups. In fact, if 
the groups linked to the hydroxy groups are bulkier than an ethyl group, it is large enough to 
fix the conformations of calix[4]arenes [141,142]. The result of the orientation depends on the 
bases [ 143 ], counterions, solvents and reaction temperatures, and also depends on the 
p-substituents of the aromatic rings. For example, the treatment of calix[4]arenes with excess 
NaH in DMF (or DMF/THF) at room temperature followed by excess halogenides leads to the 
core conformation. 25, 26, 27, 28-tetra-O-nbutyl-calix[4]arene (3) was synthesised in 52% 
yield in this way. If Cs2CO3 is used at 80 °C, the main product of the etherification is 
1,3–alternate conformers [143,144].  
2.1.3 Upper Rim Functionalizations 
The upper rim functionalization originates from electrophilic substitution reactions of the p-H 
of the calixarenes. It has been proved that the calix[4]arene ethers have better behaviours of 
electrophilic substitutions than the p-H tetrahydroxy calix[4]arene. A set of upper rim 
modifications have been made, and can be divided into three classes:  
(1). Anionic modifications: Sulfonic acid[ 145 ], nitro[ 146 ], phosphonic acid[ 147 ], carboxyl 
moieties[148], halogens derivatives[149] and so on were introduced to the p-position of the 
calixarenes. 
(2). Cationic modifications: It mainly focuses on the calixarenes containing tetraalkyl 
ammonium groups and primary amines [150,151]. 
(3). Neutral modifications: In order to avoid unspecific bindings and prevent repulsions of 
ionic groups, calixarenes with sulfonamides [152], hydroxyl groups containing amides [153], 
sugars [154], polyoxyethylenes [155], polyalcohol residues [156], etc. have been synthesized.  
Our work was to synthesize calix[4]arenes with amino (aniline) or methyl amino (benzyl 
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amine) groups on the p-positions. The synthesis of aniline [120] started with the introduction of 
nitro groups to the p-positions. It was achieved by using nitric acid in acetic acid. The nitro 
groups were then reduced to amino groups by a Pd or Ni-catalyzed hydrogenation reaction. 
While the main synthetic route to 25,26,27,28-tetrabutoxy-5,11,17,23-tetrakis (aminomethyl) 
calix[4]arene tetrahydrochloride (6) started from 25,26,27,28-tetra-O-nbutyl-calix[4]arene (3) 
which was chloromethylated with formaldehyde and HCl to give 25,26,27,28-tetrabutoxy- 
5,11,17,23-tetrakis(chloromethyl) calix[4]arene (4) in 82% yield [149]. The reaction of (4) with 
sodium azide in DMF at 80 °C followed by the reduction reaction with hydrogen over Pd/C 
gave the aminobenzyl calix[4]arene (6) (Monomer A) [157]. In order to add guanidinium 
subunits to the benzylic tetramine, N, N’-bis-Boc-2-methyl-2-thiopseudourea (15) was 
synthesized [ 158 ] by stirring the solution of 2-methyl-2-thiopseudourea sulfate and 
di-t-butyldicarbonate at room temperature for 7 days. (6) was treated with (15) under the 
assistance of silver nitrate and triethylamine to provide 5,11,17,23-tetrakis{[2,3-bis(tert- 
butoxycarbonyl)guanidino]methyl}-25,26,27,28-tetrabutoxy calix[4]arene (13) as a white 
solid (Yield: 36%). 1M HCl was used to deprotect Boc groups of (13) to afford tetraguanidine 
monomer 25,26,27,28-tetrabutoxy-5,11,17,23-tetrakis[(guanidinium)methyl] calix[4]arene 
Tetrachloride (14) (Monomer B) in 72% yield [159,160]. Both monomers are stable at room 
temperature at least for two days. Both monomers display good solubility in aqueous 
solutions, Monomer A > 1 mM, Monomer B > 0.5 mM. 
2.2 Synthesis of Dimeric Calixarenes  
In my opinion, the most important step to the synthesis of aminobenzyl and guanidinium 
calix[4]arene dimers is the trisfunctionalizations of the aminobenzyl calix[4]arene (6), i.e. the 
synthesis of (7) and (10). For the anilino-calix[4]arene series, tetraaniline was treated with 
exactly three equivalents of di-tert-butyl dicarbonate (Boc2O) in dichloromethane, and from 
the mixture of 4-fold, 3-fold and 2-fold Boc-protected anilino-calix[4]arene. The desired 
compound was isolated by chromatographic separation in 65% yield [120,160]. Inspired by 
previous experiments, I carried out similar experiments. Because Monomer A (6) displays 
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poor solubility in dichloromethane, THF, acetone and acetonitrile, dipolar aprotic solvents, 
such as DMF and DMSO were used. At the same time, triethylamine was used to remove HCl 
of Monomer A. A series of experiments were performed at different temperatures (-60-20ºC). 
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Unfortunately, the synthesis of (7) 
failed. Probably because the 
aminobenzyl group is too active 
(compared with the aniline group), 
the addition of 3 eq. Boc2O always 
formed the 4-fold-Boc protected 
aminobenzyl calix[4]arene (7b), 
and a few starting material (6) did not react with Boc2O at all and remained in the solution. 
In order to decrease the activity of the reactants, Boc2O (an anhydride) was replaced by 
tert-butyl (2,5-dioxopyrrolidin-1-yl) carbonate (7c) (an active ester) (in Figure 2.3).  
 
Figure 2.3 Synthesis of tert-butyl (2,5-dioxopyrrolidin-1-yl) carbonate (7c) 
There are several characteristics for the NHS ester (7c) [161]: (1). The half life of (7c) in 
MeOH is over 20 hours, and in water the half life is over 5 hours. (2). Primary amines are the 
principal targets for NHS esters. (3). Phosphate, bicarbonate/carbonate, Hepes and borate 
buffers were often used for crosslinking. (4). NHS esters react rapidly with amino groups in 
the pH range 6-9. But the rate of hydrolysis of the NHS ester increases with increasing pH. 
Figure 2.4 Synthesis of (7) 
Based on the experimental facts mentioned above, a new synthetic scheme was designed for 
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the synthesis of (7) (in Figure 2.4): (6) (1 eq.) and (7c) (3 eq.) were dissolved in MeOH and 
were stirred at room temperature. The saturated NaHCO3 (20 eq.) in aqueous solution was 
added dropwise to the mixture. The solution was stirred for 16 hour at room temperature. 
After chromatographic separation, 5-(Aminomethyl)-25,26,27,28-tetrabutoxy-11,17,23-tris 
{[(tertbutoxycarbonyl) amino]methyl}calix[4]arene (7) was synthesized in 25% yield. The 
base NaHCO3 is very important. On the one hand, NaHCO3 reacts with HCl of (6) to form 
free primary amines. On the other hand, NaHCO3 can adjust solution to an alkaline pH level 
in order to increase the rate of the crosslinking. Furthermore, NaHCO3 is weak alkali (pH: 
7.5-8.5 in H2O), so the rate of hydrolysis of the NHS ester decreased as low as possible. 
By chance, a surprising phenomenon was observed: Monomer A (6) (1.0 g, 1.10 mmol) was 
dissolved in a mixture of anhydrous MeOH (10 mL) and Et3N (1 mL). Di-tert-butylcarbonate 
(0.72 g, 3.30 mmol) was added to the solution. The mixture was stirred for 18 h at r.t. 
Subsequently, MeOH was removed in vacuo, and the residue was purified by flash column 
chromatography (SiO2, DCM/MeOH, 100:1). (7) was synthesized in 21% yield. 
3 eq. Boc2 O
DMSO or DMF
 
Apparently, the only 
difference between this 
procedure and previous one 
is the solvent: MeOH or 
DMF/DMSO. Because 
MeOH can react with 
Boc2O under Et3N catalysis 
to from an ester, therefore, 
at the beginning DMF and DMSO were used. But the fact is that the reaction preferred to 
form amides instead of esters when MeOH was used. This can be explained by the fact that 
the nucleophilicity of amines is better than alcohols. 
Another phenomenon should be paid more attention: in MeOH, (6) can form 4-fold, 3-fold, 
2-fold and 1-fold Boc-protected aminobenzyl calix[4]arenes; while in DMF and DMSO, only 
the 4-fold Boc-protected aminobenzyl calix[4]arene (7b) was observed. It may be explained in 
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terms of salvation [162]. MeOH belongs to protic solvents. They possess a proton-donating 
function. They have both a large dipole moment and a capacity for hydrogen bonding.  
Thus, MeOH can stabilize the substrate (free 
amines) via hydrogen bonds and increase 
activation energy. At the same time, MeOH can 
also stabilize the free amine of the 3-fold 
Boc-protected aminobenzyl calix[4]arene (7). In 
short, the protic solvent decreases the rate of the Ea2>Ea1,  ΔH2>ΔH1 
reaction and stabilizes the desired product (7). DMF and DMSO are dipolar aprotic solvents, 
which possess a large dipole moment and donor properties, but they have no acidic protons. 
Therefore, they can not stabilize the substrate and the product via hydrogen bonds, which 
leads to the 4-fold Boc-protected aminobenzyl calix[4]arene (7b).  
 
Figure 2.5 Synthesis of Dimer A (9) 
The last two steps of the dimeric calixarene synthesis were the double peptide bond formation 
between the triBoc-protected calixarene’s free benzylamino group and the adipic acid 
dichloride (Yield: 64%), and the final removal of all Boc groups by 1M HCl .The final 
product (9) was washed with acetone and was used without further purification (Yield: 85%). 
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In order to synthesize the guanidinium calix[4]arene dimer (Dimer B) (12), the six guanidine 
function groups were tried to be introduced at the dimer stage at the beginning. Unfortunately, 
although the NMR spectra seem to be right, MS spectra indicated that the six guanidine 
function groups were not completely introduced. It was also useless to increase reaction 
temperatures (from 20°C to 120°C). Thus, Monomer A (6) had to be trisguanidinylated to 
yield the desired protected trisguanidine monomer (10) (in Figure 2.6). The yield of this step 
is as low as 12%. Adipic acid dichloride was then directly used to acylate the free anime of 
(10) under Et3N catalysis. The last reaction was the HCl treatment (1M) at ambient 
temperature. This resulted in complete cleavages of all the Boc groups. The final product (12) 
was also washed with acetone and was used without further purification (Yield: 85%). 
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Figure 2.6 Synthesis of Dimer B (12) 
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2.3 Synthesis of N-Protected N-Methylimidazole Amino Acids  
Because of the use of recombinant DNA techniques and the advent of automated solid-phase 
peptide synthesis and multiple peptide synthesis, today, peptide and protein synthesis becomes 
more and more efficient and convenient.  
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Figure 2.7 The solid-phase peptide synthesis 
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In the solid-phase peptide synthesis [163], the C terminal acid is attached to an insoluble 
polymeric support. A peptide is assembled by reacting the deblocked amino (N) - terminus, 
resulting in the formation of an amide bond. The process of deblocking the N-terminus, 
activating the carboxylic acid, and performing the coupling reaction with the next amino acid 
is repeated until the peptide of interest is complete. (Figure 2.7a) The solid phase allows 
convenient removal of soluble by-products and excess reagents without loss of peptide. High 
yields in each step (over 99%) enable sequences up to 100 amino acids to be synthesised. The 
peptide is then cleaved from the support. After deprotection, the crude peptide is purified by 
RP-HPLC or gel electrophoresis (Figure 2.7b). 
Protecting groups are used for the amino groups of all amino acids. In general, they can be 
divided into four classes: alkoxycarbonyl-type (Urethane-Type) protecting groups, 
carboxamide-type protecting groups, sulfonamide and sulfenamide-type protecting groups, 
and alkyl-type protecting groups. Urethane-type amino-protecting groups were widely used, 
for example, the benzyloxycarbonyl group (Cbz or “Z”), the tert-butoxycarbonyl group (Boc), 
and the 9-fluorenylmethoxycarbonyl group (Fmoc) and so on. The Boc protecting group was 
used in my work (Figure 2.8). 
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Figure 2.8 Synthesis of the N-protected N-methylimidazole Amino Acid building block 
Reagents and conditions: (a) CCl3COCl, CH2Cl2, 12 h; (b) fuming HNO3, H2SO4, Ac2O, 0 °C 
to r.t., 24 h; (c) MeONa, MeOH, 3 h; (d )Boc2O, 10% Pd/C, H2, MeOH, 28 h; (e) t-BuOK, 
H2O, THF, r.t. 
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The synthesis of the N-methylimidazole amino acid building block (20) [164,165,166] began with 
the synthesis of 2-trichloroacety-1-methylimidazole (16) as previously reported [167]. The nitro 
derivative (17) was obtained by using HNO3 and H2SO4. The nitro ester (18) was then 
synthesized through base hydrolysis of (17). One-pot catalytic reduction and Boc-protection 
gave the desired compound (19) in 82% yield for the two steps. Final hydrolysis by using 
t-BuOK in the mixture of THF and water produced the N-methylimidazole amino acid 
building block (20) in 91% yield. Compared with traditional scheme, where the nitration of 
ethyl 1-methylimidazole- 2-carboxylate gave low yield (12%) in my work, this scheme could 
produce (17) in an improved yield (62%).  
 
 
2.4  Synthesis of Spacers and Coupling Reactions 
The formation of a peptide bond is a nucleophilic substitution reaction of an amino group (a 
nucleophile) and a carboxy group by forming a tetrahedral intermediate. In this process, 
carboxy components are first activated by the introduction of electron-accepting moieties to 
increase their electrophilicities. Several function groups which exert either an inductive (-I) 
effect or a mesomeric (-M) effect (or both) to decrease the electron density at the C=O group 
are widely used (see below). And then, the amino component attacks with its nitrogen lone 
pairs to the carboxy group to give a tetrahedral intermediate. Finally, the leaving group 
dissociates from the intermediate, and the peptide bond formation is then completed. In fact, 
the leaving group capacity (nucleofugicity) is another important factor which can influence 
the reaction rate and yield [168]. 
There are a lot of reagents to activate carboxy groups, for example, acyl azides, anhydrides, 
carbodiimides, active esters, acyl halides, phosphonium reagents and uranium reagents [168]. 
Among of these, carbodiimides (for example, DCC, DIC, EDCl, etc.), active esters (for 
example, NHS esters, OBt, etc.), phosphonium reagents (for example, BOP. PyBOP, PyBrOP, 
etc.) and uranium reagents (for example, HBTU, HATU, TBTU, etc.) are widely used in the 
solid-phase peptide synthesis. In fact, it was very important to choose proper coupling 
reagents to increase reaction rates and yields, and to reduce the formation of by-products. 
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According to previous reports [165,166,169], N-protected N-methylpyrrole amino acid building 
blocks were activated with DCC/DMAP, EDCl/DMAP or HBTU/DIEA. Coupling times were 
from 1 h to 60 h. The yield is as high as 99% for solid-phase peptide synthesis and the yield is 
higher than 50% for the liquid-phase synthesis. Unfortunately, if carbodiimides were used in 
my work for the coupling of N-protected N-methylimidazole amino acid building blocks (20), 
the yield was lower than 20%. In my opinion, there are two reasons: (1). The nucleophilicity 
of the amine of the N-methylimidazole amino acid building block (20) is weeker than the 
amine of the N-methylpyrrole amino acid building block. Therefore, the N-acylurea 
by-product formed (in Figure 2.8-2a). (2). The amine of the N-methylimidazole amino acid 
building block (20) can also react with carbodiimides and from a guanylidine moiety (in 
Figure 2.8-2b). The guanylidine moiety has been identified by MS.  
 
 
a b 
Figure 2.8-2 By-products of carbodiimide-mediated peptide couplings 
Thus, uranium reagents [170,171,172] (for example, HBTU, HATU) were used in my work. These 
reagents were added in equal molar amounts to the carboxylic acid component of the coupling 
reaction. The activation time should be over 5 minutes, because HBTU and HATU can also 
react with the unprotected N-terminus of the peptide to form a guanylidine moiety that blocks 
further elongation of the peptide. 
Figure 2.9 described the synthesis of the triimidazole spacer (27). The monoimidazole 
intermediate (21) was obtained from the N-protected N-methylimidazole amino acid building 
block (20) by coupling with the β-Alanine methyl ester hydrochloride. For the elongation of 
the spacer, it consists of two cycles of Boc deprotection (with TFA), followed by 
HBTU/DIEA coupling with (20). (23) was then equipped with the succinic acid monobenzyl 
ester (24). Final removes of the Cbz ester (by H2/Pd) and the methyl ester (by base hydrolysis) 
gave the triimidazole spacer (27) with the end of α,ω-dicarboxylic acids.
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Figure 2.9 Synthesis of the triimidazole spacer (27) 
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Unfortunately, an intramolecular reaction was encountered during the attempted coupling of 
the carboxylic acid of linker (26) with the monoamine of (7) (Figure 2.10).  
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Figure 2.10  The intramolecular reaction of the spacer (27) 
 
This intramolecular reaction originates from the proton of the amide (the color of this proton 
is red in figure 2.10 and figure 2.11). The nitrogen connects to a carbonyl group and an 
imidazole ring, both of which belong to electron withdrawing groups. They can decrease the 
electron density of the nitrogen. The proton connected to the nitrogen is acidic. A proposed 
mechanism is shown in Figure 2.11. Nucleophilic attack of the carboxylate (26) results in an 
O-acyluronium species (26a) that is further transformed into the HOBt active ester (26b) in 
the presence of HOBt. With the help of the base (DIEA), the nucleophilic attack from the 
electrons of the nitrogen to the HOBt active ester gave the pyrrolidine-2,5-dione analogue 
(28). (28) has been identified by NMR and MS.
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Figure 2.11  A proposed mechanism of the intramolecular reaction 
 
 
 
1H-NMR (300 MHz, DMSO –d6) MS (ESI-TOF, pos. MeOH) 
H-1 H-2 H-3 
[M+Na]+ [M+H]+ 
calculation found calculation found 
(26) 10.42 ppm 2.60 ppm 2.60 ppm 
C23H28N10NaO8  C23H29N10O8  
m/z 595.1984 595.2010 m/z 573.2164 573.2188 
(28) × 2.83 ppm 2.83 ppm 
C23H26N10NaO7  C23H27N10O7  
m/z 577.1878 577.1879 m/z 555.2059 555.2048 
 
 
In order to prevent the cyclization, two stratagies were carried out: 
(1). Stratagy one [160]: The β-Alanine methyl ester was not used any more. The terminal 
carboxylic acid of the N-methylimidazole amino acid building block will directly couple to 
the triBoc-protected calixarene (7). At the same time, the succinic acid linker was replaced by 
a malonic acid linker or an isophthalic acid linker (figure 2.12). Thus, another two new 
spacers (33) and (34) were synthesized.  
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Figure 2.12 Synthesis of new triimidazole spacers (33) and (34) 
The key step is the peptide bond formation between the free benzylamino group of the 
triBoc-protected calixarene (7) and the two terminal carboxylic acids of the new bridge (34). 
It was achieved by using the peptide coupling reagent HATU/DIEA (figure 2.13). There was 
no time for me to finish another coupling reaction of (7) and (33). The last reaction was the 
cleavage of all Boc groups with the treatment of TFA at ambient temperature. The final 
product (Dimer C, 40) was precipitated in chloroform to yield a white product which was 
used without further purification.  
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Figure 2.13 Synthesis of Dimer C (40) 
Compared with Dimer A and Dimer B, Dimer C displays poor solubility in water. However, 
its complex with DNA exhibits good solubility in any aqueous buffer at physiological salt 
loads. Dimer C degrades in the presence of strong acid (for example, HCl), and should be 
stored in the freezer.  
(2). Stratagy two: β-Alanine methyl ester was replaced by ethylenediamine (Figure 2.14). 
After deprotection of the Boc group, the bridge C (36) was synthesized. It contains two 
terminal amines.  
At the same time, the triBoc-protected calixarene (7) reacted with the succinic acid 
monobenzyl ester (24) and after deprotection of the Cbz group of (37), (38) provided the 
carboxyl-terminus (Figure 2.15). The new amide of (37) and (38) is a 'normal amide', because 
the nitrogen not only connects to a carbonyl group but also connects to a benzal group which 
is an electron donating group. But, I did not have time to carry out the last two steps.  
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Figure 2.14 Synthesis of  
          Bridge C (36) 
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(3). Stratagy three: This stratagy has been designed, but has not been carried out. All 
amide-NH groups of (25) will be protected to give (25a). In fact, the protection of amide-NH 
groups was received little attention at the beginning in this project. There are several 
protecting groups for the amide-NH [173], for example, N-t-butylamide [174] (t-Bu-NRCO-, 
which is cleaved with acid), N-pyrrolidinomethylamide [175] (which is cleaved with the 
mixture of MeOH with 1% HCl or with MeOH:THF=1:9), N-t-butyldimethylsilylamide [176] 
(TBDMS- NRCO-, which is cleaved with MeSNa and THF) and so on. In all, these protecting 
groups should be introduced mildly, and should be stable in base condition (because NaOH 
will be used to remove Cbz and methyl groups of (25b)), and should be deprotected by acid, 
which is the same as the deprotection of Boc groups of (25c). 
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3. Methodology 
When investigating the properties of new DNA binding molecules, one initial goal is to 
establish their modes of binding to DNA. Until now, several methods have been used for an 
assessment of DNA-binding modes [177,178,179,180,181]. Among of these, there are two absolute 
methods: X-ray diffraction of crystals and NMR spectroscopy. Unfortunately, for my Ph.D. 
work, crystallization itself was a problem. Furthermore, the conformations of DNA or the 
ligand-DNA complex in aqueous solutions and crystals are different. NMR spectroscopy 
needs a large amount of material, high concentrations, long accumulation time, a single 
discrete structure, and a short DNA molecule [ 182 , 183 , 184 ]. However, in my work, the 
concentration of the DNA-dimer complex was too low (< 0.05 mM) in any aqueous buffer 
solution, the dimer aggregated itself at room temperature, and short DNA molecules have 
dangling ends that limit the stability of hybridization. In the absence of such high resolution 
data, the mode of binding must be inferred from the results of binding assays. Thus, a number 
of other methods were deployed to investigate their mode of binding to DNA, for example, 
ethidium bromide displacement assays, circular dichroism measurements, DAPI displacement 
assays, fluorescence titrations, isothermal titration calorimetry (ITC), the assessment of 
thermal denaturation of DNA, triple helix-forming oligonucleotide displacement assays and 
so on.  
3.1 Ethidium Bromide Displacement Assay 
Ethidium bromide (abbreviated as ‘EtBr’) is an intercalating agent which contains an 
extended electron deficient planar aromatic ring system. It resembles a DNA base pair. Due to 
its unique structure, it can nondestructively intercalate into DNA double strands and become 
the sandwiching between two adjacent base pairs [185] (Figure 3.1). 
Upon binding, it extends and unwinds the deoxyribose–phosphate backbone, and then is 
stabilized by π– π stacking interactions with the planar aromatic bases, and lies in a plane 
perpendicular to the helix axis. In addition, the binding process is nondestructive and fully 
reversible. The DNA duplex structure is not destroyed by the process of its removal [186].  
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Figure 3.1 The structure of ethidium bromide and its intercalating into DNA strands [185] 
When exposed to ultraviolet light, ethidium bromide will fluoresce with an orange color. In 
addition, it displays a striking fluorescence enhancement (almost 20-fold) after binding to 
DNA. It is generally agreed that the hydrophobic environment between the base pairs is 
responsible for the strong fluorescence enhancement. Proton transfer from the excited singlet 
state of EtBr to polar solvents (for example, water) is the process primarily responsible for the 
low fluorescence yield. If EtBr intercalates into two adjacent basepairs (a hydrophobic 
environment) of a DNA double helix, it must shed water molecules that were associated with 
it, and be far away from the solvent. Without water, which is a highly efficient fluorescent 
quencher, a large increase in fluorescence is observed [187]. The ethidium bromide – DNA 
complex can be detected by using excitation spectrum peaks at 300 nm or 520 nm and the 
emission peak at 600 nm. 
Measurement of the ability of a drug to displace EtBr from DNA to solvent is established as a 
valid measurement of DNA binding ability for both intercalative and non-intercalative drugs. 
DNA molecules are treated with EtBr, yielding a fluorescence increase upon binding. 
Addition of a DNA binding compound results in decrease in fluorescence due to displacement 
of the bound intercalator, where the percent fluorescence decrease is directly related to the 
extent of binding. EtBr possesses relatively little sequence preference [188], although it 
displays a slight bias toward binding G:C-rich DNA tracts. The assay offers a qualitative 
comparison of binding affinities within a series of compounds with similar structures. It 
provides an indirect method of measuring the binding affinity (relative binding affinities) and 
stoichiometry of drugs. It also provides an indirect method of defining a compound’s 
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sequence selectivity. Please Note: it can not provide a direct measure of the binding constant 
[189]. On the one hand, the binding constant of EtBr to DNA is dependent on the molecular 
flexibility. DNA condensation might be expected to lower the affinity of EtBr for DNA. On 
the other hand, some molecules replace EtBr to solvent in the manner of a noncompetitive 
mode (in other word, binding to somewhere else also leads to displacing EtBr). For example, 
the binding of polyamines above a critical concentration induced DNA bending, which caused 
conformational changes of the double helix. The changes of the conformation facilitated the 
release of bound EtBr to solvent [190]. So it is important to ensure that binding takes place 
exclusively at intercalation sites if the assay is used for determine binding constants. 
There are two binding sites for EtBr [63]: the primary site is intercalation between base pairs, 
and the secondary site is electrostatic interactions between the cationic EtBr and the anionic 
phosphate groups on the DNA surface. The secondary binding mode is most evident at low 
salt concentrations (below 10 mM) and high dye concentrations. The absorption spectrum is 
the same as that obtained on binding in the intercalation sites of DNA. 
Base on the facts mentioned above, the assay was designed in this work [120]: 
(1). The direct excitation of EtBr was at 546 nm and the emission was at 590 nm, because 
there was no absorbance or fluorescence for our calixarenes at the critical wavelengths. 
(2). Na+ was used to stabilize the intercalative architecture (the DNA–EtBr complex). There 
were three different aqueous buffer solutions in my work: (a). 2 mM of HEPES, and 9.4 mM 
of NaCl. The pH was adjusted to 7.1 with NaOH. (b). 2 mM of HEPES, and 150 mM of NaCl. 
pH = 7.1. (3). 20 mM sodium phosphate. pH = 7.0.  
(3). EtBr was added to DNA to provide 1.26 eq. per base pair. 
(4). Because of rapidly equilibrating, after stirring for 5 min and standing for 1 min the 
fluorescence was measured. 
This assay provided very useful information in my work: (1). Whether the EtBr-displacing 
ligands can access to intercalation sites. (2). Whether the EtBr-displacing ligands bind the 
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intercalation sites with high affinities.  
The shortcomings of the assay should also be paid attention. (1). The calixarenes are too large 
to be the intercalators to replace EtBr in a competitive mode. (2). The calixarenes may change 
the conformation of the double helix (This can be proved by CD measurements. See below) to 
make bound EtBr release to solvent. Therefore, the assay does not provide a direct measure of 
binding constants. 
C50 values and CE50 values were used to evaluate displacement capacity [120]. They were also 
indirectly proportional to the apparent binding constant of the DNA ligands. 
The C50 value is the ligand concentration required for 50% displacement of the ethidium 
bromide, i.e. for 50% fluorescence reduction. 
The CE value (charge excess ratio of an EtBr-displacing ligand) was calculated as a ratio of 
positive charges in an EtBr-displacing ligand versus negative charges of DNA in the 
respective complex mixture.   
The CE50 value is the CE at 50% of the original fluorescence emission intensity gained by 
intercalated ethidium bromide.  
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3.2 Circular Dichroism Spectroscopy 
Linear polarized light can be viewed as a superposition of left circularly polarized light (LCP) 
and right circularly polarized light (RCP) with equal amplitude and phase [191]. A projection of 
any polarized light perpendicular to the propagation direction yields circularity and the 
projection of the combined amplitudes perpendicular to the propagation direction yields a line. 
When this linear polarized light passes through an optically active sample, the speed (cL ≠ cR), 
the wavelength (λL ≠ λR) and absorbance (ε L≠ εR) of the right and left polarizations will be 
different. Thus, the projection of the resulting amplitude yields an ellipse instead of the usual 
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line. The occurrence of ellipticity is called circular dichroism (CD). The CD is a function of 
wavelength. The value which is presented must specify the wavelength at which it is 
measured.  
For CD spectropolarimeters, ΔA is usually measured. ΔA (Delta Absorbance) is the difference 
between absorbance of left circularly polarized (LCP) and right circularly polarized (RCP) 
light: ΔA = AL - AR . According to Beer's law: ΔA = (εL - εR) Cl. εL and εR are the molar 
extinction coefficients for LCP and RCP light, C is the concentration, and l is the path length. 
By definition, Δε = εL - εR. Thus, ΔA = ΔεCl 
However, for CD spectropolarimeters, the value is usually reported in the form of molar 
ellipticity [θ] (instead of ΔA), which is defined by tan θ = (ER – EL) / (ER + EL). ER and EL are 
the magnitudes of the electric field vectors of the right-circularly and left-circularly polarized 
light. After data processing, the formula can be expresed in this way: θ = 3298.2 Δε.  (Δε is 
the function of ΔA, which is measured by the CD instrument.) 
Compared with traditional optical rotatory dispersion (ORD) where the phase relationship 
between the circularly polarised wave changes and the resultant linearly polarised wave 
rotates, the polarization direction of CD does not change. Optical rotation and circular 
dichroism stem from the same quantum mechanical phenomena and one can be derived 
mathematically from the other by Kronig-Kramers transformation, but, CD is only observed 
at wavelengths where absorbances of light or light components of circularly polarized light 
are not zero, i.e. in or near the UV absorption bands of the molecule of interest, while ORD 
can be measured far from these bands. This is the advantage of CD. It makes CD clearly 
distinguish structural elements because their recorded bands (CD bands) also have UV 
absoption and do not overlap extensively at particular wavelengths with non-UV absoption 
function groups. In fact, this is also the fundamental for CD of nucleic acids. 
Nucleic acid contains sugar-phosphate backbones and unsaturatesed benzenelike bases. Both 
phosphate groups and sugars have electronic transitions at high energy, and the wavelengths 
are shorter than 190 nm. The base contains π electrons, and a large number of π- π* transitions 
(with high intensity) and n- π* transitions (with low intesity) can be detected by ultraviolet 
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light and the wavelengths are within 180-300 nm range. The bases themselves have a plane of 
symmetry, so they have no optical activity. But the sugars are asymmetric and they can induce 
a CD in the absoption bands of the chromophoric bases. Therefore, this technique is often 
used to investigate the changes of nucleic acid secondary structures [192]. 
Because the theoretical description of CD spectra of DNA is very complex, CD is not able to 
provide structure information on the molecules at the atomic level. However, according to 
previous reports, we can find some valuable conclusions, which were directly used in my 
work [192,193,194]:  
(1). The typical B-form has a positive band centered near 275 nm, a negative band centered 
near 240 nm, and a crossover around 258 nm which is the wavelength maximum for the 
normal absorption. 
(2). The A-form has a more intense positive CD in the long-wavelength region, and a 
reasonably intense negative at 210 nm. 
(3). (dG + dC) rich DNA fragments exhibit A-form features in aqueous solutions. 
(4). As (dA + dT) content increases, the negative band becomes deeper and conformational 
variability increases.  
(5). CD spectra not only depend on the secondary structures, but also depend on the 
sequences of nucleic acids. 
(6). High concentrations of methanol induce the 10.2 basepairs per turn B-form, but high 
concentrations of ethanol induce the A-form for sodium salts of DNA.  
In fact, CD spectroscopy is largely used empirically in studies of DNA. It exhibits several 
special advantages in my work: 
(1). The concentrations of DNA samples can be very low (about 5 – 20 μM in terms of 
basepairs). This is advantageous in studies of calixarene – DNA samples of low solubility. 
(2). Polynucleotides can be studied by CD spectroscopy.  
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3.3 DAPI Displacement Assay  
4',6-diamidino-2-phenylindole (abbreviated as ‘DAPI’) is a blue fluorescent probe, which 
appears to associate with 3-4 nearest-neighbor A:T base pairs in the minor groove of double 
stranded DNA (Figure 3.2). Due to the displacement of water molecules from both DAPI and 
the minor groove, the fluorescence of the DAPI-DNA complex is approximately 20-fold 
greater than in the unbound state. When bound to double stranded DNA, DAPI has an 
absorption maximum at the wavelength of 358 nm and the emission maximum is at 461 nm. 
DAPI as an intercalator also binds RNA, but the fluorescence enhancement is not so strong, 
and the emission of the DAPI-RNA complex shifts to around 500 nm [195,196,197,198]. 
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Figure 3.2 The structure of DAPI and stereoview of the d(GGCCAATTGG)-DAPI structure [199] 
When DAPI binds AT-rich sequences, the conformation of the AT sequence is changed into 
stiffer B-form DNA. DAPI is edgewise inserted into the minor groove at an angle of 
approximately 45° to the helix axis [200]. DAPI itself is not chiral but acquires an induced 
circular dichroism (ICD) upon chiral perturbation through binding to the chiral DNA helix. 
The mechanism behind the induced CD is not clear in detail but it is believed to be primarily 
due to the effect of nondegenerate coupling between transitions of DAPI and transitions of the 
bases of the nucleic acid host. 
According to the facts mentioned above, another two assays were designed. The two assays 
are based on the changes in the fluorescence [201] and the changes in CD upon DAPI- 
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displacing ligand binding. The binding of the DAPI-displacing ligand to the DAPI-poly 
(dAdT) complex results in displacement of the bound DAPI, producing a decrease in the 
observed fluorescence or CD (molar ellipticity). The percent fluorescence or CD (molar 
ellipticity) decrease is directly related to the extent of binding.  
But, not only minor groove binders, but also major groove binders, intercalators, or even 
phosphate backbone binders can drive bound DAPI to solvent. All these binders can displace 
DAPI and decrease fluorescence emission of DAPI-poly(dAdT). In order to avoid the 
shortcomings, we planed to use CD to perform DAPI displacement assays. Compared with 
fluorescence techniques, circular dichroism can provide more specific information: 
(1). Because the ICD at 370 nm comes from DAPI (the UV absorption band in this region 
comes from DAPI), the value of molar ellipticity in this region indicates whether DAPI 
remains to bind DNA (Figure 3.2B). (2). For DAPI-poly(dAdT) complex, the CD band at 265 
nm is the sum of CD (DNA) and ICD of DAPI (Both DNA and DAPI have UV absorption 
bands in this region). The changes of CD at 265 nm not only describe whether DAPI remains 
to bind DNA, but also illustrate the conformational changes of DNA. The conformational 
changes of DNA are related to the binding between the DAPI-displacing ligand and the 
DAPI-poly(dAdT) complex. (3). The CD measurement records both CD and UV data at the 
same time. Therefore, it provides more information about the interaction of the DAPI- 
displacing ligands (calixarenes) and the DAPI–poly (dAdT) complex. 
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Figure 3.2B UV and CD spectra of DAPI, DNA and the complex 
In this work, CD spectropolarimeters were used to perform DAPI displacement assays. 
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3.4 Fluorescence Titration Experiments 
Fluorescence titration experiments have been developed to measure the association constants 
(Ka) of guests and hosts. In order to determine the binding constants, the following three tasks 
have to be carried out: (1). the titration of one binding partner into the other at specified 
concentration ranges to get a fluorescence titration curve. In this study, the fluorescence 
titration curve is a plot of the concentration ratio of calixarenes and nucleic acids with 
fluorophores vs. the changes of the fluorescence intensity obtained from fluorescence titration 
experiments. (2). the determination of the stoichiometry. (3). non-linear regression techniques 
for calculating Ka (1 : 1 complex stoichiometry). 
 
3.4.1 The Definition of Binding Constants 
According to the definition of thermodynamics (1) and Gibbs free energy (2) [202], binding 
constants can be described in equation (3): the van’t Hoff equation. 
ΔG = - RT ln K     (1) 
ΔG = ΔH – TΔS     (2) 
R
ΔS
T
1
R
 ΔHKln +•−=    (3) 
Our analysis to determine binding constants is based on the simple binding equilibrium model: 
equation (4) [203]  
a • H + b • G  C        (4) 
Definitions:   
(a). the association equilibrium constant: Ka, equation (5).  
Association equilibrium constants, binding constants, and stability constants are synonymous 
with each other. 
(b). the dissociation equilibrium constant: Kd, equation (6) 
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baa [G][H]
[C]K •=  
(5) H: the host; G: the guest; C: the complex 
[C]
[G][H]K
ba
d
•=
 
(6) a, b: stoichiometry 
a
d K
1K =
 
(7) [H], [G], [C]: concentrations of the host, the guest, and             the complex respectively at the final stage 
Equation (10) is derived from equations (5)–(9). 
[H]o = [H] + a • [C]  (8) [H]o: the total concentration of the host molecule at the initial state 
[G]o = [G] + b • [C]  (9) [G]o: the total concentration of the guest molecule at the initial stage 
b
0
a
0
a [C])b([G][C])a([H]
[C]K ⋅−⋅⋅−=   (10) 
Ka, a, b are unknown, [H]o and [G]o can be set up as experimental conditions, and [C] is 
related to the changes of fluorescence intensity. In order to calculate the binding constants, 
determination of stoichiometry (namely, a and b) has to be carried out. 
 
3.4.2 The Determination of Stoichiometry 
The Continuous Variation Method is adopted to determine the stoichiometry. The 
stoichiometry [a / (a + b)] is obtained from the x-coordinate at the maximum in Job’s curve, 
where the y-axis is [C] and the x-axis is: 
x = 
00
0
[G][H]
[H]
+  
For example, when 1 : 1 complexation is predominant at equilibrium, the maximum appears x 
= 0.5 (a = b = 1). In the case of 1 : 2 complexation x = 0.333 gives the maximum. 
Because the concentration of the complex ([C]) could not be measured directly, the [C] 
(y-axis) would be replaced with a property proportional to [C]. For fluorescence titration 
experiments, [C] is related to the changes of fluorescence intensity, and could be replaced by 
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the following equation: 
y =
00
0
[G][H]
[H]
+ • Δ fluorescence intensity 
For DNA experiments, a is equal to 1, and b is always integer larger than or equal to 1. 
3.4.3 Calculation 
In order to simplify the calculation, the association equilibrium constant was calculated by 
non-linear regression methods by a Sigma-Plot program for the host : guest = 1 : 1 
complexation (equation 11) 
H + G  C        (11) 
The problem is a = 1, but a ≠ b, b > 1 (equation 12) 
H + b • G  C        (12) 
Therefore, we have to think about the way to set up the experimental conditions to fulfil the 
requirement of 1 : 1 complex stoichiometry.  
We increase the concentration of [H]o b times, and get the new equation (13).  
Please note: H’ replaces H. The new equation is 1 : 1 binding mode [204]. 
     b • H’ + b • G  C        (13) 
After calculation [205], we get the binding constant. In this way, each guest molecule binds the 
host molecule with the same binding affinity, Ka1 = Ka2 = Ka3 = •••••• = Kab. 
 
If Ka1 ≠ Ka2 ≠ Ka3 ≠ •••••• ≠ Kab, 
b
KKKK
K aba3a2a1a
+⋅⋅⋅⋅⋅⋅+++=  
That is why sometimes non-linear regression methods 
of 1 : 1 stoichiometry gave increased error values. 
In several cases, the 1 : 2 or 2 : 1 complex was evaluated by a WinEQNMR program, where 
we can get a better fitting than the corrected 1 : 1 case and we can also get a better 
understanding about the binding events.  
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For example: DNA: (dGdC)10-(dGdC)10 ligand: Dimer C 
 CFl-DNA: 1.0×10-6M Cligand: 1.0×10-3M 
 Buffer: 2 mM of HEPES and 150 mM NaCl in water. pH=7.10  
   
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
Cligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1,00E-06 0,00E+00 0,00 941,984 0,000 
1 501 1,00E-06 2,00E-06 2,00 888,886 53,098 
2 502 1,00E-06 3,98E-06 3,98 829,280 112,704 
3 503 1,00E-06 5,96E-06 5,96 773,019 168,965 
5 505 1,00E-06 9,90E-06 9,90 680,197 261,787 
7,5 507,5 1,00E-06 1,48E-05 14,78 569,613 372,371 
10 510 1,00E-06 1,96E-05 19,61 469,962 472,022 
12,5 512,5 1,00E-06 2,44E-05 24,39 402,901 539,083 
15 515 1,00E-06 2,91E-05 29,13 350,799 591,185 
17,5 517,5 1,00E-06 3,38E-05 33,82 321,183 620,801 
20 520 1,00E-06 3,85E-05 38,46 303,755 638,229 
22,5 522,5 1,00E-06 4,31E-05 43,06 292,366 649,618 
25 525 1,00E-06 4,76E-05 47,62 284,672 657,312 
27,5 527,5 1,00E-06 5,21E-05 52,13 280,287 661,697 
30 530 1,00E-06 5,66E-05 56,60 275,396 666,588 
After fluorescence titrations, we got fluorescence quenching and resulting titration curves (in 
Figure 6.1a). And then, [DNA]total, [ligand]total and relative emission differences can be 
calculated. The Continuous Variation Method was used to determine the stoichiometry (in 
Figure 6.1b). In Figure 6.1b,   
x = 
totaltotal
total
[ligand][DNA]
[DNA]
+  and   y = totaltotal
total
[ligand][DNA]
[DNA]
+ • Δ fluorescence intensity 
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a. Fluorescence quenching curves b. Job’s plot for complexation of DNA and Dimer C 
Figure 6.1  
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In Figure 6.1b, when x = 0.05, y = [C]max. It indicated that the binding mode was not 1 : 1 
complexation. [DNA]total was then multiplied with a virtual correction factor, until the 
Job-Plot showed a 1 : 1 complex stoichiometry, i.e. x = 0.5, y = [C]max (in Figure 6.2a). Herein, 
the virtual correction factor was equal to 24. Thus, the stoichiometry was 24:1. 
Addition 
ligand 
(μL) 
Total 
volume 
(mL) 
CFl-DNA 
(mol/L) 
Cligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 24×1,00E-06 0,00E+00 0,00 941,984 0,000 
1 501 24×1,00E-06 2,00E-06 0,08 888,886 53,098 
2 502 24×1,00E-06 3,98E-06 0,16 829,280 112,704 
3 503 24×1,00E-06 5,96E-06 0,24 773,019 168,965 
5 505 24×1,00E-06 9,90E-06 0,41 680,197 261,787 
7,5 507,5 24×1,00E-06 1,48E-05 0,61 569,613 372,371 
10 510 24×1,00E-06 1,96E-05 0,80 469,962 472,022 
12,5 512,5 24×1,00E-06 2,44E-05 1,00 402,901 539,083 
15 515 24×1,00E-06 2,91E-05 1,19 350,799 591,185 
17,5 517,5 24×1,00E-06 3,38E-05 1,39 321,183 620,801 
20 520 24×1,00E-06 3,85E-05 1,58 303,755 638,229 
22,5 522,5 24×1,00E-06 4,31E-05 1,77 292,366 649,618 
25 525 24×1,00E-06 4,76E-05 1,95 284,672 657,312 
27,5 527,5 24×1,00E-06 5,21E-05 2,14 280,287 661,697 
30 530 24×1,00E-06 5,66E-05 2,32 275,396 666,588 
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a. Modified Job’s plot for complexation of 
DNA and Dimer C by fluorescence titrations 
b The graphical representation of 
the titration curve 
Figure 6.2 
The binding constant was calculated with the corrected concentrations of [DNA]total by 
non-linear regression methods by a Sigma-Plot program for the host : guest = 1 : 1 
complexation. After calculation, the values of Ka, statistical errors and calculated relative 
emission differences were provided. We could compare the calculated values with the original 
values (relative emission differences) to evaluate the effect of the calculation (in Figure 6.2b). 
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3.4.4 Fluorescence Titration Curves and Binding Constants 
Fluorescence titration curves [206] themselves can be used to evaluate the binding constants, 
because dissociation was shown in the neighborhood of the stoichiometric point. If the 
binding constant is high (the red curve in Figure 3.3), there will be no appreciable dissociation 
of the complex at or near the stoichiometric point. If the complex is moderately stable (the 
green curve and the orange curve in Figure 3.3), the plot consists of two straight-line portions 
with a central curved portion. If the binding constant is low, a large excess of ligands have to 
be used to drive the binding to completion, and there is no detectable break in the curve, from 
which to obtain the stoichiometry (the blue curves in Figure 3.3). 
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Figure 3.3 Fluorescence titration curves reflect the stability of the complex 
                    in the neighborhood of the stoichiometric point 
In my work, fluorescence titration experiments have been used to measure the binding 
constants (affinity) between nucleic acids and calixarenes. The affinity includes three parts: 
electrostatic interactions, hydrophobic interactions and hydrogen bond interactions. The 
electrostatic interaction between DNA phosphate groups and the amino groups of calixarenes 
enhances the affinity but not the specificity of the binding. The specificity of the binding is 
determined by the non-electrostatic interaction, i.e. the hydrogen bond interactions between 
amino groups of calixarenes and DNA base pairs. In other word, high specificity does not 
demand high affinity [207]. In order to investigate the specificity of the binding, buffers with 
high concentration NaCl (150 mM) were used to decrease the electrostatic interactions. 
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Fluorescence titration experiments, ethidium bromide displacement assays, and CD 
measurements complement each other in my work. The fluorescence titration experiment was 
performed to determine the binding constants between calixarenes and DNA (the binding sites 
include nucleobases and phosphate backbones). The ethidium bromide displacement assay 
was performed to determine the relative binding affinities between calixarenes and 
intercalation sites (the binding site is the nucleobases). The CD experiment was performed to 
observe the conformational changes of the phosphate backbone (between 260nm and 300 nm). 
The binding site is phosphate backbones. The calixarene dimer sometimes showed similar 
affinities for different nucleic acids (measured by fluorescence titration experiments), but 
exhibited different EtBr displacement capacities, and induced different conformational 
changes of the phosphate backbones. These methods were combined together to infer DNA 
binding modes. 
 
 
3.5  Isothermal Titration Calorimetry 
When guest molecules bind nucleic acids, heat (ΔH) is either generated or absorbed, which 
can be measured directly by isothermal titration calorimetry (ITC) during the biomolecular 
binding event. The measurement of heat allows accurate determinations of binding constants 
(Ka), reaction stoichiometry (n), enthalpy (∆H) and entropy (ΔS), thereby providing a 
complete thermodynamic profile of molecular interactions in a single experiment (in Figure 
3.5b).   
In the view of energetic profiles of protein–DNA systems, the research from Peter L. Privalov 
[95] proved that: (1). There are no dramatic differences in the Gibbs free energies of protein 
binding to the major and minor grooves of DNA (the top panel of the Figure 3.4a). (2). The 
enthalpies of binding to minor grooves are always positive, but the enthalpies of binding to 
major grooves are invariably negative (the middle panel of the Figure 3.4a) (3). Because the 
Gibbs free energies of binding at 20 °C are similar, the enthalpy differences are essentially 
balanced by entropic factors. The entropic contribution (i.e. TΔS) of minor groove binding is 
significantly larger than that of major groove binding (the bottom panel of the Figure 3.4a).  
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(b). Display of primary (blue) 
and secondary (yellow) layers of 
the spine of water in the minor 
groove of the X-ray 
crystallography of dodecamer 
d(CGCGAATTCGCG) 
(a). The thermodynamic parameters of association for 
various DBDs to major and minor grooves of DNA. 
 
Figure 3.4 The different energetic profiles of minor groove binders  
and major groove binders [93,94,95] 
Therefore, association with major grooves is primarily an enthalpy driven process, whereas 
binding to minor grooves is characterized by an unfavorable enthalpy that is compensated by 
favorable entropic contributions. These results mentioned above can be explained by the fact 
that the water hydrating in the minor groove of A:T-rich DNA is more ordered than the water 
hydrating in the major groove (Figure 3.4b). The removal of water results in a substantial 
positive contribution to the binding entropy. The removal of water hydrating in minor grooves 
is expected to require a greater enthalpy and thereby provide a larger entropy increase than 
removal of water hydrating in major grooves. 
In contrast, the binding of intercalators is typically an enthalpy driven process [208]. For 
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intercalation, the DNA must undergo reorganization to accommodate a more rigid architecture, 
which is entropically less favourable. The entropic penalty must be overcome by enthalpy 
values (arising in part from van der Waals stacking interactions between the base pairs and the 
intercalated chromophores). Therefore, intercalators have large negative enthalpy, and near 
zero, or even large positive values for the –TΔS (in Figure 3.5a). 
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a. The enthalpic and entropic contributions to DNA 
binding for groove binders and intercalators 
b. The top panel shows the primary 
titration data, and the lower panel shows 
the binding isotherm constructed from 
the primary data. 
 
Figure 3.5 The different energetic profiles of groove binders and intercalators [208] 
 
 
3.6 The Assessment of Thermal Denaturation of DNA 
DNA denaturation, also called DNA melting, refers to the melting of the double stranded 
DNA to generate two single strands, through the breaking of hydrogen bonding between the 
bases in the duplex. This process can be monitored experimentally by observing the 
absorption of ultraviolet light at 260 nm, where the bases absorb light. As DNA is heated and 
the strands separate, the amount of light absorbed increases until all of the DNA is melted. 
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This is called the hypochromic effect. Under a given set of conditions, there is a midpoint of 
the melting curve, which is called melting temperature. The melting temperature or the 
melting point (Tm) is defined as the temperature at which half of the DNA strands are in the 
double-helical state and half are in the random coil state (Figure 3.6, left). The Tm value of a 
given piece of DNA depends on several factors, for example, the length of the DNA sequence 
(shorter pieces of DNA will tend to melt more easily than longer pieces), the base 
composition of the DNA (as G:C base pairs have three hydrogen bonds and A:T base pairs 
only have two, the higher is the percentage of G:C base pairs, the higher is the melting point 
of a DNA molecule), the topological condition of the DNA, and the composition of the buffer 
(Na+ and K+ can stablize the duplex) and so on. The difference between the Tm of a nucleic 
acid and the Tm observed in the presence of a drug is termed ΔTm.  
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Figure 3.6 The melting curve of a nucleic acid (left) and 
 the effects of drugs on melting curves (right) 
 
Melting curves can provide binding information [209,210,211]: 
(1). The change in absorbance, termed hyperchromicity, is a physical property. An apparent 
decrease of hyperchromicity means a substantial fraction of the DNA was already dissociated 
into single strands prior to heating. 
(2). ΔTm is related to the affinity of binding of a drug to a nucleic acid. The increase of Tm 
indicates that the drug binds to the double strands with higher affinity than to the single 
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strands. If the drug binds to the single strands stronger than the double strands, Tm decreases.             
(3). The change of the shape of a melting curve also indicates the interaction between the drug 
and the nucleic acid. For example, an increase in the breadth of the transition in the presence 
of drugs indicates the stronger binding of the drug to one specific region than other regions of 
nucleic acids (in Figure 3.6, right, curve b; curve a is a normal melting curve). 
(4). Most of intercalators and groove binders can stabilize the double-stranded DNA better 
than the single-stranded DNA. Tm values increase. 
 
 
3.7 Triple Helix-Forming Oligonucleotide Displacement Assay 
An oligonucleotide can bind as a third strand of DNA in a sequence specific manner in the 
major groove in polypurine-polypyrimidine stretches in duplex DNA [212]. There are two basic 
mannars. The first, a polypyrimidine oligonucleotide binds in a direction parallel to the purine 
strand in the duplex. The second, a polypurine strand binds anti-parallel to the purine strand. 
In all cases, the third strand binds in the major groove and recognizes the purine strand by 
establishing a pair of hydrogen bonds with the hydrogen bond donor and acceptor groups 
available on the major groove edge of purine bases (Figure 1.3b). Different base triplets can 
form through either Hoogsteen or reverse Hoogsteen hydrogen bond formation. Beside 
nucleotides, peptide nucleic acids (PNA), which is a mimic of nucleic acids where the natural 
sugar phosphate backbone has been replaced by achiral N-(2-aminoethyl) glycine units, also 
bind DNA on the major groove side [17,18]. In this thesis, triple helix-forming oligonucleotides 
(TFOs) specifically refer to nucleic acids. 
Because the third strand of a triple helical DNA binds in the major groove, triple 
helix-forming oligonucleotide displacement assays have been designed to infer the DNA 
binding mode.  
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For example: 
(1). The CD studies from Seog K. Kim [213] showed that the third strand in the triplex inhibited 
the formation of the TMPyP – double stranded DNA. Therefore, TMPyP stacking occured in 
the major groove of both the d(A)12-d(T)12 and the d(G)12-d(C)12 duplexes. [TMPyP: 
meso-tetrakis(N-methylpyridium-4-yl)porphyrin] 
(2). The melting curve studies from Dev P. Arya [119,214] showed that triplex melting was not 
observed for poly(dA)-2poly(dT) in the presence of the neomycin-Hoechst 33258 conjugate. 
This result suggested that the drug binding prevents the third strand polypyrimidine from 
binding in the major groove, and therefore indicated the major groove recognition of the 
neomycin-Hoechst 33258 conjugate. 
(3). The linear dichroism studies from Bengt Nordén [117] showed that methyl green was found 
to be excluded from binding to the triple helical poly(dA)-2poly(dT) in which the major 
groove was filled by the third strand. Therefore, methyl green thus appeared to be a DNA 
major groove binding drug. 
 73
4. Results and Discussion 
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Structures of dimeric and monomeric calixarenes which were studied in this work 
 
 
4.1 The Mechanism of DNA Binding by Dimeric Calixarenes 
It was observed that in DMSO-d6 and MeOD-d4 all the calixarene characteristic signals 
(Dimer A, Dimer B, Monomer A and Monomer B) of NMR spectra were sharp at room 
temperature; but in D2O the signals of Dimer A and Dimer B were much broader (Figure 4.1 a, 
c). As temperature increased, the signals of Dimer A and Dimer B became sharper and sharper 
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in D2O. These clearly showed a dynamic effect, and indicated that the two molecules (Dimer 
A and Dimer B) formed self-aggregations. Compared with the two dimers, monomers did not 
show self aggregations (the NMR signals of Monomer A and Monomer B in D2O were the 
same sharp as in DMSO-d6 and MeOD-d4, Figure 4.1 b, d). 
In my opinion, the aggregation (Dimer A and Dimer B) should be due to the amphiphilic 
nature of the calixarenes. In addition, it is probably related to intramolecular reorganizations, 
because dimers may use internal dynamics to arrange the two monomer subunits to form a 
specific shape (for example, a tightly packed ball) through noncovalent interactions, which 
could minimize the free energy. This characteristic makes the properties of dimers (Dimer A 
and Dimer B) different from the properties of monomers (Monomer A and Monomer B). 
Because of the amphiphilic property of the calixarenes, it would also be necessary to check 
whether these calixarenes were in the form of vesicles at lower concentrations, which were 
used for binding assays. Results: the UV/VIS absorbency values of studied compounds in 
aqueous buffer solutions were proportional to their concentrations up to 20 μM, while for the 
two dimers, deviations from a linear dependence between absorbance and the solution 
concentration were observed at higher concentrations. Therefore, there were no vesicles at 
low concentrations at room temperature. Temperature increase didn’t influence UV-vis spectra 
significantly until 50°C, however at higher temperatures all spectra changed, probably 
because of the formation of precipitations. 
Table 4.1. UV-Vis molar absorption coefficients of compounds at 20°C, pH=7.0 a 
 
 λmax  (nm) ε (× 10
3) 
(mmol-1 cm2) 
Dimer A 276 14.1 
Monomer A 276 6.5 
Dimer B 276 26.1 
Monomer B 276 13.1 
a The buffer solution contained 20 mM sodium phosphate. The pH was adjusted to 7.00. 
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T = 2 7 8 k
T = 2 8 8 K
T = 2 9 8 K
T = 3 0 3 K
T = 3 1 3 K
T = 3 2 3 K
T = 3 3 3 K
0.01.02.03.04.05.06.07.0
T = 3 4 3 K
 
Figure 4.1a. 1 H-NMR spectra of Dimer A with different temperatures (500 MHz, D2O) 
 
 
T = 298K
T = 313K
 
1.02.03.04.05.06.07.0
T = 333K
 
 
Figure 4.1b. 1 H-NMR spectra of Monomer A with different temperatures (500 MHz, D2O) 
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T = 2 9 8 K
 
T = 3 0 3 K
 
T = 3 1 3 K
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Figure 4.1c. 1 H-NMR spectra of Dimer B with different temperatures (500 MHz, D2O) 
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Figure 4.1d. 1 H-NMR spectra of Monomer B with different temperatures (500 MHz, D2O) 
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4.1.1 DAPI Displacement Assay 
4.1.1.1 Results (Figure 4.2 a-d) 
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Figure 4.2a. DAPI Displacement of Dimer A (DA) Measured by CD Spectroscopy  
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Figure 4.2b. DAPI Displacement of Dimer B (DB) Measured by CD Spectroscopy  
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Figure 4.2c. DAPI Displacement of Monomer A (MA) Measured by CD Spectroscopy  
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Figure 4.2d. DAPI Displacement of Monomer B (MB) Measured by CD Spectroscopy  
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For figure 4.2 a-d: 
(1). The buffer solution contained 20 mM sodium phosphate. The pH was adjusted to 7.00. 
DAPI displacement assays were measured at 20°C 
(2). (i) CD signature of the poly (dAdT) – poly (dAdT) (5 μM in basepairs) (ii) the induced 
CD band at 370 nm from added DAPI (0.6 eq. = 3 μM in basepairs); (iii) negligible changes 
on addition of the stoichiometric amount of calixarenes (0.4 eq. in basepairs); (iv) rapid dye 
displacement by excess calixarenes (except for Monomer A). All calixarene equivalents were 
calculated per basepairs. 
4.1.1.2 Discussion 
The discussions were based on the following facts: 
(1). DAPI binds to the minor groove of poly (dAdT) – poly (dAdT). 
(2). The induced CD band at 370 nm comes from DAPI, and the CD bands at 265nm and 245 
nm come from DNA and DAPI. 
(3). Neither of calixarenes had CD bands over 230 nm, and therefore they could not interfere 
this assay by any means. 
(4). Compared with DAPI, calixarene dimers (Dimer A and Dimer B) and monomers 
(Monomer A and Monomer B) have higher affinities (Ka) for poly (dAdT) – poly (dAdT). The 
binding affinities have been measured by fluorescence titration experiments. 
Table 4.2 Association constants between (dAdT)10- (dAdT)10 and calixarenes / DAPI 1 
 
 Dimer A Dimer B Monomer A Monomer B DAPI 
Ka (M-1) 2 5.6 e+5 2.3 e+6 2.9 e+6 7.3 e+6 1.3 e+5 
Statistical error 24% 24% 20% 23% 8% 
Stoichiometry 3 10:1 14:1 30:1 12:1 6:1 
No. of data 4 No.2 No.5 No.8 No.11 No.13 
1. The buffer solution contained 2 mM Hepes buffer with 150 mM NaCl in water. pH = 7.1. 
2. 5.6 e+5 represents 5.6×105. 
3. Stoichiometry: [Guest] / [DNA duplex] 
4. The fluorescence titration data were provided in Chapter 6.5.  
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Discussion: 
CD experiments revealed that (1). in the beginning, stoichiometric amounts of the calixarene 
dimers were bound to the DNA-DAPI complex (Figure 4.2a iii, 4.2b iii). (2). if more than 
stoichiometric amounts of the calixarene dimers were added to the DNA-DAPI complex, the 
induced CD band declines and DAPI displacement begins (Figure 4.2a iv, 4.2b iv). This 
experiment suggests that the calixarene dimers and DAPI can simultaneously bind to poly 
(dAdT) – poly (dAdT) (Figure 4.2a iii, 4.2b iii). Because DAPI occupies the minor groove, 
the dimeric calixarenes should reside in the major groove.  
(1). For the DNA-DAPI complex, the CD band at 265 nm is the sum of CD (DNA) and ICD 
of DAPI, and the CD band at 370 nm is only ICD of DAPI. Upon addition of Dimer A, Dimer 
B and Monomer B, the CD bands at 265 nm and 245nm decreased measurably even at r=0.2 
and 0.4, but, the ICD band of DAPI at 370 nm didn’t change at all. Previous CD experiments 
of DNA with calixarenes showed a strong decrease in CD bands of poly (dAdT) – poly (dAdT) 
at 265 nm and 245nm (see below: circular dichroism measurements). Therefore, the changes 
at 265 nm and 245 nm in this assay most likely originate from the decrease of DNA bands due 
to the binding of calixarenes. There was no change at 370 nm, which pointed out that DAPI 
was not displaced. So, the assumption that Dimer A, Dimer B and Monomer B at low ratio 
bind to the major groove of poly (dAdT) – poly (dAdT) simultaneously with minor groove 
bound DAPI, could explain these results. For Monomer A, the displacement is not so obvious. 
(2). Even if we assumed that the calixarenes bound to the minor groove of DNA, they should 
replace DAPI immediately, because their affinities for poly (dAdT) – poly (dAdT) are higher 
than DAPI’s (table 4.2). But, this assumption was in contrast with the experimental results.  
(3). Excess calixarenes dimers can pull DAPI out of its minor groove via a non-competitive 
binding mode and form a complex with the dye itself: additions of Dimer A or Dimer B 
resulted in a fluorescence increase of DAPI solution , but the addition of Monomer A or 
Monomer B didn’t cause any fluorescence change of DAPI (Figure 4.2e).  
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Figure 4.2e. Fluorescence titrations of DAPI with Dimer A (DA), Dimer B (DB), 
                     Monomer A (MA) and Monomer B (MB) 
 
The buffer solution contained 20 mM sodium phosphate. The pH was adjusted to 7.00. 
 
 
 
4.1.2 Ethidium Bromide Displacement Assay 
 
4.1.2.1 Results (Figure 4.3 a-h) 
 
(1). The buffer solution contained 20 mM sodium phosphate in water. pH = 7.1  
(2). The buffer solution contained 2 mM Hepes with 9.4 mM of NaCl in water. pH = 7.1 
(3). The buffer solution contained 2 mM Hepes with 9.4 mM of NaCl in methanol/water 
   (1:1). pH = 7.1  
(4). The buffer solution contained 2 mM Hepes with 150 mM of NaCl in methanol/water 
   (1:1). pH = 7.1 
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Figure 4.3 Ethidium bromide displacement curves for different nucleic acids by calixarenes 
 83
4.1.2.2 Discussion 
1. Phosphate backbone binders exhibit high C50 and CE50 values. All calixarenes showed 
much lower C50 and CE50 values. This is the strong evidence for groove binding. 
2. The bindings of calixarenes to nucleic acids can not cause entire release of EtBr, which 
excluded intercalation. Furthermore, each curve contains two parts: efficient displacement and 
weak displacement. The second part probably means that conformational changes of 
phosphate backbones make bound EtBr release to free solvent. Therefore, phosphate anion 
recognition may exist simultaneously. 
3. It is important that, for polynucleotides, the best displacement was done with poly(dGdC) - 
poly(dGdC), followed by poly(dAdT)-poly(dAdT) and polydA-polydT, and the worst 
displacement was done on RNA (Figure 4.3a, 4.3b).  
Table 4.3. Corresponding CE50 values for complexes between dimers and different polynucleotides 
  
poly(dGdC)- 
poly(dGdC) 
poly (dAdT)- 
poly (dAdT) 
poly dA- 
poly dT poly A-polyU 
Major 
Groove 
Width(Å) 13.5 11.2 11.4 3.8 
shape smooth curve not smooth, because of the methyl group of thymine smooth curve
CE50 
Dimer A 1.5 6.3 5.8 >30 
Dimer B 1.1 5.2 6.0 18.4 
Minor 
groove 
Width(Å) 9.5 6.3 3.3 10.9 
shape 
not smooth, 
because of amino 
groups of guanine 
smooth curve smooth curve smooth curve
Table 4.3 indicated that the nucleic acid with a wide and smooth major groove showed an 
efficient displacement (lower CE50 value); the nucleic acid with a narrow and rugged major 
groove showed a weak displacement. This characteristic implies that the accessible area for 
our ligands is on the major groove side.  
4. Poly (dAdT) - poly (dAdT) and poly dA - poly dT have similar steric geometry of major 
grooves, but poly dA - poly dT contrasts itself from poly (dAdT) - poly (dAdT) in terms of a 
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very narrow minor groove. Table 4.3 indicated that the two different nucleic acids showed the 
similar CE50 values. It implies that changes in shape and width of the minor groove had no 
influence on the ligands’ displacement capacity of EtBr. Thus, the minor groove binding is 
excluded. 
 
 
4.1.3 Circular Dichroism Spectroscopy 
4.1.3.1 Results (Figure 4.4 a-d) 
4.1.3.2 Discussion 
1. Because the calixarene monomers and dimers are achiral and hence CD silent, they could 
not interfere this assay by any means. Therefore, the changes of CD spectra showed the 
binding characteristics of calixarenes and nucleic acids. 
2. In some experiments isoelliptic points were observed, strongly supporting the existance of 
only one type of complex geometry. 
3. Addition of calixarenes invariably decreased molar ellipticities at all wavelengths of CD 
bands of polynucleotides. It pointed toward the decrease in helicity and the disruption of the 
DNA/RNA double helix, i.e. the decrease in twisting between the base pair layers, the 
lengthening of the DNA itself, the stiffening of the helix, and the decrease in mass per unit 
length. 
4. It was observed that all calixarenes induced weak effects to the CD spectra (between 
260nm and 300 nm) of ds-DNA, but induced the strongest effect to the CD spectra (between 
260nm and 300 nm) of ds-RNA (poly A – poly U) (Figure 4.4 vi). Furthermore, CD maxima 
continuously shift during an RNA titration with calixarenes, and at the end the new CD 
spectrum closely resembled that of B-DNA. 
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Figure 4.4 a.  CD titration series for polynucleotides complexed by Dimer A (DA) 
The CD spectrum between 260nm and 300 nm indicates the conformational changes of the 
phosphate backbone. The spectra above imply a major groove binding mode, because a 
superb fit into DNA’s wide and shallow major groove induced a weaker effect to the 
phosphate backbone and an inaccessible binding to RNA’s narrow and deep groove induced a 
stronger effect to the phosphate backbone. The deep and narrow major groove of the RNA 
duplex must first be widened by the calixarene to accommodate the sterically demanding 
calixarene guest itself [215,216,217,218]. 
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Figure 4.4 b.  CD titration series for polynucleotides complexed by Dimer B (DB) 
 
 
5. Amino analogues (Dimer A and Monomer A) induce significantly weaker changes in CD 
spectra than guanidinium analogues (Dimer B and Monomer B). That could be correlated to 
more possible binding interactions of the latter class of compounds.  
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Figure 4.4 c.  CD titration series for polynucleotides complexed by Monomer A (MA) 
 
6. The increase of ionic strength (addition of 0.1M NaCl) had a little impact on the changes of 
poly(dGdC) – poly(dGdC) CD spectra (Figure 4.4 ii). It indicated that the interactions 
between calixarenes and polynucleotides are not dominated by electrostatic interactions but 
are more likely controlled by the hydrogen bonding pattern. 
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Figure 4.4 d.  CD titration series for polynucleotides complexed by Monomer B (MB) 
(1). i, iii, iv, v, vi : The buffer solution contained 20 mM sodium phosphate. pH = 7.00 
(2). ii : The buffer solution contained 20 mM sodium phosphate with 0.1M NaCl in water. 
      pH = 7.00 
 
4.1.4 The Assessment of Thermal Denaturation of DNA 
4.1.4.1 Results (Figure 4.5 a-d) 
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Figure 4.5a. UV-Vis melting curves for dimers and monomers with polynucleotides 1   
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Figure 4.5b. UV-Vis melting curves for calixarenes with oligonucleotides in the H2O buffer2
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Figure 4.5c. UV-Vis melting curves for calixarenes with oligonucleotides in the MeOH/H2O buffer 3 
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1. The buffer solution contained 20 mM sodium phosphate. The pH was adjusted to 7.00.  
2. The buffer solution contained 1 mM Hepes in water. pH = 7.1  
3. The buffer solution contained 1 mM Hepes in methanol/water (1:1). pH = 7.1  
 
4.1.4.2 Discussion 
1. All studied compounds showed non-linear UV-Vis melting curves at T > 50°C. It hampered 
the accurate experiments with nucleic acids which melt above mentioned temperatures. 
2. Addition of 0.2 eq. or 0.3 eq. calixarenes (in terms of basepairs) could not stabilize 
polynucleotides (ΔTm < 2 °C) (Figure 4.5a). Furthermore, the hyperchromicity decreased. It 
means that a substantial fraction of the DNA was already dissociated into single strands prior 
to heating. This result is in line with the CD measurement, and indicates the decrease in 
helicity and the disruption of the DNA or RNA double helix. 
3. For oligonucleotides (Figure 4.5b, 4.5c), addition of 30 eq. calixarenes (in terms of duplex 
DNA) could stabilize DNA (Table 4.4, Table 4.5). It is probably because electrostatic 
interactions and hydrogen bond interactions between calixarenes and oligonucleotides. There 
is another argument for strand end chelation. 
Table 4.4. UV-vis Melting points and shifts induced by calixarenes in water 1 
 
Calixarenes  12 bp dG12-dC12 dA12-dT12 20 bp 
Dimer A 50°C (+14°C) 56°C (+08°C) 44°C (+6°C) 46°C (+11°C) 
Dimer B a a 58°C (+20°C) a 
Monomer A 52°C (+16°C) 48°C (+0°C) - a 
Monomer B a a - a 
1. The buffer solution contained 1 mM Hepes in water. pH=7.1. In all cases 30 eq. calixarene. 
a. UV spectra of DA, DB, MA and MB revealed decreasing extinction values with time at T > 
50 °C, thus hampering accurate experiments with nucleotides which melt above this 
temperature. 
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Table 4.5. UV-vis Melting points and shifts induced by calixarenes in methanol/water 2 
Calixarenes  12 bp dG12-dC12 dA12-dT12 20 bp 
Dimer A 42°C (+13°C) 44°C (+1°C) 47°C (+19°C) 47°C (+16°C) 
Dimer B 50°C (+21°C) 48°C (+5°C) 42°C (+14°C) 51°C (+20°C) 
Monomer A 39°C (+10°C) 39°C (-4°C) - 35°C (+4°C) 
Monomer B 39°C (+10°C) 44°C (+1°C) - 35°C (+4°C) 
2. 1 mM Hepes buffer in methanol/water (1:1), pH=7.1. In all cases 30 eq. calixarene. 
 
4.1.5 Fluorescence Titration Experiments 
4.1.5.1 Results (Table 4.6, Table 4.7) 
Table 4.6 Association constants between various DNA/RNA strands and calixarenes 1    
 
 
 
DNA/RNA (dGdC)10 -(dGdC)10 
(dAdT)10 
-(dAdT)10 
A20 - U20 12 bp dG12-dC12 dA12-dT12 A12-U12
DA2 
 
Ka(M-1)3 
 
1.4 e+6 
 
5.6 e+5 
 
1.7 e+5 
 
5.7 e+6
 
7.3 e+6 
 
5.9 e+7 
 
1.4 e+7
Statistical error 23% 24% 22% 31% 30% 32% 22% 
Stoichiometry4 11:1 10:1 23:1 10:1 5:1 9:1 41:1 
No. of data5 No.1 No.2 No.3 No.15 No.16 No.17 No.18 
DB 
 
Ka(M-1) 
 
4.7 e+6 
 
2.3 e+6 
 
7.8 e+5 
 
9.0 e+5
 
5.0 e+5 
 
1.4 e+7 
 
3.2 e+6
Statistical error 22% 24% 8% 31% 39% 32% 24% 
Stoichiometry 12:1 14:1 15:1 23:1 7:1 11:1 13:1 
No. of data No.4 No.5 No.6 No.19 No.20 No.21 No.22 
MA 
 
Ka(M-1) 
 
7.7 e+6 
 
2.9 e+6 
 
3.1 e+6 
 
6.3 e+6
 
1.0 e+7 
 
1.5 e+7 
 
9.5 e+7
Statistical error 25% 20% 24% 19% 15% 20% 10% 
Stoichiometry 10:1 30:1 10:1 4:1 14:1 18:1 3:1 
No. of data No.7 No.8 No.9 No.23 No.24 No.25 No.26 
MB 
 
Ka(M-1) 
 
1.4 e+6 
 
7.3 e+6 
 
3.5 e+5 
 
7.4 e+4
 
2.3 e+6 
 
1.3 e+4 
 
1.2 e+6
Statistical error 18% 23% 18% 24% 35% 28% 25% 
Stoichiometry 24:1 12:1 23:1 78:1 61:1 67:1 90:1 
No. of data No.10 No.11 No.12 No.27 No.28 No.29 No.30 
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1. The buffer solution contained 2 mM Hepes with 150 mM NaCl in water. pH = 7.1  
2. DA: Dimer A, DB: Dimer B, MA: Monomer A, MB: Monomer B 
3. 1.4 e+6 represents 1.4×106. 
3. Stoichiometry: [Guest] / [DNA duplex] 
5. The fluorescence titration data were provided in Chapter 6.5.  
 
 
Table 4.7 Association constants between various DNA/RNA strands and calixarenes 6    
 
 
 
 
DNA/RNA 12 bp dG12-dC12 dA12-dT12 A12-U12 
DA2 
 
Ka(M-1) 
 
3.5 e+7 
 
1.5 e+7 
 
5.9 e+6 
 
9.0 e+7 
Statistical error 15% 17% 4% 44% 
Stoichiometry 9:1 2:1 10:1 5:1 
No. of data3 No.31 No.32 No.33 No.34 
DB 
 
Ka(M-1) 
 
9.1 e+6 
 
3.1 e+6 
 
1.0 e+7 
 
1.2 e+7 
Statistical error 31% 9% 18% 11% 
Stoichiometry 11:1 2:1 12:1 6:1 
No. of data No.35 No.36 No.37 No.38 
MA 
 
Ka(M-1) 
sigmoidal × × × Statistical error 
Stoichiometry 
No. of data 
MB 
 
Ka(M-1) 
sigmoidal × × × Statistical error 
Stoichiometry 
No. of data 
6.  The buffer solution contained 2 mM Hepes with 150 mM NaCl in MeOH/H2O (1:1).  
    pH = 7.1  
 
 
4.1.5.2 Discussion 
1. The titration of fluorescence-labeled nucleic acids with the calixarenes reveals strong 
binding. Compared with previous results [120,131], benzyl series often display superior affinities 
over the anilino series (about 100 times). 
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2. For Dimer A and Dimer B, Ka values: (dGdC)10-(dGdC)10 > (dAdT)10-(dAdT)10 > A20-U20 
(RNA), dA12-dT12 > A12-U12 (RNA). It indicates that the nucleic acid with a wide and smooth 
major groove showed a higher binding affinity; the nucleic acid with a narrow and rugged 
major groove showed a lower binding affinity. Similar to EtBr displacement assays, this 
characteristic implies that the accessible area for our ligands is on the major groove side.  
3. Obviously, the linear alignment of dimer molecules inside the major groove would produce 
much lower stoichiometries (the dimer : basepair ≈ 1 : 6), but the stoichiometry values (the 
dimer : basepair) are about 0.6 : 1. It indicates that the calixarene dimer with higher charges 
tends to form self-aggregate inside DNA’s major groove, presumably with favorable van der 
Waals contacts between their butoxy tails and nonpolar arene faces. 
4. With the increase of DNA length, affinities for each calixarene unit decreased. It pointed to 
a potential clamping effect on the loose strand ends. 
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4.2 Sequence-Specific Major Groove Recognition with Dimer C 
4.2.1 Ethidium Bromide Displacement Assay and Fluorescence Titrations 
4.2.1.1 Results (EtBr Displacement Assay: Figure 4.6, Fluorescence Titration: Table 4.8-4.9) 
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Figure 4.6 Ethidium bromide displacement curves for different nucleic acids by Dimer C 
(a1 and a2), Bridge C (b), Linker C (c) and Dimer A (d) 
(1). The buffer solution contained 20 mM sodium phosphate. The pH was adjusted to 7.00.   
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Table 4.8 Association constants between various DNA strands and calixarenes / Bridge C 1 
 
 
 
DNA/RNA dG20-dC20 
(dGdC)10-
(dGdC)10 
dA20-dT20 
(dAdT)10-
(dAdT)10 
Dimer C 
 
Ka(M-1)2 
 
3.7 e+7 
 
6.4 e+5 
 
4.8 e+5 
 
1.2 e+7 
Statistical error 36% 7% 30% 38% 
Stoichiometry3 15:1 24:1 10:1 14:1 
No. of data4 No. 41 No. 39 No. 42 No. 40 
Dimer A 
 
Ka(M-1) 
 
1.5 e+6 
 
1.4 e+6 
 
1.1 e+6 
 
5.6 e+5 
Statistical error 29% 23% 27% 24% 
Stoichiometry 28:1 11:1 29:1 10:1 
No. of data No. 43 No.1 No. 44 No.2 
Monomer A 
 
Ka(M-1) 
× 
 
7.7 e+6 
× 
 
2.9 e+6 
Statistical error 25% 20% 
Stoichiometry 10:1 30:1 
No. of data No.7 No.8 
Bridge C 
 
Ka(M-1) 
 
The change of the 
fluorescence 
emission intensity 
was little. 
 
1.1 e+5 
 
3.8 e+4 
 
3.3 e+4 
Statistical error 23% 7% 10% 
Stoichiometry 192:1 60:1 136:1 
No. of data No. 49 No. 51 No. 50 
1. The buffer solution contained 2 mM Hepes with 150 mM NaCl in water. pH = 7.1 
2. 3.7 e+7 represents 3.7×107. 
3. Stoichiometry: [Guest] / [DNA duplex] 
4. The fluorescence titration data were provided in Chapter 6.5. 
 
 
Table 4.9 Association constants between various DNA strands and Dimer C 5    
 
 
 
DNA/RNA dG20-dC20 
(dGdC)10-
(dGdC)10 
dA20-dT20 
(dAdT)10-
(dAdT)10 
Dimer C 
 
Ka(M-1)2 
 
1.8 e+7 
 
1.0 e+6 
 
2.3 e+6 
 
2.3 e+7 
Statistical error 29% 21% 24% 36% 
Stoichiometry3 36:1 55:1 33:1 39:1 
No. of data4 No. 47 No. 45 No. 48 No. 46 
5. The buffer solution contained 20 mM sodium phosphate. The pH was adjusted to 7.00. 
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4.2.1.2 Discussion 
1. Compared with Dimer A, Bridge C and Linker C showed higher CE50 values and lower 
association constants for all nucleic acids. Both experiments indicated that benzyl series 
calixarenes could drive the triimidazole bridge (probably a minor groove binder) to the major 
groove of DNA. 
2. For Dimer C, the best displacement was done with polydG-polydC, followed by 
polydA-polydT, poly(dAdT)-poly(dAdT) and poly(dGdC)-poly(dGdC), and the worst 
displacement was done on RNA. In addition, Ka values: dG20-dC20 > (dAdT)10-(dAdT)10 > 
dA20-dT20. Figure 4.6a1 and Table 4.8 indicated that the nucleic acid with a wide and smooth 
major groove showed an efficient displacement (lower CE50 value) and high affinity; the 
nucleic acid with a narrow and rugged major groove showed a weak displacement and low 
affinity. These characteristics imply that the accessible area for Dimer C is on the major 
groove side. We interpret these results as compelling argument for the postulated major 
groove binding mechanism of Dimer C. 
3. Obviously, the linear alignment of Dimer C inside the major groove would produce much 
lower stoichiometries (the dimer : basepair ≈ 1 : 6), but stoichiometry values (the dimer : 
basepair) are about 0.8 : 1. It indicates that the Dimer C tends to form self-aggregate inside 
DNA’s major groove, presumably with favorable van-der-Waals contacts between their butoxy 
tails and nonpolar arene faces. 
4. Both experiments also indicated that Dimer C, which contained a triimidazole bridge, 
showed stronger preference for one specific DNA duplex: polydG-polydC. The specificity 
originates from the triimidazole bridge, and is also related to the special properties of the 
major groove of polydG-polydC: 
(1). PolydG-polydC is similar to A-form. It has a wider minor groove (9.5Å) and a narrower 
major groove (8.1Å) (Table 1.3). The triimidazole bridge, which is slim, can fit into this 
narrow major groove superbly. 
(2). The major groove of polydG-polydC can be approximated by a single smooth curve,  
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 H-bond acceptor   H  H-bond donor
which allow favorable van der Waals contacts 
between Dimer C and the functional groups of 
nucleobases. Whereas, A:T-rich sequences 
produce steric hindrance within the major 
groove by the presence of the methyl group of 
thymine, which affect the groove geometry. 
This prevents Dimer C from attaining the 
multiple close contacts with the floor in A:T 
sequences that are possible in G:C regions. 
(3). In the major groove, G:C base pairs 
[C-4-NH2 (δ+), G-6-CO (δ-), and G-N7 (δ-)] 
have a larger electrostatic potential gradient 
than T:A base pairs [T-4-CO (δ-), A-6-NH2 
(δ+), and A-N7(δ-)]. In addition, the nearest- 
neighbor interaction of polydG-polydC base 
pairs reinforces the intrinsic base pair 
potentials. For polydG-polydC, one side of 
the major groove is negative, and the other 
side is positive. The calixarene unit of Dimer 
C can carry cationic charges to complement 
the negative potential, and the nitrogen of the 
triimidazole bridge offers lone pair electrons 
to recognize the positive potential. Therefore, 
the electrostatic potential properties of this 
major groove lead to excellent recognition by 
Dimer C. 
By contrast, in major grooves, poly(dGdC) 
-poly(dGdC) has more neutral areas than does 
  ring H atom  
Figure 4.6a. A Proposed binding mechanism 
          of Dimer C and polydG-polydC 
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polydG-polydC because the neighboring base pair potentials  somewhat cancel each other, 
and T:A base pairs also have more neutral areas than does polydG-polydC. The unfavorable 
electrostatic potentials lead to their poor recognitions by Dimer C. 
5. Compared with Dimer A, Dimer C showed much higher CE50 values for polydA-polydT, 
poly(dAdT)-poly(dAdT) and poly(dGdC)-poly(dGdC), and lower association constants for 
dA20-dT20 and (dGdC)10-(dGdC)10. It indicated that Dimer C frequently showed reduced 
affinities to other DNA duplexes. The reduced affinities probably originate from the 
triimidazole bridge. Because the major groove of B-form DNA is wide, the slim triimidazole 
bridge will not produce extensive close van der Waals contacts with the floor of a wide major 
groove, and the whole ligand itself shows orientational disorder. Another explanation is the 
unfavorable electrostatic potentials, because these DNA duplexes have more neutral areas in 
major grooves than does poly dG - poly dC. 
6. For Dimer C, with the increase of ionic strength (addition of 150 mM NaCl), the binding 
affinities decreased about 2-3 times (table 4.8, table 4.9). The ionic strength had a little impact 
on the binding affinities. It indicated that the interactions between Dimer C and DNA are not 
dominated by electrostatic interactions but are more likely controlled by the hydrogen 
bonding pattern. 
4.2.2 Circular Dichroism Spectroscopy 
4.2.2.1 Results (Figure 4.7) 
4.2.2.2 Discussion 
1. It was observed that Dimer C induced very weak effects to the CD spectra (between 260nm 
and 300 nm) of poly(dGdC)-poly(dGdC), poly(dAdT)-poly(dAdT) and polydA-polydT, but 
induced stronger effects to the CD spectra of poly dG – poly d C (A-form DNA) and poly A – 
poly U (A-form RNA). 
The CD spectrum between 260nm and 300 nm indicates the conformational changes of the 
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phosphate backbone. These spectra imply a major groove binding mode, because a superb fit 
into DNA’s wide and shallow major groove induced a weaker effect to the phosphate 
backbone and an inaccessible binding to RNA’s narrow and deep groove induced a stronger 
effect to the phosphate backbone. The deep and narrow major groove of the RNA duplex must 
first be widened by Dimer C to accommodate the sterically demanding calixarene guest itself 
[219,220,221,222]. 
2. Addition of Dimer C invariably decreased molar ellipticities at all wavelengths of CD 
bands of polynucleotides. It pointed toward the decrease in helicity and the disruption of the 
DNA/RNA double helix.  
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Figure 4.7 CD titration series for polynucleotides complexed by Dimer C 
The buffer solution contained 20 mM sodium phosphate. The pH was adjusted to 7.00.  
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4.2.3 The Assessment of Thermal Denaturation of DNA 
4.2.3.1 Results (Figure 4.8) 
4.2.2.3 Discussion 
1. Addition of 0.2 eq. – 1.6 eq. Dimer C (in terms of basepairs) could not stabilize both 
polynucleotides and oligonucleotides ((ΔTm < 2 °C) (Figure 4.8). 
2. With the increase of the concentration of Dimer C, the hyperchromicity decreased. It 
incicates that the binding of Dimer C to the nucleic acid duplex is very strong, and it also 
means that a substantial fraction of the DNA was already dissociated into single strands prior 
to heating. This result is in line with the CD measurements, and indicates the decrease in 
helicity and the disruption of the nucleic acid double helix. 
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Figure 4.8 UV-Vis melting curves for Dimer C with nucleic acids 
The buffer solution contained 20 mM sodium phosphate. The pH was adjusted to 7.00. 
 102 
4.2.4 NMR Spectroscopy 
The advancement of NMR instrumentation and methodology has made solution NMR 
spectroscopy an increasingly powerful tool for investigations of biomolecular structure and 
dynamics under physiological conditions, and also allows for studies of ligand binding and 
reaction mechanisms in solution [223]. However, the inherent sensitivity limitation of NMR 
requires the complex samples of biomolecules and ligands to be stable at high concentrations 
(> 50 μM for structural studies) for an extended period (typically over a couple of days). 
Unfortunately, in my work, the DNA-calixarene complex has low solubility in any H2O buffer 
solution. Therefore, it is impossible to investigate the NMR signals of any complex. 
For NMR experiments, the Dickerson dodecamer d(CGCGAATTCGCG) was used. NMR 
samples for observation of the imino proton spectrum were prepared by dissolving 0.12 μmol 
DNA in 0.6 ml H2O buffer consisting of 20 mM sodium phosphate (pH = 7.0, Fluka, Product 
Number: 82591). The samples were lyophilized to dryness and redissolved in 0.6 ml of the 
mixture (H2O : DMSO-d6 = 80 : 20). The assignment of protons and phosphates can be found 
in the references [182, 183, 184]. 
 
Figure 4.8 c 
In figure 4.8b, it was observed that with the addition of Dimer C, the NMR 
signals of the Dickerson dodecamer became weaker and weaker. In addition, 
the signals of Dimer C can not be found. It was also observed that 
precipitations of the DNA-Dimer C complex formed in NMR tubes (in figure 
4.8c). These figures indicated that the solubility of the DNA-Dimer C complex 
was too low to be investigated by NMR spectroscopy.  
In my work, preparation of a concentrated and stable DNA-Dimer complex sample was a 
difficult task. In my opinion, there are three reasons. (1). The dimers (Dimer A, Dimer B and 
Dimer C) aggregate at higher concentrations in any H2O buffer solution at r.t. (2). The 
DNA-Dimer complex formed precipitations at higher concentrations in any buffer solution. (3). 
Probably, the DNA-Dimer complex is sometimes subject to spontaneous degradation. Thus, 
preparation of well-behaved, non-aggregated samples at sufficiently high concentrations 
remains a serious challenge for structural and dynamic studies by NMR in our work. 
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Figure 4.8b. 1H-NMR spectra (500 MHz, 25 °C) 
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I declare that the proliferation experiments were performed by Marijeta Kralj, Lidija Šuman, 
and Ivo Piantanida in the Laboratory of Experimental Therapy, Division of Molecular 
Medicine, Ruđer Bošković Institute, Bijenička 54, 10000 Zagreb, Croatia. In this part, I only 
synthesized and purified the following studied molecules: Dimer A, Dimer B, Monomer A 
and Monomer B. 
4.3 Antiproliferative Effects of Various Calixarenes in vitro 
In order to investigate the effects of these calixarenes on proliferation of living cells, four 
different human tumor cell lines were cultivated: MCF-7 (breast carcinoma), SW 620 (colon 
carcinoma), HCT 116 (colon carcinoma) and H 460 (lung carcinoma). After 72 hours of 
incubation, the cell growth rate was evaluated by performing the MTT assay, which detects 
the dehydrogenase activity in viable cells. The MTT cell proliferation assay measures the 
reduction of a tetrazolium component (MTT) into an insoluble formazan product by the 
mitochondria of viable cells. The insoluble formazan product was dissolved in DMSO, and 
quantified by microplate readers at 570 nm. The absorbance is directly proportional to the cell 
viability. PG value (the percentage of growth) is used to evaluate the cell viability. 
(1). If mean ODtest – mean ODtzero ≥ 0     PG = 
tzerlctrl
tzerotest
ODmean ODmean 
)ODmean OD(mean 100
−
−×
 
(2). If mean ODtest – mean ODtzero < 0     PG = 
tzero
tzerotest
ODmean 
)ODmean OD(mean 100 −×
  
Mean ODtzero = the average of optical density measurements before exposure of cells to the 
test compound. 
Mean ODtest = the average of optical density measurements after the desired period of time. 
Mean ODctrl = the average of optical density measurements after the desired period of time 
with no exposure of cells to the test compound.  
The GI50 measures the growth inhibitory power of the test agent and represents the 
concentration that causes 50% growth inhibition, and can be defined as PG values of 50 in 
this work. If antiproliferative activities are rather high, GI50 values should be very low.  
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4.3.1 Results (Table 4.10, Figure 4.9, 4.10) 
Table 4.10  GI50 values (µM) of calixarenes on human tumor cell lines 
GI50a (µM) 
Compound 
ID 
(LET)b 
Compound 
ID 
Cell lines 
HCT 116 SW 620 MCF-7 H 460 
852 Monomer B 2 ± 0.5 2 ± 0.04 1.5 ± 0.2 1.5 ± 0.1 
853 Dimer A 3 ± 0.1 4 ± 4 5 ± 0.4 2 ± 1 
854 Monomer A 2 ± 0.1 2 ± 0.01 2 ± 0.5 1.6 ± 0. 04 
855 Dimer B 14 ± 1 9 ± 4 3 ± 0.4 4 ± 0.03 
a. GI50; the concentration that causes 50% growth inhibition 
b. LET; Laboratory of Experimental Therapy 
Figure 4.9  Dose-response profiles for compounds 852-855 tested in vitro 
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Figure 4.10 Preliminary testing of 853 & 854 for the potential disturbances of tumor cell cycle 
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4.3.2 Discussion 
1. Compared with anilino series, benzyl series (Dimer A, Dimer B, Monomer A and Monomer 
B) have rather high antiproliferative activities, probably because the much higher pKa values 
of the latter bears highly positive charges at experimental conditions (pH = 7). 
2. The cell growth inhibition might originate from DNA complexation inside the tumor cells. 
However, more and more evidence showed that the cationic calixarenes could not pass the 
cell membranes. On the one hand, the studied molecules have a large size. On the other hand, 
as amphiphilic molecules, the dimeric (and monomeric) calixarenes may self-assemble inside 
the cell membrane, where the lypophilic part of calixarenes (-O-Bu tails) could be oriented 
inside a membrane and the positively charged side towards aqueous solutions (in the direction 
of both inside and outside of the cell). This architecture could alter membrane potential as 
well as ion flux across the double layer, and leads to the cell apoptosis. 
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3. The cell cycle analysis (Figure 4.10) indicated that there was no DNA damage during 
apoptosis. It means that the target of studied compounds is not DNA. 
(1). Dimer A (853) did not induce any specific cell cycle disturbance, but induces 
time-dependent cell death (as evidenced by subG1 percentage of cells) at both concentrations 
(5 µM and 10 µM) 
(2). Monomer A (854) induced strong delay of cell cycle progression from G1 phase to S 
(DNA synthesis) phase. The strong accumulation of cells in G1 cell cycle phase leads to the 
drastic reduction of cells in S phase. In G1 phase, Monomer A interacts with the target in the 
cell. During G1 phase, new organelles are being synthesized, so the cell requires both 
structural proteins and enzymes, resulting in great amount of protein synthesis and a high 
metabolic rate in the cell. Monomer A probably interferes with the protein synthesis. 
In all, the mechanism of the action is sophisticated, and more specific experiments should be 
performed in the future. 
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5. Conclusions and Outlook 
5.1 Conclusions 
1. Compared with dimeric anilino-calix[4]arenes, dimeric aminobenzyl calixarene Dimer A 
and its guanidinium counterpart Dimer B are water-soluble, and bind to DNA with much 
higher affinity (binding constants: 106–108 M-1 in 2 mM Hepes buffer with 150 mM NaCl). 
Although direct structure information from a crystal or NMR structure was not yet available, 
the following results from established binding assays strongly support a major groove binding 
mode: 
(1). The DAPI displacement assay indicates that the calixarene dimers and DAPI can 
simultaneously bind to poly (dAdT) – poly (dAdT). Because DAPI occupies the minor groove, 
the dimeric calixarenes must reside in the major groove. 
(2). Ethidium bromide displacement assays, fluorescence titrations, and circular dichroism 
measurements indicate that calixarene dimers strongly prefer nucleic acids with a wide, 
shallow or even major groove; while low affinities are observed for nucleic acids with a 
narrow, deep or rugged major groove, which must be widened before complexation occurs. 
This characteristic also implies that the accessible area for our ligands is on the major groove 
side, contrary to the well-known slim oligoamide binders, which target the minor groove. 
Binding Properties of Dimer A and Dimer B with Different Nucleic Acids  
 poly(dGdC)- poly(dGdC) 
poly (dAdT)- 
poly (dAdT) 
poly dA- 
poly dT poly A-polyU 
Major Groove 
Width 
wide medium narrow  
13.5 Å 11.2 Å 11.4 Å 3.8 Å 
Major Groove 
Shape smooth curve 
not smooth, because of 
methyl group of thymine smooth curve 
EtBr 
Displacement 
Assays 
efficient 
displacement medium 
weak 
displacement 
Binding 
Constants high medium low 
CD Spectra no induced conformational changes (B-DNA remains B-DNA) 
shift from A-form 
to B-form 
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In line with these observations, it was noticed that changes in shape and width of the minor 
groove had no influence on the ligands’ affinities.  
2. Because in minor grooves, N-methylimidazoles of polyamides could recognize the positive 
electrostatic potential of amino groups of guanine bases via hydrogen bonds, it was assumed 
that Dimer C, which contained a triimidazole bridge, could prefer a major groove with large 
positive potentials. Moreover, because the triimidazole bridge is slim, it was also assumed that 
Dimer C should prefer a narrow major groove, which could offer the appropriate shape for the 
bridge’s recognition. In view of the above-mentioned assumptions, we found that the major 
groove of poly dG – poly dC fulfilled both requirements. Therefore, it was predicted that 
Dimer C should show the high affinity for poly dG – poly dC.  
Ethidium bromide displacement assays, fluorescence titrations, and circular dichroism 
measurements imply that Dimer C is a major groove binder. Furthermore, as we expected, 
these experiments indicate that Dimer C showed stronger preference for this specific DNA 
duplex: poly dG - poly dC. 
It was also observed that Dimer C frequently showed reduced affinity to other DNA duplexes. 
Probably, the decrease in affinity is related to their wider major grooves, in which the slim 
triimidazole bridge will not produce extensive close van der Waals contacts, and the whole 
ligand itself shows orientational disorder. Another explanation is the unfavorable electrostatic 
potentials, because these DNA duplexes have more neutral areas in major grooves than does 
poly dG - poly dC. 
Herein, we present the mechanism of DNA binding by Dimer C: the cationic moieties on the 
upper rim of the calixarenes form hydrogen bonds with nucleobases as well as phosphate 
groups of the nucleic acid, the butoxy tail is toward the free solution, and the triimidazole 
bridge binds along the major groove and recognizes the amino groups of nucleobases. 
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3. Dimer A, Dimer B, Monomer A and Monomer B have rather high antiproliferative 
activities. The cell cycle analysis indicates that Dimer A induces time-dependent cell death, 
and Monomer A induced strong delay of cell cycle progression from G1 phase to S phase. 
There was no evidence that the apoptosis was the consequence of DNA damage. Therefore, 
the target of the studied molecules is probably not DNA. Because the size of studied 
molecules is large and the calixarene head groups are known to interact with various metal 
cations and anions, it is assumed that as amphiphilic molecules, the dimeric and monomeric 
calixarenes may self-assemble inside the cell membrane, and alter membrane potential as well 
as ion flux across the double layer. More specific experiments should be performed to 
interpret the mechanism of the antiproliferative activity.
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5.2 Outlook 
1. In the future, we intend to synthesize the analogues of Dimer C, i.e. dimeric aminobenzyl 
calix[4]arenas connected by different linear heterocyclic oligomers, for example, Dimer D, 
Dimer E, etc. and assay their DNA-binding properties (especially binding affinities and 
sequence specificities) by a series of biophysical studies.  
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2. Inspired by the hairpin binding motif [89], which results from covalent linkages between two 
antiparallel polyamide strands, we plan to design and synthesize calix[4]arene dimers with 
cyclic polyamide bridges (the third generation calix[4]arene dimers). These dimers with large 
dimensional bridges could superbly fit into DNA’s wide major groove and recognize different 
hydrogen bond profiles, and probably they will show improved affinities and specificities. 
 
 
The first 
generation 
 
Dimeric Calix[4]arenas with Alkyl Bridges   
 
The second 
generation 
Dimeric Calix[4]arenas with Single Linear Polyamide Bridges  
 
The third 
generation 
Dimeric Calix[4]arenas with Cyclic Polyamide Bridges  
-------: N-Methylpyrrole or N-Methylimidazole or 3-hydroxypyrrole Amino Acid 
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3. We will explore pairing rules for major groove recognition (for example, Figure 5.2), and 
discuss the scope and limitations of the pairing rules. 
 
    
  H-bond acceptor H  H-bond donor ring H atom  methyl group 
 
Figure 5.2. A Proposed Major Groove Alphabet 
 
 
4. The ultimate goal behind this work is to design dimeric calixarene drugs capable of 
recognizing a specific sequence in DNA. It may be possible for them to control gene 
expression by blocking a specific promoter sequence, for example, to block a specific 
oncogene, inhibit the expression of this oncogene and thereby control the development of 
tumor cells. Specificity for much longer sequences is required in order to have site uniqueness 
at the genome level. It has been estimated that the minimum nucleotide binding site for the 
polyamide bridge is about 20 bases long. Thus, it is necessary to carry out solid-phase peptide 
synthesis to complete the synthesis of the macrocyclic polyamide bridges.  
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6. Experiments  
6.1 Chemicals and Equipments 
Chemicals. All the commercial chemicals were purchased from Sigma - Aldrich, Acros 
Organics, Merck and Fluka. All reagents were purchased at the highest commercial grade and 
were used without further purification.  
 
Solvents. All the technical level organic solvents were distilled before use. Dry solvents were 
prepared with standard methods [224,225].  
 
Nucleic Acids: Oligonucleotides used in the work were purchased from Metabion 
international AG. Polynucleotides were purchased from Aldrich. 
 
Chromatography. Thin layer chromatography (TLC) with Merck silica-gel 60 F254 plates 
were used to monitor reactions. The detection was performed under 254 nm UV light. The 
eluting solvent and Rf value depend on the substance [226]. Flash chromatography was 
performed with silica gel 60 (200-400 mesh) from Merck. Yields referred to 
chromatographically and spectroscopically pure compounds unless otherwise noted. HPLC 
was performed by a Merck–Hitachi system with an L-7150 analytical pump, a K-1800 
preparative pump, an L-7400 or K-2501 UV detector and an L-7614 solvent degasser.  
 
NMR Spectroscopy. NMR spectra were recorded at 300 K on Bruker AMX 300 or Bruker 
DRX 500. The signals of some commonly used deuterated solvents were reported in the 
literature [227] and were used for calibrations. Chemical shifts were reported in ppm relative to 
tetramethylsilane. Multiplicities were indicated by s (singlet), d (doublet), t (triplet), m 
(multiplet) and br (broad). The unit of the coupling constant is herz (Hz). 13C spectra were 
broadband decoupled and calibrated on the particular solvent signal. 
 
UV-Vis Spectroscopy. UV-Vis experiments were performed on a V-550 spectrometer from 
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Jasco with a Peltier thermostatted single cell holder with a stirring unit. Helma cuvettes with 2 
mm inner diameter were used for the experiments. 
 
Fluorescence Spectroscopy. Fluorescence experiments were performed at 25 °C on a Jasco 
FP-6500 spectrofluorometer with a stirring unit and a Haake water-temperating unit. 
 
Mass Spectroscopy. High-resolution electron spray ionisation (ESI) mass spectra were 
recorded on a Bruker BioTOF III spectrometer. 
 
Molecular Modeling. Force-field calculations were carried out with the program 
MacroModel 9.7 using the OPLS 2005 force-field and the GB/SA solvation model for water. 
Monte-Carlo simulations were conducted using 1000 starting structures and up to 2500 
minimization steps without any constraint. 
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6.2 DNA / RNA Binding Experiments 
6.2.1 Hybridization of Nucleic Acids 
To prepare duplexes of oligonucleotides, equimolar amounts of the complementary strands 
were mixed, heated at 90 °C for 5 min, and slowly cooled to room temperature.  
The structures of oligonucleotides, which were studied in this work: 
12bp 5’-[FL]dGdTdG dAdCdG dAdAdC dCdTdC-3’ 
     3’-dCdAdC dTdGdC dTdTdG dGdAdG-5’ 
 
20bp 5’-dGdAdG dGdTdT dCdGdT dCdAdC dGdCdA dGdCdT dGdC-3’ 
 3’-dCdTdC dCdCdA dGdCdA dGdTdG dCdGdT dCdGdA dCdG-5’ 
 
dA12-dT12 5’-[Fl]dAdAdA dAdAdA dAdAdA dAdAdA-3’ 
 3’-dTdTdT dTdTdT dTdTdT dTdTdT -5’ 
 
dG12-dC12 5’-[Fl]dGdGdG dGdGdG dGdGdG dGdGdG-3’ 
 3’-dCdCdC dCdCdC dCdCdC dCdCdC-5’ 
 
A12-U12 5’-[Fl]AAA AAA AAA AAA-3’ 
    3’-UUU UUU UUU UUU -5’ 
 
(dGdC)10- 
(dGdC)10 
5’-[Fl]dGdCdGdCdGdCdGdCdGdCdGdCdGdCdGdCdGdCdGdC-3’ 
   3’-dCdGdCdGdCdGdCdGdCdGdCdGdCdGdCdGdCdG dCdG-5’ 
 
(dAdT)10- 
(dAdT)10 
5’-[Fl]dAdTdAdTdAdTdAdTdAdTdAdTdAdTdAdTdAdTdAdT-3’ 
   3’-dTdAdTdAdTdAdTdAdTdAdTdAdTdAdTdAdTdAdTdA-5’ 
 
A20 - U20 5’-[Fl]AAAAAAAAAAAAAAAAAAAA-3’ 
    3’-UUUUUUUUUUUUUUUUUUUU-5’ 
 
dG20-dC20 5’-[Fl]dGdGdGdGdGdGdGdGdGdGdGdGdGdGdGdG dGdGdGdG -3’ 
 3’-dCdCdCdCdCdCdCdCdCdCdCdCdCdCdCdCdCdCdCdC -5’ 
 
dA20-dT20 5’-[Fl]dAdAdAdAdAdAdAdAdAdAdAdAdAdAdAdAdAdAdAdA -3’ 
 3’-dTdTdTdTdTdTdTdTdTdTdTdTdTdTdTdTdTdTdTdT -5’ 
Polynucleotides were purchased from Aldrich and were dissolved in the aqueous buffer 
consisting of 20 mM sodium phosphate (pH = 7.0, Fluka, Product Number: 82591), and were 
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kept at room temperature overnight. The concentrations of polynucleotides were calculated in 
basepairs, and stoichiometries or equivalents of ligands were related to basepairs accordingly. 
The phosphate concentration of polynucleotides was then determined spectroscopically. This 
was also the base concentration, which was multiplied by 2 to furnish the nucleic acid 
concentration in base pairs. 
poly dA - poly dT λ = 260 nm ε = 6000 L mol-1 cm-1 
poly (dAdT) - poly (dAdT) λ = 260 nm ε = 6000 L mol-1 cm-1 
poly A - poly U λ = 260 nm ε = 6300 L mol-1 cm-1 
poly(dGdC) - poly(dGdC) λ = 253 nm ε = 7400 L mol-1 cm-1 
poly dG – poly dC λ = 253 nm ε = 7400 L mol-1 cm-1 
 
6.2.2 Ethidium Bromide Displacement 
A Jasco FP-6500 spectrofluorimeter was used to record the data. The samples were excited at 
a wavelength of 546 nm and the change of the emission intensity around 595 nm was 
recorded. Ethidium bromide was dissolved in buffers to provide 1.26 eq. per base pair. Short 
oligonucleotides were used in 1 μM duplex concentration [i.e., 12 μM (12 mer) or 20 μM (20 
mer) in basepairs]. After stirring for 5 min and standing for 1 min the fluorescence was 
measured. For the graph, the relative decrease in fluorescence emission intensity of the 
intercalated dye EB is plotted against the ligand concentration corrected for its charge excess 
(CE value).  
6.2.3 Circular Dichroism Spectroscopy 
CD spectra were recorded on a Jasco J815 spectrometer, in all cases using quartz cuvettes 
(1 cm). The measurements were performed in the aqueous buffer consisting of 20 mM sodium 
phosphate (pH = 7.0, Fluka, Product Number: 82591). Under the experimental conditions 
used, the absorbance and fluorescence intensities of the studied compounds were proportional 
to their concentrations while none of studied compounds showed a CD spectrum. The samples 
containing DNA (5 µM in basepairs for Dimer A, Dimer B, Monomer A and Monomer B; 20 
µM in basepairs for Dimer C) or its complex with calixarenes were scanned from 200 to 350 
nm at a constant temperature of 20 °C. Eq. calixarene are also calculated per basepair. 
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6.2.4 DAPI Displacement 
CD spectra were recorded on a Jasco J815 spectrometer, in all cases using quartz cuvettes (1 
cm). The measurements were performed in the aqueous buffer consisting of 20 mM sodium 
phosphate (pH = 7.0, Fluka, Product Number: 82591). Under the experimental conditions 
used, the absorbance and fluorescence intensities of the studied compounds were proportional 
to their concentrations while none of studied compounds showed a CD spectrum. Poly (dAdT) 
- poly (dAdT) was purchased from Aldrich. The samples containing poly (dAdT) - poly 
(dAdT) (5 µM in basepairs), DAPI (3 µM = 0.6 eq. per base pair) or its complex with 
calixarenes were scanned from 230 to 450nm at a constant temperature of 20 °C. Eq. 
calixarene are also calculated per basepair. 
 
6.2.5 UV-vis Melting Curves  
The profiles of UV absorbance versus temperature were measured using a JASCO V-550 
UV–vis spectrophotometer by monitoring the sample absorption at 260 nm. The sample cell 
was equipped with a Peltier type cell holder (ETC-273T) and the profiles of UV–vis 
absorption versus temperature were recorded. The concentration of oligonucleotides in each 
sample was 1 µM (in duplex DNA) in buffer solutions. The concentration of polynucleotides 
in each sample was 10 µM (in basepairs) in buffer solutions. The experiments were carried 
out by increasing the temperature at a rate of 1.0 °C / min from 20 to 95 °C and the 
temperature was recorded every minute (equal to each additional 1.0 °C). 
 
6.2.6 Fluorescence Titration Experiments 
Fluorescence titrations were performed with 5’- Fluorescein-labeled DNA or RNA of varying 
sequences. The guests were dissolved in Hepes-buffered solutions (pH = 7.1). For 
convenience, the host compounds were diluted in the DNA or RNA solutions, so that there 
was no change in the DNA or RNA concentration throughout the entire titration. A Jasco 
FP-6500 spectrofluorimeter was used to record the data. The samples were excited at a 
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wavelength of 488 nm and the change of the emission intensity around 520 nm was recorded. 
700 µl of these solutions were filled into cuvettes and up to 500 µl of the ligand solutions 
were added stepwise. The change of the emission intensity was measured at a constant 
temperature of 20 °C. The binding isotherms were fitted by standard nonlinear regression 
methods.  
 
6.2.7 Preparation of NMR Samples 
NMR samples for observation of the imino proton spectrum were prepared by dissolving 1.2 
μmol of the DNA in 0.6 ml of the aqueous buffer consisting of 20 mM sodium phosphate (pH 
= 7.0, Fluka, Product Number: 82591). The samples were lyophilized to dryness and 
redissolved in 0.6 ml of the mixture (H2O : D2O = 95 : 5). For non-exchangeable proton 
spectra these samples were repeatedly lyophilized to dryness in the NMR tube and 
redissolved in 99.996% D2O.
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6.3 Synthesis 
 
p-tert-butylcalix[4]arene (1) [134] 
 
 
A mixture of 10 g (0.067 mol) of p-tert-butylphenol, 6.2 mL (0.083 mol) of 37% 
formaldehyde solution and 0.12 g (0.003 mol) of sodium hydroxide in 0.3 mL of water was 
placed in a 500 mL flask, stirred for 15 min at room temperature, and then heated for 2 hours 
at 111°C. The reaction mixture was cooled to room temperature. 80 mL of warm diphenyl 
ether was added to the flask. The contents of the flask were stirred and heated at 111°C while 
a stream of nitrogen was blown rapidly over the reaction mixture to facilitate the removal of 
the water as it was evolved. Then the content of the flask was heated at reflux for 2 hours and 
cooled to room temperature. The product was precipitated by the addition of 150 mL of ethyl 
acetate. The solid was washed twice with 50 mL ethyl acetate, twice with 50 mL acetic acid, 
twice with 50 mL water, and twice with 50 mL acetone to yield 5.1 g (48%) of crude product.  
1H-NMR (300 MHz, C6D6): δ (ppm) = 1.08 (s, 36H, H-4), 3.30 (bs, 4H, H-2), 4.34 (bs, 4H, 
H-2), 6.95 (s, 8H, H-3), 10.37 (s, 4H, H-1). 
13C-NMR (75 MHz, C6D6): δ (ppm) = 147.12, 144.42, 127.41, 126.11, 33.93, 32.69, 31.40.  
MS (ESI-TOF, pos. toluene): [M+Na]+ calc. for C44H56NaO4 m/z 671.4071, found m/z 
671.4132. 
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calix[4]arene (2) [228] 
 
3.0 g (4.63 mmol) of p-tert-butylcalix[4]arene was dissolved in 50 mL of anhydrous toluene 
at 80°C, and was cooled to 50°C. 3.0 g (22.5 mmol) of AlCl3 was added. The solution was 
vigorously stirred for 2 hours at 50°C, and was cooled to 5°C. The reaction was quenched 
using 1M HCl. The toluene phase was evaporated, and the solid in the flask was washed twice 
with 50 mL water and twice with 10 mL acetone to yield 1.2 g (61%) of product.  
1H-NMR (300 MHz, DMSO-d6): δ (ppm) = 3.87 (bs, 8H, H-2), 6.64 (t, 4H, H-4), 7.11 (d, 8H, 
J = 7.54, H-3), 9.80 (bs, 4H, H-1). 
13C-NMR (75 MHz, DMSO-d6): δ (ppm) = 149.41, 128.65, 128.59, 121.10, 30.58. 
MS (ESI-TOF, pos. toluene): [M+Na]+ calc. for C28H24NaO4 m/z 447.1567, found m/z 
447.1628; [M+H]+ calc. for C28H25O4 m/z 425.1747, found m/z 425.1810. 
 
 
 
25,26,27,28-tetra-O-nbutyl-calix[4]arene (3) [228] 
 
20 mL of anhydrous DMF was added to 100 mL round bottom flask containing 0.88 g (2.07 
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mmol) of calix[4]arene at 80°C. 0.34 g (8.5 mmol) of NaH (60% dispersion in mineral oil) 
were added slowly to the flask followed by 1.1 mL of 1-bromobutane (10.2 mmol). The 
solution was stirred for 1 hour at 80°C and cooled to room temperature. DMF is removed in 
vacuo. The residue was washed with 150 mL of n-hexane. The organic layer was evaporated 
to dryness to yield 0.7 g (52%) of product. 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 6.55-6.65 (m, 12H, H-1, H-2), 4.47 (d, 4H, J = 
13.29, H-3), 3.91 (t, 8H, J = 7.50, H-4), 3.17 (d, 4H, H-3), 1.92 (quintet, 8H, H-5), 1.46 
(sextet, 8H, H-6), 1.02 (t, 12H, H-7).  
13C-NMR (75 MHz, CDCl3): δ (ppm) = 156.57, 135.14, 128.09, 121.86, 74.81, 32.31, 22.70, 
19.36, 14.08.  
MS (ESI-TOF, pos. CH2Cl2): [M+Na]+ calc. for C44H56NaO4 m/z 671.4071, found m/z 
671.4148. 
 
 
25,26,27,28-Tetrabutoxy-5,11,17,23-tetrakis(chloromethyl)calix[4]arene (4) [149] 
 
 
25,26,27,28-tetra-O-nbutyl-calix[4]arene (12.11 g, 18.5 mmol) and paraformaldehyde (36.0 g) 
were suspended in dioxane (500 mL). After addition of acetic acid (86 mL), phosphoric acid 
(200 mL), and concentrated HCl (250 mL), the reaction mixture was heated at 80°C for 6 
days. After cooling, the mixture was diluted with ice-water and extracted with chloroform. 
The organic layer was washed twice with water and dried over MgSO4. The solution was 
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evaporated to dryness, and the residue was recrystallized from hexane. Yield: 83% 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 6.65 (s, 8H, H-2), 4.41 (d, 4H, J = 13.28, H-3), 4.3 
(s, 8H, H-1), 3.88 (t, 8H, J = 7.48, H-4), 3.15 (d, 4H, H-3), 1.89 (quintet, 8H, H-5), 1.42 
(sextet, 8H, H-6), 1.00 (t, 12H, H-7).  
13C-NMR (75 MHz, CDCl3): δ (ppm) = 156.72, 135.09, 130.84, 128.52, 75.02, 46.58, 32.15, 
30.80, 19.24, 13.99.  
MS (ESI-TOF, pos. CH2Cl2): [M+Na]+ calc. for C48H60Cl4NaO4 m/z 865.3118, found m/z 
865.3169. 
 
25,26,27,28-Tetrabutoxy-5,11,17,23-tetrakis(azidomethyl)calix[4]arene (5) [157] 
 
 
25,26,27,28-Tetrabutoxy-5,11,17,23-tetrakis(chloromethyl)calix[4]arene (0.4214 g, 0.5 mmol) 
and sodium azide (0.325 g, 5 mmol) were stirred for 18 h at 60°C in DMF (30 mL). 
Subsequently DMF is removed in vacuo. The residue was washed with 100 mL of n-hexane. 
The organic layer was evaporated to dryness to yield 0.43 g (99%) of product. 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 6.61 (s, 8H, H-2), 4.45 (d, 4H, J = 13.21, H-3), 3.95 
(s, 8H, H-1), 3.90 (t, 8H, J = 7.48, H-4), 3.17 (d, 4H, H-3), 1.91 (quintet, 8H, H-5), 1.44 
(sextet, 8H, H-6), 1.01 (t, 12H, H-7).  
13C-NMR (75 MHz, CDCl3): δ (ppm) = 156.57, 135.18, 128.63, 128.52, 75.06, 54.22, 32.24, 
 125
30.80, 19.29, 14.03.  
MS (ESI-TOF, pos. CH2Cl2): [M+Na]+ calc. for C48H60N12NaO4 m/z 891.4753, found m/z 
891.4810. 
 
 
 
25,26,27,28-Tetrabutoxy-5,11,17,23-tetrakis(aminomethyl)calix[4]arene 
tetrahydrochloride (6) [157] 
OO O
NH3Cl
O
NH3Cl
Bu Bu Bu
ClH3N ClH3N
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8  
25,26,27,28-Tetrabutoxy-5,11,17,23-tetrakis(azidomethyl)calix[4]arene (1.0 g, 1.15 mmol) 
were dissolved in methanol (100 mL) and Pd/C (0.10 g, 10 weight-%) was added. After 
addition of 1 M hydrochloric acid (15 mL) the hydrogenation was carried out for 24 h. The 
catalyst was filtered off over Celite and the solution was evaporated to dryness. The residue 
was washed with acetone to yield 0.8 g (90%) of product.  
1H-NMR (300 MHz, DMSO-d6): δ (ppm) = 8.47 (bs, 12H, H-1), 7.17 (s, 8H, H-3), 4.36 (d, 
4H, J = 12.45, H-4), 3.82 (t, 8H, J = 7.36, H-5), 3.75 (m, 8H, H-2), 3.20 (d, 4H, H-4), 1.93 
(quintet, 8H, H-6), 1.43 (sextet, 8H, H-7), 0.98 (t, 12H, H-8).  
13C-NMR (75 MHz, DMSO-d6): δ (ppm) = 156.57, 135.18, 128.63, 128.52, 75.06, 54.22, 
32.24, 30.80, 19.29, 14.03.  
MS (ESI-TOF, pos. MeOH, free base): [M+Na]+ calc. for C48H68N4NaO4 m/z 787.5133, 
found m/z 787.5178; [M+H]+ calc. for C48H69N4O4 m/z 765.5313, found m/z 765.5378.
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5-(Aminomethyl)-25,26,27,28-tetrabutoxy-11,17,23-tris{[(tert-butoxycarbonyl) 
amino]methyl}calix[4]arene (7) 
 
 
 
25,26,27,28-Tetrabutoxy-5,11,17,23-tetrakis(aminomethyl)calix[4]arene tetrahydrochloride 
(1.0 g, 1.10 mmol) was dissolved in a mixture of anhydrous MeOH (10 mL) and Et3N (1 mL). 
Di-tert-butylcarbonate (0.72 g, 3.30 mmol) was added to the solution. The mixture was stirred 
for 18 h at r.t. Subsequently, MeOH was removed in vacuo, and the residue was purified by 
flash column chromatography (SiO2, DCM/MeOH, 100:1). Yield: 0.25 g (21%) 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 6.60 (s, 2H, Ar-H), 6.55 (s, 2H, Ar-H), 6.50 (s, 2H, 
Ar-H), 6.48 (s, 2H, Ar-H), 4.39 (d, 2H, J = 13.09, Ar-CH2-Ar), 4.38 (d, 2H, J = 13.07, 
Ar-CH2-Ar), 4.01 (bs, 4H, Ar-CH2-N), 3.92 (bs, 2H, Ar-CH2-N), 3.87 (m, 4H, J = 7.37, 
Ar-O-CH2-), 3.82 (m, 4H, Ar-O-CH2-), 3.72 (t, 2H, J = 4.79, Ar-CH2-N),  3.09 (d, 2H, 
Ar-CH2-Ar), 3.08 (d, 2H, Ar-CH2-Ar), 1.87 (m, 8H, Ar-O-CH2-CH2-), 1.43-1.45 (m, 35H, 
Ar-O-CH2-CH2-CH2-, -C(CH3)3), 0.98 (t, 12H, Ar-O-CH2-CH2-CH2-CH3). 
13C-NMR (75 MHz, CDCl3): δ (ppm) =  156.18, 156,01, 155.85, 155.44, 135.39, 135.24, 
134.91, 134.80, 132.15, 132.10, 127.43, 127.41, 126.90, 126.87, 75.09, 75.05, 75.00, 72.32, 
32.37, 32.32, 32.25, 31.09, 28.57, 28.49, 19.45, 19.38, 14.16, 14.14. 
MS (ESI-TOF, pos. CH2Cl2): [M+Na]+ calc. for C63H92N4NaO10 m/z 1087.6706, found m/z 
1087.6785; [M+H]+ calc. for C63H93N4O10 m/z 1065.6886, found m/z 1065.6972. 
 127
N,N’-Bis[(25,26,27,28-tetrabutoxy-11,17,23-tris{[(tert-butoxycarbonyl)amino]methyl]} 
calix[4]aren-5-yl)methyl]hexanediamide (8) 
 
 
 
5-(Aminomethyl)-25,26,27,28-tetrabutoxy-11,17,23-tris{[(tert-butoxycarbonyl) 
amino]methyl}calix[4]arene (250 mg, 0.235 mmol) was dissolved in the mixture of 
anhydrous CH2Cl2 (10 mL) and Et3N (1 mL). Adipic acid dichloride (21.5 mg, 0.117 mmol) 
was added to the solution. The reaction mixture was stirred for 1 h at r.t. and subsequently 
evaporated to dryness. The resulting residue was purified by flash column chromatography 
(SiO2, CH2Cl2/MeOH, 100:1). Yield: 0.17 g (64 %). 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 6.49-6.53 (m, 16H, Ar-H), 4.38 (d, 8H, J = 13.20, 
Ar-CH2-Ar), 4.37 (d, 8H, J = 12.96, Ar-CH2-Ar), 4.11 (bs, 4H, Ar-CH2-N), 3.96 (bs, 12H, 
Ar-CH2-N), 3.84 (m, 16H, Ar-O-CH2-), 3.08 (d, 16H, Ar-CH2-Ar), 2.27 (m, 4H, N-CO-CH2-), 
1.86 (m, 16H, Ar-O-CH2-CH2-), 1.73 (m, 4H, N-CO-CH2-CH2-), 1.44-1.46 (m, 70H, 
Ar-O-CH2 -CH2-CH2-, -C(CH3)3), 0.98 (t, 12H, Ar-O-CH2-CH2-CH2-CH3). 
13C-NMR (75 MHz, CDCl3): δ (ppm) =  172.91, 156.09, 156.02, 155.93, 135.12, 132.13, 
127.28, 79.30, 79.25, 75.04, 70.30, 68.78, 64.28, 54.83, 53.53, 50.83, 44.33, 42.84, 36.25, 
32.33, 31.12, 31.07, 29.80, 28.58, 27.44, 25.55, 19.44, 14.17. 
MS (ESI-TOF, pos. CH2Cl2): [M+Na]+ calc. for C132H190N8NaO22 m/z 2263.3920, found m/z 
2263.3994; [M+H]+ calc. for C132H191N8O22 m/z 2241.4100, found m/z 2241.4260. 
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N,N’-Bis{[11,17,23-tris(aminomethyl)-25,26,27,28-tetrabutoxycalix[4]aren-5-yl]methyl} 
hexanediamide Hexahydrochloride (9) 
 
 
N,N’-Bis[(25,26,27,28-tetrabutoxy-11,17,23-tris{[(tert-butoxycarbonyl)amino]methyl]}calix[
4]aren-5-yl)methyl]hexanediamide (0.17 g, 0.1mmol) was dissolved in anhydrous MeOH 
(10 mL). To this solution was added 1 M HCl (1 mL). The resulting solution was stirred for 
16 h at r.t. and subsequently evaporated to dryness. The solid was washed with acetone to 
yield 0.12 g (85%) of product. 
1H-NMR (300 MHz, DMSO-d6): δ (ppm) = 8.39 (bs, 18H, Benzal-NH3Cl), 7.18 (s, 4H, 
Ar-H), 7.08 (s, 4H, Ar-H), 7.01 (s, 4H, Ar-H), 6.75 (s, 4H, Ar-H), 4.40 (d, 4H, J = 12.25, 
Ar-CH2-Ar), 4.37 (d, 4H, J = 12.27, Ar-CH2-Ar), 3.96 (bs, 4H, Ar-CH2-N), 3.87 (bs, 16H, 
Ar-O-CH2-), 3.78 (m, 12H, Ar-CH2-N), 3.24 (d, 4H, Ar-CH2-Ar), 3.19 (d, 4H, Ar-CH2-Ar), 
2.21(m, 4H, N-CO-CH2-), 1.92 (m, 16H, Ar-O-CH2-CH2-), 1.47 (m, 20H, N-CO-CH2-CH2-, 
Ar-O-CH2- CH2-CH2-), 1.02 (t, 24H, Ar-O-CH2-CH2-CH2-CH3) 
13C-NMR (75 MHz, DMSO-d6): δ (ppm) =  172.11, 155.98, 155.71, 154.43, 134.80, 134.64, 
134.19, 133.68, 133.05, 129.40, 129.22, 127.88, 127.76, 127.31, 74.86, 74.70, 41.72, 35.09, 
31.86, 31.79, 29.94, 25.16, 18.82, 18.76, 13.91. 
MS (ESI-TOF, pos. MeOH, free base): [M+H]+ calc. for C102H143N8O10 m/z 1641.0954, 
found m/z 1641.1108. 
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5-(Aminomethyl)-11,17,23-tris{[2,3-bis(tert-butoxycarbonyl)guanidino]methyl}-25,26,27,
28-tetrabutoxycalix[4]arene (10) 
 
25,26,27,28-Tetrabutoxy-5,11,17,23-tetrakis(aminomethyl)calix[4]arene tetrahydrochloride 
(0.091 g, 0.1 mmol) was dissolved in the mixture of anhydrous MeOH (10 mL) and Et3N 
(1 mL). N,N’-bis-Boc-2-methyl-2-thiopseudourea (0.087 g, 0.3 mmol) was added to the 
solution followed by AgNO3 (0.11 g, 0.65 mmol). The mixture was stirred for 24 h at r.t. The 
catalyst was filtered off over celite and the solution was evaporated to dryness. The residue 
was purified by flash column chromatography (SiO2, DCM/cyclohexane, 80:20). Yield: 0.018 
g (12%) 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 11.52 (s, 2H, Boc-NH-), 11.48 (s, 1H, Boc-NH-), 
11.44 (s, 1H, Boc-NH-), 8.76 (s, 1H, Benzal-NH), 8.47 (s, 2H, Benzal-NH), 8.05 (s, 1H, 
Benzal-NH), 6.87 (s, 2H, Ar-H), 6.84 (s, 2H, Ar-H), 6.30 (s, 2H, Ar-H), 6.26 (s, 2H, Ar-H), 
4.45 (d, 4H, J = 13.08, Ar-CH2-Ar), 4.01 (m, 2H, Ar-CH2-N), 3.73 (m, 6H, Ar-CH2-N, 
Ar-O-CH2-), 3.62 (m, 8H, Ar-CH2-N, Ar-O-CH2-), 3.10 (d, 4H, Ar-CH2-Ar), 1.89 (m, 8H, 
Ar-O-CH2-CH2-), 1.46-1.51 (m, 62H, Ar-O-CH2-CH2-CH2-, -C(CH3)3), 0.98 (m, 12H, 
Ar-O-CH2-CH2-CH2-CH3). 
13C-NMR (75 MHz, CDCl3): δ (ppm) =  163.77, 163.62, 156.24, 155.92, 155.53, 153.47, 
153.26, 153.08, 137.02, 136.48, 136.18, 134.18, 133.68, 130.51, 130.05, 83.54, 83.02, 82.86, 
79.49, 79.25, 79.14, 75.20, 75.17, 75.02, 72.51, 69.12, 61.98, 53.55, 45.05, 40.46, 29.14, 
28.89, 28.54, 28.45, 28.20, 27.74, 27.69, 27.48, 19.66, 19.26, 14.75, 14.65, 13.65. 
MS (ESI-TOF, pos. CH2Cl2): [M+Na]+ calc. for C81H122N10NaO16 m/z 1513.8932, found m/z 
1513.8998; [M+H]+ calc. for C81H123N10O16 m/z 1491.9113, found m/z 1491.9163.
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N,N’-Bis(11,17,23-Tris{[2,3-bis(tert-butoxycarbonyl)guanidino]methyl}-25,26,27,28- 
tetrabutoxycalix[4]aren-5-ylmethyl}hexanediamide (11) 
 
 
5-(Aminomethyl)-11,17,23-tris{[2,3-bis(tert-butoxycarbonyl)guanidino]methyl}-25,26,27,28-
tetrabutoxycalix[4]arene (0.018 g, 0.012 mmol) was dissolved in the mixture of anhydrous 
CH2Cl2 (10 mL) and Et3N (1 mL). Adipic acid dichloride (1.1 mg, 0.006 mmol) was added to 
the solution. The reaction mixture was stirred for 1 h at r.t. and subsequently evaporated to 
dryness. The resulting residue was purified by flash column chromatography (SiO2, 
DCM/cyclohexane, 20:80). Yield: 0.012 g (66 %). 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 11.48 (s, 4H, Boc-NH-), 11.46 (s, 2H, Boc-NH-), 
8.44 (s, 2H, Benzal-NH), 8.35 (s, 2H, Benzal-NH), 8.29 (s, 2H, Benzal-NH), 8.20 (s, 2H, 
Benzal-NH), 6.64 (s, 8H, Ar-H), 6.49 (s, 4H, Ar-H), 6.42 (s, 4H, Ar-H), 4.38 (m, 8H, J = 
12.50, Ar-CH2-Ar), 4.11 (m, 4H, Ar-CH2-N), 3.90 (m, 8H, Ar-CH2-N), 3.85 (m, 8H, 
Ar-O-CH2-), 3.76 (m, 8H, Ar-O-CH2-), 3.62 (m, 4H, Ar-CH2-N), 3.09 (m, 8H, Ar-CH2-Ar), 
2.20 (m, 4H, N-CO-CH2-), 1.86 (m, 16H, Ar-O-CH2-CH2-), 1.65 (m, 4H, N-CO-CH2-CH2-), 
1.45-1.50 (m, 124H, Ar-O-CH2-CH2-CH2-, -C(CH3)3), 0.98 (m, 24H, Ar-O-CH2-CH2-CH2 
-CH3). 
13C-NMR (75 MHz, CDCl3): δ (ppm) =  163.69, 155.75, 153.18, 135.47, 135.09, 134.51, 
130.41, 130.03, 130.00, 129.09, 129.05, 129.01, 128.94, 128.90, 128.84, 128.34, 82.96, 79.16, 
29.15, 28.91, 28.48, 28.20, 27.73, 27.48, 14.73, 14.65, 13.68, 13.62. 
MS (ESI-TOF, pos. CH2Cl2): [M+2Na]2+ calc. for C168H250N20Na2O34 m/2z 1569.4132, 
found m/2z 1569.4113; [M+2H]2+ calc. for C168H252N20O34 m/2z 1547.4313, found m/2z 
1547.4319.
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N,N’-Bis({25,26,27,28-Tetrabutoxy 11,17,23-tris[(guanidinium)methyl]calix[4]arene-5-yl} 
methyl)hexanediamide Hexachloride (12) 
 
 
 
N,N’-Bis(11,17,23-Tris{[2,3-bis(tert-butoxycarbonyl)guanidino]methyl}-25,26,27,28- 
tetrabutoxycalix[4]aren-5-ylmethyl}hexanediamide (0.012 g, 0.004 mmol) was dissolved in 
anhydrous MeOH (10 mL). To this solution was added 1 M HCl (1 mL). The resulting 
solution was stirred for 16 h at r.t. and subsequently evaporated to dryness. The solid was 
washed with acetone to yield 0.007 g (85%) of product. 
 
1H-NMR (300 MHz, DMSO-d6): δ (ppm) = 7.84 (bs, 2H, CNH2Cl), 7.00-7.50 (bs, 8H, 
Benzal-NH), 6.71 (s, 4H, Ar-H), 6.70 (s, 4H, Ar-H), 6.66 (s, 4H, Ar-H), 6.60 (s, 4H, Ar-H), 
4.31 (m, 8H, Ar-CH2-Ar), 4.05 (m, 16H, Ar-CH2-N), 3.80 (m, 16H, Ar-O-CH2-), 3.10 (m, 8H, 
Ar-CH2-Ar), 2.13 (m, 4H, N-CO-CH2-), 1.86 (m, 16H, Ar-O-CH2-CH2-), 1.36-1.52 (m, 20H, 
N-CO-CH2-CH2-, Ar-O-CH2-CH2-CH2-), 0.95 (m, 24H, Ar-O-CH2-CH2-CH2-CH3). 
 
13C-NMR (125.6 MHz, CD3OD): 159.32, 158.55, 158.50, 157.81, 157.51, 156.81, 137.08, 
136.91, 136.42, 135.90, 133.34, 130.88, 129.14, 129.07, 128.95, 128.70, 76.27, 73.78, 70.62, 
46.13, 43.90, 43.05, 36.89, 33.71, 33.67, 33.61, 32.04, 31.97, 28.38, 26.75, 20.74, 20.69, 
20.62, 14.65, 14.63, 14.60. 
 
MS (ESI-TOF, pos. MeOH, free base): [M+3H]3+ calc. for C108H157N20O10 m/3z 631.4125, 
found m/3z 631.4155. 
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5,11,17,23-Tetrakis{[2,3-bis(tert-butoxycarbonyl)guanidino]methyl}-25,26,27,28- 
tetrabutoxycalix[4]arene (13) 
 
 
25,26,27,28-Tetrabutoxy-5,11,17,23-tetrakis(aminomethyl)calix[4]arene tetrahydrochloride 
(0.091 g, 0.1 mmol) was dissolved in the mixture of anhydrous MeOH (10 mL) and Et3N 
(1 mL). N,N’-bis-Boc-2-methyl-2-thiopseudourea (0.17 g, 0.59 mmol) was added to the 
solution followed by AgNO3 (0.11 g, 0.65 mmol). The mixture was stirred for 24 h at r.t. The 
catalyst was filtered off over celite and the solution was evaporated to dryness. The residue 
was purified by flash column chromatography (SiO2, DCM/cyclohexane, 70:30). Yield: 0.062 
g (36%) 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 11.45 (s, 4H, H-11), 8.26 (t, 4H, J = 4.62, H-3), 6.59 
(s, 8H, H-5), 4.38 (d, 4H, J = 12.99, H-6), 4.27 (d, 4H, H-4), 3.85 (t, 8H, J = 7.55, H-7), 3.10 
(d, 4H, H-6), 1.89 (quintet, 8H, H-8), 1.45-1.48 (m, 80H, H-9, H-1, H-2), 0.98 (t, 12H, H-10). 
13C-NMR (75 MHz, CDCl3): δ (ppm) = 163.68, 156.00, 155.66, 153.10, 135.01, 130.56, 
127.88, 82.78, 81.96, 75.07, 44.96, 32.31, 28.41, 28.15, 26.96, 19.40, 14.14. 
MS (ESI-TOF, pos. CH2Cl2): [M+Na]+ calc. for C92H140N12NaO20 m/z 1756.0199, found m/z 
1756.0345; [M+H]+ calc. for C92H141N12O20 m/z 1734.0380, found m/z 1734.0510. 
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25,26,27,28-Tetrabutoxy-5,11,17,23-tetrakis[(guanidinium)methyl]calix[4]arene 
Tetrachloride (14) 
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5,11,17,23-Tetrakis{[2,3-bis(tert-butoxycarbonyl)guanidino]methyl}-25,26,27,28- 
tetrabutoxycalix[4]arene (0.062 g, 0.036 mmol) was dissolved in anhydrous MeOH (10 mL). 
To this solution was added 1 M HCl (1 mL). The resulting solution was stirred for 16 h at r.t. 
and subsequently evaporated to dryness. The solid was washed with acetone to yield 0.028 g 
(72%) of product. 
1H-NMR (300 MHz, DMSO-d6): δ (ppm) = 7.90 (t, 4H, J = 5.41, H-1), 7.02-7.36 (bs, 16H, 
H-9, H-10, H-11), 6.69 (s, 8H, H-3), 4.32 (d, 4H, J = 12.91, H-4), 4.08 (d, 4H, H-2), 3.80 (t, 
8H, J = 7.22, H-5), 3.15 (d, 4H, H-4), 1.85 (quintet, 8H, H-6), 1.41 (sextet, 8H, H-7), 0.96 (t, 
12H, H-8). 
13C-NMR (75 MHz, DMSO-d6): δ (ppm) = 156.66, 155.50, 134.50, 130.17, 127.58, 74.54, 
44.03, 31.77, 30.12, 18.81, 13.87. 
MS (ESI-TOF, pos. MeOH, free base): [M+H]+ calc. for C52H77N12O4 m/z 933.6185, found 
m/z 933.6296. 
 134 
N, N’-bis-Boc-2-methyl-2-thiopseudourea (15) [158] 
 
 
A mixture of di-tert-butyl dicarbonate (10 g, 45.82 mmol) and 2-methyl-2-thiopseudourea 
sulphate (2.0 g, 9.0 mmol) in 100 mL of 1:1 CH2Cl2 and saturated NaHCO3 were stirred for 2 
weeks at room temperature. Afterwards it was extracted with dichloromethane (100 mL) and 
purified by flash column chromatography (n-hexane: ethyl acetate 80:20) gave a white 
product. Yield: 78 % 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 1.51 (s, 18 H, H-1), 2.39 (s, 3 H, H-2), 11.59 (s, 1H, 
H-3).  
13C-NMR (75 MHz, CDCl3): δ (ppm) = 161.26, 151.30, 149.19, 83.92, 81.48, 28.57, 14.93. 
MS (ESI-TOF, pos. CH2Cl2): [M+Na]+ calc. for C12H22N2NaO4S m/z 313.1192, found m/z 
313.1230. 
 
 
 
2-Trichloroacety-1-methylimidazole (16) [164] 
 
 
N-Methylimidazole (50 g, 0.60 mol) in DCM (500 mL) was added dropwise to trichloroacetyl 
chloride (110 g, 0.60 mol) in CH2Cl2 (500 mL) over a period of 12 h. The mixture was then 
stirred for 12 h and cooled to 0 °C, and Et3N (85 mL, 0.60 mol) was added dropwise over 10 
h. The solvent was evaporated and the residue purified by flash chromatography (silica gel, 
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1:1 ethyl acetate/cyclohexane) to yield 94.6g, 68% as a white solid. 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 7.26 (s, 1H, H-1), 7.08 (s, 1H, H-2), 3.98 (s, 3H, 
H-3). 
13C-NMR (75 MHz, CDCl3): δ (ppm) = 172.45, 136.35, 130.97, 128.78, 95.03, 77.26, 37.36. 
MS (ESI-TOF, pos. CH2Cl2): [M+H]+ calc. for C6H6Cl3N2O m/z 226.9540, found m/z 
226.9555. 
 
 
4-Nitro-2-trichloroacety-1-methylimidazole (17) [164] 
 
 
To acetic anhydride (100 mL) at 0 °C was added dropwise fuming HNO3 (15 mL), followed 
by H2SO4 (0.10 mL). 2-trichloroacety-1-methylimidazole (15.0 g, 0.066 mol) was added 
slowly, and the solution was warmed slowly to room temperature and stirred overnight. The 
mixture was diluted with ice-water and extracted with chloroform. The organic layer was 
washed with NaHCO3 (sat.) and dried (MgSO4) and concentrated. The residue was purified by 
flash chromatography (silica gel, 1:1 ethyl acetate/cyclohexane) to yield 11.2 g, 62% as a 
white solid. 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 7.96 (s, 1H, H-1), 4.16 (s, 3H, H-2). 
13C-NMR (75 MHz, CDCl3): δ (ppm) = 172.96, 133.73, 130.68, 126.12, 93.62, 38.44. 
MS (ESI-TOF, pos. CH2Cl2): [M+H]+ calc. for C6H5Cl3N3O3 m/z 271.9391, found m/z 
271.9399. 
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Methyl 1-Methyl-4-nitroimidazole-2-carboxylate (18) [164] 
 
 
To 4-nitro-2-trichloroacety-1-methylimidazole (5.4 g, 0.02 mol) in anhydrous methanol (200 
mL) was added sodium methoxide (4.32 g, 0.08 mol) and the solution stirred for 6 h. The 
reaction was quenched by the addition of HCl (pH=7.0). The solvent was evaporated. Water 
and DCM was added. The organic layer was dried by MgSO4, and the residue was purified by 
flash chromatography (silica gel, 1:1 ethyl acetate/cyclohexane) to yield 3.0 g (80%) as a 
white solid. 
1H-NMR (300 MHz, DMSO-d6): δ (ppm) = 8.60 (s, 1H, H-1), 3.97 (s, 3H, H-3), 3.86 (s, 3H, 
H-2). 
13C-NMR (75 MHz, DMSO-d6): δ (ppm) = 158.13, 144.88, 134.68, 126.77, 52.57, 36.70. 
MS (ESI-TOF, pos. CH2Cl2): [M+Na]+ calc. for C6H7N3NaO4 m/z 208.0329, found m/z 
208.0344; [M+H]+ calc. for C6H8N3O4 m/z 186.0509, found m/z 186.0528. 
 
 
 
Methyl 4-[(tert-Butoxycarbonyl)amino]-1-methylimidazole-2-carboxylate (19) [164] 
 
 
To methyl 1-methyl-4-nitroimidazole-2-carboxylate (1.85 g, 0.01 mol) in anhydrous methanol 
(100 mL) was added tert-butyl dicarbonate (6.5 g, 0.03 mol) followed by 10% Pd/C (0.10 g), 
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and the mixture was stirred under a hydrogen atmosphere for 24 h. H2 was removed. The 
catalyst was filtered off over Celite and the solvent was evaporated. Water and DCM was 
added. The organic layer was dried by MgSO4 and the residue was purified by flash 
chromatography (silica gel, 1:1 ethyl acetate/cyclohexane) to yield 2.1 g (82%) as a white 
solid. 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 7.23 (s, 1H, H-2), 6.85 (s, 1H, H-3), 3.97 (s, 3H, 
H-5), 3.92 (s, 3H, H-4), 1.50 (s, 9H, H-1). 
13C-NMR (75 MHz, CDCl3): δ (ppm) = 159.31, 152.64, 149.72, 137.99, 113.33, 81.08, 52.35, 
35.98, 28.41. 
MS (ESI-TOF, pos. CH2Cl2): [M+Na]+ calc. for C11H17N3NaO4 m/z 278.1111, found m/z 
278.1124; [M+H]+ calc. for C11H18N3O4 m/z 256.1292, found m/z 256.1306. 
 
 
 
4-[(tert-Butoxycarbonyl)amino]-1-methylimidazole-2-carboxylic Acid (20) [164] 
 
To sodium tert-butoxide (9.6 g, 0.1 mol) in dry THF (60 mL) at 0 °C was added water (100 
mL) and the solution stirred for one hour. Methyl 4-[(tert-Butoxycarbonyl)amino]-1- 
methylimidazole-2-carboxylate (2.6 g, 0.01 mol) was added and the mixture stirred at room 
temperature for 3 h. It was then diluted with cold water and ethyl acetate, the layers were 
separated. The aqueous layer was acidified by HCl. The aqueous layer was extracted with 
ethyl acetate, dried (MgSO4), and concentrated to yield 2.2 g (91%) as a white solid.  
1H-NMR (300 MHz, CDCl3): δ (ppm) = 10.92 (s, 1H, H-4), 7.18 (s, 1H, H-2), 4.14 (s, 3H, 
H-3), 1.54 (s, 9H, H-1). 
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13C-NMR (75 MHz, CDCl3): δ (ppm) = 159.72, 152.78, 133.90, 132.83, 109.28, 81.53, 35.57, 
28.23. 
MS (ESI-TOF, pos. CH2Cl2): [M+Na]+ calc. for C10H15N3NaO4 m/z 264.0955, found m/z 
264.0991; [M+H]+ calc. for C10H15N3O4 m/z 241.1057, found m/z 241.1007. 
 
 
 
3-[(4-tert-Butoxycarbonylamino-1-methyl-1H-imidazole-2-carbonyl)-amino]-propionic 
acid methyl ester (21) [165] 
 
 
4-[(tert-Butoxycarbonyl)amino]-1-methylimidazole-2-carboxylic Acid (2.41 g, 0.01 mol) was 
dissolved in 20 mL of anhydrous DMF. HBTU (3.79 g, 0.01 mol) was added followed by 
DIEA (10 mL) and the solution stirred for 10 min. β-Alanine methyl ester hydrochloride (1.40 
g, 0.01 mol) was added to the solution. The mixture stirred at room temperature for 18 h. 
DMF was removed in vacuo. The residue was purified by flash chromatography (silica gel, 
1:1 ethyl acetate/cyclohexane) to yield 2.3 g (71%) as a white solid. 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 7.63 (bs, 1H, H-5), 7.19 (s, 1H, H-2), 7.08 (s, 1H, 
H-3), 3.97 (s, 3H, H-8), 3.68 (s, 3H, H-4), 3.62 (q, 2H, H-6), 2.60 (t, 2H, J = 6.38, H-7), 1.49 
(s, 9H, H-1). 
13C-NMR (75 MHz, CDCl3): δ (ppm) = 172.62, 158.94, 152.66, 136.53, 133.79, 112.01, 
80.93, 51.95, 35.66, 34.63, 34.04, 28.39. 
MS (ESI-TOF, pos. CH2Cl2): [M+Na]+ calc. for C14H22N4NaO5 m/z 349.1482, found m/z 
349.1514.
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3-({4-[(4-tert-Butoxycarbonylamino-1-methyl-1H-imidazole-2-carbonyl)-amino]-1-methy
l-1H-imidazole-2-carbonyl}-amino)-propionic acid methyl ester (22) [165] 
 
 
2 mL of the mixture (80% TFA/DCM/0.4 M PhSH) was added to (21) (2.3 g, 7 mmol), and 
the reaction mixture was stirred for 10 min. The solvent was removed in vacuo. 
Separately, (20) (1.68 g, 7 mmol) was dissolved in 20 mL anhydrous DMF. HBTU (2.6 g, 7 
mmol) was added followed by DIEA (10 mL). The reaction mixture was stirred for 10 min 
and immediately added to the deprotected compound. The mixture was stirred at room 
temperature for 18 h. DMF was removed in vacuo. The residue was purified by flash 
chromatography (silica gel, 1:1 ethyl acetate/cyclohexane) to yield 2.3 g (73%) as a white 
solid. 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 9.45 (s, 1H, H-3), 7.69 (t, 1H, J = 6.29, H-4), 7.40 
(m, 2H, H-2, Im-H), 7.16 (s, 1H, Im-H), 4.01 (s, 3H, Im-CH3), 4.00 (s, 3H, Im-CH3), 3.69 (s, 
3H, H-7), 3.65 (q, 2H, H-5), 2.62 (t, 2H, J = 6.23, H-6), 1.50 (s, 9H, H-1). 
13C-NMR (75 MHz, CDCl3): δ (ppm) = 172.68, 159.10, 156.00, 152.75, 137.07, 135.44, 
134.26, 113.87, 112.79, 80.99, 51.99, 35.75, 35.68, 34.69, 34.03, 28.41. 
MS (ESI-TOF, pos. CH2Cl2): [M+Na]+ calc. for C19H27N7NaO6 m/z 472.1915, found m/z 
472.1946; [M+H]+ calc. for C19H28N7O6 m/z 450.2096, found m/z 450.2129. 
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3-{[4-({4-[(4-tert-Butoxycarbonylamino-1-methyl-1H-imidazole-2-carbonyl)-amino]-1- 
methyl-1H-imidazole-2-carbonyl}-amino)-1-methyl-1H-imidazole-2-carbonyl]-amino}- 
propionic acid methyl ester (23) [165] 
 
 
2 mL of the mixture (TFA : DCM = 4 : 1) was added to (22) (2.3 g, 5.12 mmol), and the 
reaction mixture was stirred for 10 min. The solvent was removed in vacuo. 
Separately, (20) (1.23 g, 5.12 mmol) was dissolved in 20 mL anhydrous DMF. HBTU (1.94 g, 
5.12 mmol) was added followed by DIEA (10 mL). The reaction mixture was stirred for 10 
min and immediately added to the deprotected compound. The mixture was stirred at room 
temperature for 18 h. DMF was removed in vacuo. The residue was purified by flash 
chromatography (silica gel, 1:1 ethyl acetate/cyclohexane) to yield 2.0 g (68%) as a white 
solid. 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 9.40 (s, 1H, H-3), 9.38 (s, 1H, H-4), 7.47 (s, 1H, 
H-2), 7.41 (s, 1H, Im-H), 7.18 (bs, 2H, Im-H), 4.05 (s, 3H, Im-CH3), 4.04 (s, 3H, Im-CH3), 
4.02 (s, 3H, Im-CH3), 3.72 (s, 3H, H-8), 3.67 (q, 2H, H-6), 2.64 (t, 2H, J = 6.22, H-7), 1.52 (s, 
9H, H-1). 
13C-NMR (75 MHz, CDCl3): δ (ppm) = 172.60, 159.18, 156.13, 156.01, 152.80, 137.24, 
135.84, 135.46, 134.33, 133.78, 133.36, 125.59, 114.59, 113.90, 112.79, 80.87, 51.96, 35.71, 
35.67, 34.72, 34.05, 28.40. 
MS (ESI-TOF, pos. CH2Cl2): [M+Na]+ calc. for C24H32N10NaO7 m/z 595.2348, found m/z 
595.2384; [M+H]+ calc. for C24H33N10O7 m/z 573.2528, found m/z 573.2560. 
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Succinic acid monobenzyl ester (24) 
 
To succinyl chloride (1.55 g, 0.01 mol) in anhydrous DCM (100 mL) at -20 °C was added 
benzyl alcohol (1.08 g, 0.01 mol) and the reaction mixture was warmed slowly to room 
temperature and stirred for 3 days. Water (100 mL) was added followed by NaHCO3 (1.68 g, 
0.02 mol). The mixture was stirred at room temperature for 3 h. The layers were separated. 
The organic layer was dried by MgSO4. The residue was purified by flash chromatography 
(silica gel, 1:1 ethyl acetate/cyclohexane) to yield 0.35 g (17%) as a white solid. 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 7.23-7.28 (m, 5H, H-1, H-2, H-3), 5.06 (s, 2H, H-4), 
2.57-2.64 (m, 4H, H-5, H-6). 
13C-NMR (75 MHz, CDCl3): δ (ppm) = 177.83, 172.10, 135.82, 128.72, 128.44, 128.35, 
66.80, 29.04, 28.98. 
MS (ESI-TOF, pos. CH2Cl2): [M+Na]+ calc. for C11H12NaO4 m/z 231.0628, found m/z 
231.0653. 
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N-(2-{2-[2-(2-Methoxycarbonyl-ethylcarbamoyl)-1-methyl-1H-imidazol-4-ylcarbamoyl]-
1-methyl-1H-imidazol-4-ylcarbamoyl}-1-methyl-1H-imidazol-4-yl)-succinamic acid 
benzyl ester (25) 
 
2 mL of the mixture (TFA : DCM = 4 : 1) was added to (23) (0.98 g, 1.48 mmol), and the 
reaction mixture was stirred for 10 min. The solvent was removed in vacuo. 
Separately, (24) (0.308 g, 1.48 mmol) was dissolved in 20 mL anhydrous DMF. HBTU (0.56 
g, 1.48 mmol) was added followed by DIEA (10 mL). The reaction mixture was stirred for 10 
min and immediately added to the deprotected compound. The mixture was stirred at room 
temperature for 18 h. DMF was removed in vacuo. The residue was purified by flash 
chromatography (silica gel, 1:1 ethyl acetate/cyclohexane) to yield 0.64 g (65%) as a white 
solid. 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 9.62 (bs, 2H, H-1, H-2), 8.90 (s, 1H, H-4), 7.81 (t, 
1H, J = 6.09, H-3), 7.39 (s, 1H, Im-H), 7.37 (s, 1H, Im-H), 7.36 (s, 1H, Im-H), 7.26 (m, 5H, 
H-5, H-6, H-7), 5.05 (s, 2H, H-8), 3.95 (s, 3H, Im-CH3), 3.94 (s, 3H, Im-CH3), 3.93 (s, 3H, 
Im-CH3), 3.61 (q, 2H, H-12), 3.60 (s, 3H, H-9), 2.72 (t, 2H, J = 4.67, H-11), 2.69 (t, 2H, 
H-10), 2.57 (t, 2H, J = 6.34, H-13). 
13C-NMR (75 MHz, CDCl3): δ (ppm) = 172.77, 172.69, 169.43, 158.65, 156.02, 155.78, 
136.04, 135.83, 135.71, 134.75, 134.02, 133.66, 132.97, 128.68, 128.39, 128.29, 114.94, 
114.90, 114.03, 66.77, 52.00, 35.94, 35.85, 34.94, 33.92, 30.93, 29.41. 
MS (ESI-TOF, pos. CH2Cl2): [M+Na]+ calc. for C30H34N10NaO8 m/z 685.2453, found m/z 
685.2504; [M+H]+ calc. for C30H35N10O8 m/z 663.2634, found m/z 663.2679.
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N-(2-{2-[2-(2-Methoxycarbonyl-ethylcarbamoyl)-1-methyl-1H-imidazol-4-ylcarbamoyl]-
1-methyl-1H-imidazol-4-ylcarbamoyl}-1-methyl-1H-imidazol-4-yl)-succinamic acid (26) 
 
 
(25) (0.3 g, 0.36 mmol) were dissolved in 20 mL of the mixture (THF : H2O = 4 : 1) and Pd/C 
(0.03 g, 10 weight-%) was added. The hydrogenation was then carried out for 24 h. The 
catalyst was filtered off over Celite and the solution was evaporated to dryness. The residue 
was washed with DCM to yield 0.185 g (90%) as a white solid.  
1H-NMR (300 MHz, DMSO-d6): δ (ppm) = 10.40 (s, 1H, Im-NH-CO), 9.66 (s, 1H, 
Im-NH-CO), 9.62 (s, 1H, Im-NH-CO), 8.24 (t, 1H, J = 5.51, H-1), 7.63 (s, 1H, Im-H), 7.52 (s, 
1H, Im-H), 7.49 (s, 1H, Im-H), 4.00 (s, 3H, Im-CH3), 3.95 (s, 3H, Im-CH3), 3.95 (s, 3H, 
Im-CH3), 3.61 (s, 3H, H-6), 3.45 (q, 2H, H-2), 2.52-2.60 (m, 6H, H-3, H-4, H-5). 
13C-NMR (75 MHz, DMSO-d6): δ (ppm) = 173.70, 171.84, 169.01, 158.36, 155.51, 155.37, 
136.45, 135.06, 134.55, 134.12, 133.27, 132.72, 114.68, 114.53, 114.10, 51.40, 35.21, 35.08, 
34.98, 34.46, 33.49, 29.95, 28.78. 
MS (ESI-TOF, pos. MeOH): [M+Na]+ calc. for C23H28N10NaO8 m/z 595.1984, found m/z 
595.2010; [M+H]+ calc. for C23H29N10O8 m/z 573.2164, found m/z 573.2188. 
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N-(2-{2-[2-(2-Carboxy-ethylcarbamoyl)-1-methyl-1H-imidazol-4-ylcarbamoyl]-1-methyl
-1H-imidazol-4-ylcarbamoyl}-1-methyl-1H-imidazol-4-yl)-succinamic acid (27) 
 
 
To sodium tert-butoxide (0.1 g, 0.001 mol) in dry THF (10 mL) at 0 °C was added water (10 
mL) and the solution was stirred for one hour. (26) (0.64 g, 1 mmol) was added and the 
mixture was stirred at room temperature for 3 h. The reaction was cooled and quenched by the 
addition of HCl. The solvent was removed in vacuo. The product was extracted with methanol. 
Yield: 0.32 g (60%) 
1H-NMR (300 MHz, D2O): δ (ppm) = 7.16 (s, 1H, Im-H), 7.00 (s, 1H, Im-H), 6.95 (s, 1H, 
Im-H), 3.81 (s, 3H, Im-CH3), 3.80 (s, 3H, Im-CH3), 3.78 (s, 3H, Im-CH3), 3.33 (t, 2H, J = 
7.31, H-1), 2.38-2.44 (m, 6H, H-2, H-3, H-4). 
13C-NMR (75 MHz, D2O): δ (ppm) = 180.85, 180.13, 172.27, 159.16, 155.23, 155.08, 135.43, 
135.07, 134.75, 133.63, 132.67, 132.58, 114.98, 114.40, 114.04, 37.42, 36.73, 36.39, 35.70, 
35.49, 32.43, 31.96. 
MS (ESI-TOF, pos. CH2Cl2): [M+Na]+ calc. for C22H26N10NaO8 m/z 581.1827, found m/z 
581.1848; [M+H]+ calc. for C22H27N10O8 m/z 559.2008, found m/z 559.2017. 
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3-({4-[(4-{[4-(2,5-Dioxo-pyrrolidin-1-yl)-1-methyl-1H-imidazole-2-carbonyl]-amino}-1- 
methyl-1H-imidazole-2-carbonyl)-amino]-1-methyl-1H-imidazole-2-carbonyl}-amino)- 
propionic acid methyl ester (28) 
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(26) (57.3 mg, 0.1 mmol) was dissolved in 20 mL anhydrous DMF. HBTU (38.0 mg, 0.1 
mmol) was added followed by DIEA (10 mL). The reaction mixture was stirred for 10 min 
and immediately added to (7) (107 mg, 0.1 mmol). The mixture was stirred at room 
temperature for 18 h. DMF was removed in vacuo. The residue was purified by flash 
chromatography (silica gel, 1:1 ethyl acetate/cyclohexane) to yield 42.1 mg (74%) as a white 
solid. 
1H-NMR (300 MHz, DMSO-d6): δ (ppm) = 10.09 (s, 1H, Im-NH-CO), 9.81 (s, 1H, 
Im-NH-CO), 8.32 (t, 1H, J = 5.51, Im-CO-NH), 7.64 (s, 1H, Im-H), 7.52 (s, 1H, Im-H), 7.52 
(s, 1H, Im-H), 4.05 (s, 3H, Im-CH3), 4.02 (s, 3H, Im-CH3), 3.96 (s, 3H, Im-CH3), 3.62 (s, 3H, 
H-1), 3.46 (q, 2H, H-3), 2.83 (m, 4H, H-4, H-5), 2.59 (t, 2H, H-2). 
13C-NMR (125.6 MHz, DMSO-d6): δ (ppm) = 176.58, 171.84, 158.42, 155.49, 155.44, 
155.35, 136.03, 134.99, 134.64, 134.50, 134.12, 134.08, 133.36, 128.75, 123.00, 51.44, 45.67, 
35.58, 35.23, 35.10, 34.50, 33.51, 28.38. 
MS (ESI-TOF, pos. MeOH): [M+Na]+ calc. for C23H26N10NaO7 m/z 577.1878, found m/z 
577.1879; [M+H]+ calc. for C23H27N10O7 m/z 555.2059, found m/z 555.2048. 
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4-[(4-tert-Butoxycarbonylamino-1-methyl-1H-imidazole-2-carbonyl)-amino]-1-methyl-1
H-imidazole-2-carboxylic acid methyl ester (29) [165] 
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2 mL of the mixture (TFA : DCM = 4 : 1) was added to methyl 4-[(tert-butoxycarbonyl) 
amino]-1-methylimidazole-2-carboxylate (19) (2.55 g, 10 mmol), and the reaction mixture 
was stirred for 10 min. The solvent was removed in vacuo. 
Separately, 4-[(tert-Butoxycarbonyl)amino]-1-methylimidazole-2-carboxylic Acid (20) (2.40 
g, 10 mmol) was dissolved in 20 ml anhydrous DMF. HBTU (3.79 g, 10 mmol) was added 
followed by DIEA (10 mL). The reaction mixture was stirred for 10 min and immediately 
added to the deprotected compound. The mixture was stirred at room temperature for 18 h. 
DMF was removed in vacuo. The residue was purified by flash chromatography (silica gel, 
1:1 ethyl acetate/cyclohexane) to yield 2.65 g (70%) as a white solid. 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 7.57 (s, 1H, Im-NH), 7.17 (s, 1H, Im-H), 6.87 (s, 1H, 
Im-H), 4.04 (s, 3H, Im-CH3), 4.02 (s, 3H, Im-CH3), 3.96 (s, 3H, Im-COOCH3), 1.52 (s, 9H, 
-C(CH3)3). 
13C-NMR (75 MHz, CDCl3): δ (ppm) = 159.15, 156.17, 152.62, 137.19, 136.83, 133.09, 
131.66, 114.99, 112.75, 80.83, 52.40, 35.98, 35.56, 28.33. 
MS (ESI-TOF, pos. CH2Cl2): [M+Na]+ calc. for C16H22N6NaO5 m/z 401.1544, found m/z 
401.1582; [M+H]+ calc. for C16H23N6O5 m/z 379.1724, found m/z 379.1755. 
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4-({4-[(4-tert-Butoxycarbonylamino-1-methyl-1H-imidazole-2-carbonyl)-amino]-1- 
methyl-1H-imidazole-2-carbonyl}-amino)-1-methyl-1H-imidazole-2-carboxylic acid 
methyl ester (30) [165] 
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2 mL of the mixture (TFA : DCM = 4 : 1) was added to (29) (2.65 g, 7 mmol), and the 
reaction mixture was stirred for 10 min. The solvent was removed in vacuo. 
Separately, 4-[(tert-butoxycarbonyl)amino]-1-methylimidazole-2-carboxylic Acid (20) (2.40 g, 
10 mmol) was dissolved in 20 mL anhydrous DMF. HBTU (3.79 g, 10 mmol) was added 
followed by DIEA (10 mL). The reaction mixture was stirred for 10 min and immediately 
added to the deprotected compound. The mixture was stirred at room temperature for 18 h. 
DMF was removed in vacuo. The residue was purified by flash chromatography (silica gel, 
1:1 ethyl acetate/cyclohexane) to yield 2.18 g (62%) as a white solid. 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 9.62 (s, 1H, Im-NH), 9.32 (s, 1H, Im-NH), 7.58 (s, 
1H, Im-H), 7.45 (s, 1H, Im-H), 7.16 (s, 1H, Im-H), 4.04 (s, 3H, Im-CH3), 4.01 (s, 3H, 
Im-CH3), 4.00 (s, 3H, Im-CH3), 3.90 (s, 3H, Im-COOCH3), 1.50 (s, 9H, -C(CH3)3). 
13C-NMR (75 MHz, CDCl3): δ (ppm) = 159.10, 156.14, 156.00, 152.74, 137.16, 136.71, 
135.96, 133.41, 133.17, 131.67, 115.06, 114.59, 112.87, 80.94, 52.45, 36.12, 35.75, 35.68, 
28.41. 
MS (ESI-TOF, pos. CH2Cl2): [M+Na]+ calc. for C21H27N9NaO6 m/z 524.1977, found m/z 
524.2023; [M+H]+ calc. for C21H28N9O6 m/z 502.2157, found m/z 502.2200. 
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4-[(4-{[4-(3-Methoxycarbonyl-benzoylamino)-1-methyl-1H-imidazole-2-carbonyl]-amino
}-1-methyl-1H-imidazole-2-carbonyl)-amino]-1-methyl-1H-imidazole-2-carboxylic acid 
methyl ester (31) 
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2 mL of the mixture (TFA : DCM = 4 : 1) was added to (30) (1.00 g, 2 mmol), and the 
reaction mixture was stirred for 10 min. The solvent was removed in vacuo. 
Separately, mono-methyl isophthalate (0.36 g, 2 mmol) was dissolved in 20 mL anhydrous 
DMF. HBTU (0.76 g, 2 mmol) was added followed by DIEA (10 mL). The reaction mixture 
was stirred for 10 min and immediately added to the deprotected compound. The mixture was 
stirred at room temperature for 18 h. DMF was removed in vacuo. The residue was purified 
by flash chromatography (silica gel, 1:1 ethyl acetate/cyclohexane) to yield 0.47 g (42%) as a 
white solid. 
1H-NMR (300 MHz, DMSO-d6): δ (ppm) = 11.25 (s, 1H, Im-NH), 10.08 (s, 1H, Im-NH), 
9.59 (s, 1H, Im-NH), 8.31 (m, 1H, benzene-H), 8.15 (m, 3H, benzene-H), 7.74 (s, 1H, Im-H), 
7.74 (s, 1H, Im-H), 7.66 (s, 1H, Im-H), 4.03 (s, 3H, Im-CH3), 3.94 (s, 3H, Im-CH3), 3.91 (s, 
3H, Im-CH3), 3.88 (s, 3H, Im-COOCH3), 3.81 (s, 3H, benzene -COOCH3). 
13C-NMR (75 MHz, DMSO-d6): δ (ppm) = 165.71, 163.18, 158.69, 155.63, 155.30, 136.40, 
136.20, 135.00, 134.05, 133.72, 133.37, 133.16, 133.10, 132.21, 131.19, 129.86, 129.71, 
129.33, 129.00, 128.56, 52.33, 51.83, 35.60, 35.24, 35.08. 
MS (ESI-TOF, pos. CH2Cl2): [M+Na]+ calc. for C25H25N9NaO7 m/z 586.1769, found m/z 
586.1773; [M+H]+ calc. for C25H26N9O7 m/z 564.1950, found m/z 564.1911. 
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4-[(4-{[4-(2-Methoxycarbonyl-acetylamino)-1-methyl-1H-imidazole-2-carbonyl]-amino}-
1-methyl-1H-imidazole-2-carbonyl)-amino]-1-methyl-1H-imidazole-2-carboxylic acid 
methyl ester (32) 
 
N
N
HN
O
O
C
N
N
HN
OC
N
N
HN
O
O
O
O
 
2 mL of the mixture (TFA : DCM = 4 : 1) was added to (30) (1.00 g, 2 mmol), and the 
reaction mixture was stirred for 10 min. The solvent was removed in vacuo and then the 
residue was dissolved in 20 mL anhydrous DCM. Et3N (10 mL) was added to the solution. 
Methyl malonyl chloride (0.27 g, 2 mmol) was added to the deprotected compound. The 
mixture was stirred at room temperature for 18 h. DCM was removed in vacuo. The residue 
was purified by flash chromatography (silica gel, 1:1 ethyl acetate/cyclohexane) to yield 0.80 
g (80%) as a white solid. 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 9.78 (s, 1H, Im-NH), 9.39 (s, 1H, Im-NH), 9.28 (s, 
1H, Im-NH), 7.68 (s, 1H, Im-H), 7.50 (s, 1H, Im-H), 7.46 (s, 1H, Im-H), 4.06 (s, 6H, Im-CH3), 
4.06 (s, 3H, Im-CH3), 3.99 (s, 3H, Im-COOCH3), 3.83 (s, 3H, -CH2-COOCH3), 3.55 (s, 2H, 
-CH2-COOCH3). 
13C-NMR (75 MHz, CDCl3): δ (ppm) = 169.24, 162.32, 159.25, 156.20, 155.97, 136.77, 
135.91, 135.86, 133.54, 133.38, 131.70, 115.17, 114.66, 52.84, 52.43, 41.47, 36.12, 35.80, 
29.82. 
MS (ESI-TOF, pos. CH2Cl2): [M+Na]+ calc. for C20H23N9NaO7 m/z 524.1613, found m/z 
524.1680. 
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4-[(4-{[4-(3-Carboxy-benzoylamino)-1-methyl-1H-imidazole-2-carbonyl]-amino}-1- 
methyl-1H-imidazole-2-carbonyl)-amino]-1-methyl-1H-imidazole-2-carboxylic acid (33) 
 
N
N
HN
OH
O
C
N
N
HN
OC
N
N
HN
O
O
HO
O
 
To sodium hydroxide (0.1 g, 2.5 mmol) in dry THF (10 mL) at 0 °C was added water (10 mL) 
and the solution was stirred for one hour. (31) (0.47 g, 0.83 mmol) was added and the mixture 
was stirred at room temperature for 3 h. The reaction was cooled and quenched by the 
addition of HCl. The solvent was removed in vacuo. The residue was washed with acetone to 
yield 0.32 g (72%) as a white solid. 
1H-NMR (300 MHz, DMSO-d6): δ (ppm) = 11.20 (s, 1H, Im-NH), 10.01 (s, 1H, Im-NH), 
9.67 (s, 1H, Im-NH), 8.26 (d, 1H, benzene-H), 8.12 (d, 1H, benzene-H), 7.74 (s, 1H, 
benzene-H), 7.63-7.66 (m, 4H, Im-H, benzene-H), 4.04 (s, 3H, Im-CH3), 4.01 (s, 3H, 
Im-CH3), 3.94 (s, 3H, Im-CH3). 
13C-NMR (125.6 MHz, DMSO-d6): δ (ppm) = 166.79, 163.43, 159.80, 155.62, 155.41, 
136.48, 135.74, 135.06, 133.99, 133.46, 133.16, 132.31, 132.20, 131.79, 131.08, 128.84, 
128.82, 115.73, 115.26, 114.47, 35.67, 35.25, 35.10. 
MS (ESI-TOF, pos. DMSO): [M+Na]+ calc. for C23H21N9NaO7 m/z 558.1456, found m/z 
558.1472; [M+H]+ calc. for C23H22N9O7 m/z 536.1637, found m/z 536.1670. 
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4-[(4-{[4-(2-Carboxy-acetylamino)-1-methyl-1H-imidazole-2-carbonyl]-amino}-1-methyl
-1H-imidazole-2-carbonyl)-amino]-1-methyl-1H-imidazole-2-carboxylic acid (34) 
 
N
N
HN
OH
O
C
N
N
HN
OC
N
N
HN
O
O
HO
O
 
To sodium hydroxide (0.1 g, 2.5 mmol) in dry THF (10 mL) at 0 °C was added water (10 mL) 
and the solution was stirred for one hour. (32) (0.40 g, 0.80 mmol) was added and the mixture 
was stirred at room temperature for 3 h. The reaction was cooled and quenched by the 
addition of HCl. The solvent was removed in vacuo. The residue was washed with acetone to 
yield 0.30 g (79%) as a white solid. 
1H-NMR (300 MHz, DMSO-d6): δ (ppm) = 10.62 (s, 1H, Im-NH), 10.05 (s, 1H, Im-NH), 
9.62 (s, 1H, Im-NH), 7.66 (s, 1H, Im-H), 7.64 (s, 1H, Im-H), 7.52 (s, 1H, Im-H), 4.02 (s, 3H, 
Im-CH3), 4.01 (s, 3H, Im-CH3), 3.98 (s, 3H, Im-CH3), 3.94 (s, 2H, -CH2-COOH). 
13C-NMR (125.6 MHz, DMSO-d6): δ (ppm) = 169.29, 163.49, 159.73, 155.56, 155.44, 
136.12, 135.70, 135.04, 133.36, 132.88, 132.30, 115.15, 114.72, 114.65, 42.64, 35.31, 35.23, 
35.07. 
MS (ESI-TOF, pos. DMSO): [M+Na]+ calc. for C18H17N9NaO7 m/z 494.1154, found m/z 
494.1182. 
 152 
(2-{[4-({4-[(4-Amino-1-methyl-1H-imidazole-2-carbonyl)-amino]-1-methyl-1H-imidazole
-2-carbonyl}-amino)-1-methyl-1H-imidazole-2-carbonyl]-amino}-ethyl)-amine 
di(trifluoroacetate) (36) 
 
 
(30) (0.1 g, 0.2 mmol) was dissolved in ethylenediamine (1 mL). The mixture was stirred for 
18 h at 80 °C. Subsequently, ethylenediamine was removed in vacuo. The residue was 
dissolved in anhydrous DCM (8 mL). To this solution was added 2 mL TFA. The reaction 
mixture was stirred for 16 h at r.t. and subsequently evaporated to dryness. The solid was 
washed with acetone to yield 0.07 g (81%) as a white solid. 
1H-NMR (300 MHz, CD3OD): δ (ppm) = 7.40 (s, 1H, Im-H), 7.36 (s, 1H, Im-H), 4.89 (s, 1H, 
Im-H), 3.98 (s, 3H, Im-CH3), 3.95 (s, 3H, Im-CH3), 3.94 (s, 3H, Im-CH3), 3.57 (t, 2H, 
Im-CONH-CH2-), 3.12 (t, 2H, Im-CONH-CH2-CH2-). 
13C-NMR (75 MHz, CD3OD): δ (ppm) = 161.88, 157.45, 157.12, 137.24, 137.17, 135.50, 
135.44, 135.10, 120.39, 116.42, 116.09, 115.65, 41.07, 38.09, 38.00, 36.23, 36.07. 
MS (ESI-TOF, pos. MeOH): [M+H]+ calc. for C17H24N11O3 m/z 430.2058, found m/z 
430.2097. 
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Succinic acid monobenzyl ester 4-{5,11,17-tris[(tert-butoxycarbonyl)-aminomethyl]- 
25,26,27,28- tetrabutoxycalix[4]arene-23-yl-methyl} amide (37) 
 
OO O
NHBoc
O
H
N
Bu Bu Bu Bu
BocHN BocHN
O
O
O
 
 
(24) (0.021 g, 0.1 mmol) was dissolved in 2 mL anhydrous DMF. HBTU (0.038 g, 0.1 mmol) 
was added followed by DIEA (1 mL). The reaction mixture was stirred for 10 min and 
immediately added to (7) (0.107 g, 0.1 mmol). The mixture was stirred at room temperature 
for 18 h. DMF was removed in vacuo. The residue was purified by flash chromatography 
(silica gel, 1:1 ethyl acetate/cyclohexane) to yield 0.056 g (45%) as a white solid. 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 7.23-7.28 (m, 5H, Ar-H of Cbz), 6.37-6.54 (m, 8H, 
Ar-H ), 5.06 (s, 2H, CH2 of Cbz), 4.30 (m, 4H, Ar-CH2-Ar), 3.92-4.02 (m, 8H, Ar-CH2-N), 
3.76 (m, 8H, Ar-O-CH2-), 3.00 (m, 4H, Ar-CH2-Ar), 2.67 (t, 2H, -NHCO-CH2-), 2.47 (t, 2H, 
-NHCO-CH2-CH2-COO-), 1.79 (m, 8H, Ar-O-CH2-CH2-), 1.37 (m, 35H, Ar-O-CH2-CH2- 
CH2-, -C(CH3)3), 0.90 (m, 12H, Ar-O-CH2-CH2-CH2-CH3). 
13C-NMR (75 MHz, CDCl3): δ (ppm) = 173.05, 156.14, 156.09, 136.03, 135.32, 132.15, 
132.03, 131.71, 128.64, 128.30, 127.36, 79.43, 79.31, 75.03, 66.58, 44.32, 42.91, 32.39, 32.31, 
31.14, 31.06, 30.86, 29.73, 28.57, 19.43, 14.17. 
MS (ESI-TOF, pos. CH2Cl2): [M+Na]+ calc. for C74H102N4NaO13 m/z 1277.7336, found m/z 
1277.7458. 
 154 
Succinic acid 4-{5,11,17-tris[(tert-butoxycarbonyl)-aminomethyl]- 25,26,27,28- 
tetrabutoxycalix[4]arene-23-yl-methyl} amide (38) 
 
OO O
NHBoc
O
H
N
Bu Bu Bu Bu
BocHN BocHN OH
O
O
 
 
 
(37) (0.056 g, 0.045 mmol) were dissolved in 20 mL of the mixture (THF : H2O = 4 : 1) and 
Pd/C (0.006 g, 10 weight-%) was added. The hydrogenation was then carried out for 24 h. 
The catalyst was filtered off over Celite and the solution was evaporated to dryness. The 
residue was washed with DCM to yield 0.048 g (93%) as a white solid. 
 
1H-NMR (300 MHz, DMSO-d6): δ (ppm) = 8.09 (t, 1H, Ar-CH2-NH-), 7.05-7.07 (m, 2H, 
Ar-CH2-NH- ), 6.57 (m, 8H, Ar-H ), 4.31 (m, 4H, Ar-CH2-Ar), 3.79-3.91 (m, 8H, Ar-CH2-N), 
3.79 (m, 8H, Ar-O-CH2-), 3.10 (m, 4H, Ar-CH2-Ar), 2.30-2.38 (m, 4H, -NHCO-CH2-CH2- 
COO-), 1.85 (m, 8H, Ar-O-CH2-CH2-), 1.37 (m, 35H, Ar-O-CH2-CH2-CH2-, -C(CH3)3), 0.95 
(m, 12H, Ar-O-CH2-CH2-CH2-CH3). 
 
13C-NMR (75 MHz, DMSO-d6): δ (ppm) = 174.20, 170.88, 162.13, 155.59, 154.85, 134.23, 
134.19, 134.05, 133.17, 132.36, 127.21, 127.04, 126.99, 126.87, 126.84, 77.52, 74.41, 60.77, 
57.03, 31.74, 30.35, 28.23, 18.81, 13.85. 
 
MS (ESI-TOF, pos. CH2Cl2): [M+Na]+ calc. for C67H96N4NaO13 m/z 1187.6866, found m/z 
1187.6963. 
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4-[(4-{[4-(2-Carboxy-acetylamino)-1-methyl-1H-imidazole-2-carbonyl]-amino}-1-methyl
-1H-imidazole-2-carbonyl)-amino]-1-methyl-1H-imidazole-2-carboxylic acid N, N’ 
-Bis-{5,11,17-tris[(tert-butoxycarbonyl)-aminomethyl]-25,26,27,28- tetrabutoxy 
calix[4]arene-23-yl-methyl} diamide (39) 
(34) (0.047 g, 0.1 mmol) was dissolved in 2 mL anhydrous DMF. HATU (0.076 g, 0.2 mmol) 
was added followed by DIEA (1 mL). The reaction mixture was stirred for 10 min and 
immediately added to (7) (0.214 g, 0.2 mmol). The mixture was stirred at room temperature 
for 18 h. DMF was removed in vacuo. The residue was purified by flash chromatography 
(silica gel, 3:2 ethyl acetate/cyclohexane) and then by preparative TLC (silica gel, 1:4 ethyl 
acetate/cyclohexane) to yield 0.034 g (13%) as a white solid. 
1H-NMR (300 MHz, DMSO-d6): δ (ppm) = 10.54 (s, 1H, Im-NH), 9.72 (m, 2H, Im-NH), 
8.40 (t, 1H, Ar-CH2-NH-), 8.25 (t, 1H, Ar-CH2-NH-), 7.62 (s, 1H, Im-H), 7.52 (s, 1H, Im-H), 
7.51 (s, 1H, Im-H), 7.01 (m, 6H, Ar-CH2-NH-), 6.54-6.63 (m, 16H, Ar-H ), 4.30 (m, 8H, 
Ar-CH2-Ar), 4.00 (s, 3H, Im-CH3), 3.96 (s, 3H, Im-CH3), 3.94 (s, 3H, Im-CH3), 3.78 (m, 32H, 
Ar-O-CH2-, Ar-CH2-N), 3.50 (s, 2H, -NHCO-CH2-CONH-), 3.10 (m, 8H, Ar-CH2-Ar), 1.83 
(m, 16H, Ar-O-CH2-CH2-), 1.36 (m, 70H, Ar-O-CH2-CH2-CH2-, -C(CH3)3), 0.93 (m, 24H, 
Ar-O-CH2-CH2-CH2-CH3). 
13C-NMR (125.6 MHz, DMSO-d6): δ (ppm) = 155.61, 155.59, 155.55, 155.38, 155.19, 
154.95, 154.93, 154.89, 154.80, 136.09, 135.09, 134.60, 134.44, 134.42, 134.29, 134.27, 
134.22, 134.14, 134.11, 134.09, 134.02, 133.96, 133.92, 133.26, 133.18, 133.15, 133.12, 
133.07, 133.04, 132.87, 127.44, 127.42, 127.17, 127.10, 127.08, 127.04, 127.02, 126.99, 
126.95, 126.91, 126.87, 126.84, 126.82, 126.76, 77.53, 74.40, 53.30, 45.37, 35.23, 35.11, 
35.05, 31.74, 30.36, 30.34, 30.27, 28.23, 18.83, 13.86. 
MS (ESI-TOF, pos. CH2Cl2): [M+2Na]2+ calc. for C144H199N17Na2O25 m/2z 1306.7320, 
found m/2z 1306.7379.
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4-[(4-{[4-(2-Carboxy-acetylamino)-1-methyl-1H-imidazole-2-carbonyl]-amino}-1-methyl
-1H-imidazole-2-carbonyl)-amino]-1-methyl-1H-imidazole-2-carboxylic acid N, N’ 
-Bis-{5,11,17-tris-(aminomethyl)-25,26,27,28-tetrabutoxycalix[4]arene -23-yl-methyl} 
diamide hexakis(trifluoroacetate) (40) 
(39) (0.013 g, 0.0.5 mmol) was dissolved in DCM (8 mL). To this solution was added 2 mL 
TFA. The mixture was stirred for 15 min at r.t. and subsequently was evaporated to dryness. 
The solid was washed with CHCl3 to yield 0.011 g (79%) as a white solid. 
1H-NMR (500 MHz, DMSO-d6): δ (ppm) = 10.58 (s, 1H, Im-NH), 9.80 (s, 1H, Im-NH), 9.75 
(s, 1H, Im-NH), 8.09 (m, 18H, Ar-CH2-NH3), 7.65 (s, 1H, Im-H), 7.55 (s, 1H, Im-H), 7.54 (s, 
1H, Im-H), 6.64-6.93 (m, 16H, Ar-H ), 4.36 (m, 8H, Ar-CH2-Ar), 4.01 (s, 3H, Im-CH3), 3.98 
(s, 3H, Im-CH3), 3.97 (s, 3H, Im-CH3), 3.69-3.84 (m, 32H, Ar-O-CH2-, Ar-CH2-N), 3.50 (s, 
2H, -NHCO-CH2-CONH-), 3.17 (m, 8H, Ar-CH2-Ar), 1.87 (m, 16H, Ar-O-CH2-CH2-), 1.42 
(m, 16H, Ar-O-CH2-CH2-CH2-), 0.97 (m, 24H, Ar-O-CH2-CH2 -CH2-CH3). 
13C-NMR (125.6 MHz, DMSO-d6): δ (ppm) = 158.21, 156.45, 156.25, 155.67, 154.99, 
136.37, 136.23, 136.08, 135.87, 135.66, 135.55, 135.36, 135.29, 135.24, 135.19, 135.14, 
135.11, 134.92, 134.79, 134.72, 134.65, 134.51, 134.46, 134.39, 134.29, 134.25, 134.03, 
133.97, 133.85, 133.43, 133.38, 133.29, 133.07, 132.50, 132.15, 129.21, 129.17, 129.14, 
127.58, 127.53, 127.49, 127.43, 74.68, 74.60, 69.79, 42.07, 35.29, 35.17, 35.09, 31.82, 31.79, 
31.75, 30.18, 30.10, 18.84, 18.77, 13.88. 
MS (ESI-TOF, pos. CH2Cl2, free base): [M+2H]2+ calc. for C114H153N17O13 m/2z 984.5927, 
found m/2z 984.5879. 
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6.4  NMR and MS Spectra of Synthetic Compounds 
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Compound (1), 1H-NMR (300 MHz, C6D6) 
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Compound (1), 13C-NMR (75 MHz, C6D6) 
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Compound (2), 1H-NMR (300 MHz, DMSO-d6) 
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Compound (2), 13C-NMR (75 MHz, DMSO-d6) 
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Compound (3), 1H-NMR (300 MHz, CDCl3) 
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Compound (3), 13C-NMR (75 MHz, CDCl3) 
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Compound (4), 1H-NMR (300 MHz, CDCl3) 
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Compound (4), 13C-NMR (75 MHz, CDCl3) 
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Compound (5), 1H-NMR (300 MHz, CDCl3) 
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Compound (5), 13C-NMR (75 MHz, CDCl3) 
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Compound (6), 1H-NMR (300 MHz, DMSO-d6) 
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Compound (6), 13C-NMR (75 MHz, DMSO-d6) 
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Compound (7), 1H-NMR (300 MHz, CDCl3) 
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Compound (7), 13C-NMR (75 MHz, CDCl3) 
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Compound (7), MS (ESI-TOF, pos. CH2Cl2) 
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Compound (8), 1H-NMR (300 MHz, CDCl3) 
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27
.4
4
25
.5
5
19
44
14
18
 
Compound (8), 13C-NMR (75 MHz, CDCl3) 
 
Compound (8), MS (ESI-TOF, pos. CH2Cl2) 
 166 
0.01.02.03.04.05.06.07.08.09.0
8.
39
7.
18
7.
08
7.
01
6.
75
4.
43
4.
39
4.
35
3.
96
3.
87
3.
79
3.
77
3.
26
3.
21
3.
17
2.
21
1.
93
1.
47
1.
02
19.9
16.0
24.6
8.8
35.1
8.7
18.3
15.4
4.3
 
Compound (9), 1H-NMR (300 MHz, DMSO-d6) 
0102030405060708090100110120130140150160170
17
2.
12
15
5.
99
15
5.
72
15
4.
43
13
4.
81
13
4.
64
13
4.
19
13
3.
68
13
3.
06
12
9.
41
12
9.
22
12
7.
89
12
7.
76
12
7.
31
74
.8
6
74
.7
1
41
.7
3
35
.1
0
31
.8
6
31
.7
9
29
.9
5
25
.1
6
18
.8
2
18
.7
6
13
.9
1
 
Compound (9), 13C-NMR (75 MHz, DMSO-d6) 
 167
 
 
Compound (9), MS (ESI-TOF, pos. MeOH, free base) 
 168 
0.01.02.03.04.05.06.07.08.09.010.011.012.0
11
.5
2
11
.4
8
11
.4
4
8.
76
8.
47
8.
05
6.
87
6.
84
6.
30
6.
26
4.
42
4.
37
4.
01
3.
73
3.
62
3.
13
3.
08
1.
89
1.
51
1.
49
1.
48
1.
47
1.
46
0.
98
1.0
4.0
4.3
8.2
12.4
5.9
8.2
68.9
2.5
4.0
0.7
1.7
3.4
3.4
 
Compound (10), 1H-NMR (300 MHz, CDCl3) 
0102030405060708090100110120130140150160170
16
3.
62
15
6.
24
15
5.
93
15
5.
54
15
3.
48
15
3.
27
15
3.
08
13
7.
02
13
6.
48
13
6.
19
13
4.
19
13
3.
68
13
0.
52
13
0.
05
83
.5
4
83
.0
3
82
.8
6
79
.4
9
79
.2
5
79
.1
5
75
.2
0
75
.1
8
75
.0
3
72
.5
1
69
.1
2
61
.9
8
53
.5
6
45
.0
5
40
.4
7
29
.1
5
28
.9
0
28
.5
4
28
.4
6
28
.2
1
27
.7
5
27
.7
0
27
.4
9
19
.6
6
19
26
14
76
14
65
 
Compound (10), 13C-NMR (75 MHz, CDCl3) 
 169
 
Compound (10), MS (ESI-TOF, pos. CH2Cl2) 
0.01.02.03.04.05.06.07.08.09.010.011.0
11
.4
8
11
.4
6
8.
44
8.
35
8.
29
8.
20
6.
64
6.
49
6.
42
4.
38
4.
11
3.
85
3.
76
3.
62
3.
09
2.
20
1.
88
1.
65
1.
50
1.
48
1.
47
1.
45
0.
98
18.3
27.7
135.4
6.3
3.1
8.4
46.1
16.0
5.3
6.1
 
Compound (11), 1H-NMR (300 MHz, CDCl3) 
 170 
0102030405060708090100110120130140150160
16
3.
69
15
5.
76
15
3.
18
13
5.
47
13
5.
10
13
4.
52
13
0.
42
13
0.
04
13
0.
00
12
9.
09
12
9.
05
12
9.
01
12
8.
94
12
8.
91
12
8.
85
12
8.
34
82
.9
7
79
.1
6
29
.1
6
28
.9
2
28
.4
9
28
.2
1
27
.7
4
27
.4
9
14
.7
3
14
.6
5
13
.6
8
13
.6
3
 
Compound (11), 13C-NMR (75 MHz, CDCl3) 
 
Compound (11), MS (ESI-TOF, pos. CH2Cl2) 
 171
0.01.02.03.04.05.06.07.0
6.
79
6.
74
6.
65
6.
54
4.
45
4.
15
4.
06
3.
94
3.
88
3.
18
2.
28
1.
92
1.
66
1.
48
1.
01
8.0
8.0
28.1
3.7
15.6
4.2
24.0
15.7
15.0
 
Compound (12), 1H-NMR (300 MHz, CD3OD) 
0102030405060708090100110120130140150160170
15
9.
32
15
8.
56
15
8.
51
15
7.
82
15
7.
51
15
6.
82
13
7.
08
13
6.
91
13
6.
42
13
5.
90
13
3.
35
13
0.
89
12
9.
14
12
9.
08
12
8.
96
12
8.
71
76
.2
8
73
.7
8
70
.6
3
46
.1
4
43
.9
1
43
.0
5
36
.9
0
33
.7
1
33
.6
8
33
.6
2
32
.0
5
31
.9
7
28
.3
9
26
.7
6
20
.7
5
20
.7
0
20
.6
2
14
.6
6
 
Compound (12), 13C-NMR (125.6 MHz, CD3OD) 
 172 
 
 
Compound (12), MS (ESI-TOF, pos. MeOH, free base) 
 173
0.01.02.03.04.05.06.07.08.09.010.011.0
11
.4
5
8.
26
6.
59
4.
40
4.
36
4.
27
4.
26
3.
85
3.
12
3.
08
1.
89
1.
46
1.
45
1.
45
0.
98
12.0
91.7
8.4
3.7
7.0
7.0
4.1
7.1
3.5
3.9
 
Compound (13), 1H-NMR (300 MHz, CDCl3) 
0102030405060708090100110120130140150160170
16
3.
68
15
6.
01
15
5.
67
15
3.
11
14
9.
78
13
5.
01
13
0.
56
12
7.
88
82
.7
9
81
.9
6
78
.9
2
77
.5
8
77
.1
6
76
.7
4
75
.0
7
44
.9
6
32
.3
1
31
.0
5
28
.4
1
28
.1
5
28
.0
9
26
.9
7
19
.4
1
14
.1
5
 
Compound (13), 13C-NMR (75 MHz, CDCl3) 
 174 
 
Compound (13), MS (ESI-TOF, pos. CH2Cl2) 
0.01.02.03.04.05.06.07.08.09.0
7.
92
7.
90
7.
88
7.
36
7.
19
7.
02
6.
69
4.
34
4.
30
4.
09
4.
07
3.
80
3.
17
3.
13
1.
85
1.
41
0.
96
8.0
7.7
12.0
7.8
6.8
4.0
4.6
7.5
3.8
 
Compound (14), 1H-NMR (300 MHz, DMSO-d6) 
 175
0102030405060708090100110120130140150160170
15
6.
66
15
5.
50
13
4.
51
13
0.
17
12
7.
58
74
.5
4
44
.0
4
31
.7
8
18
.8
1
13
.8
7
 
Compound (14), 13C-NMR (75 MHz, DMSO-d6) 
 
Compound (14), MS (ESI-TOF, pos. MeOH, free base) 
 176 
-2.0-1.00.01.02.03.04.05.06.07.08.09.010.011.012.013.014.0
11
.5
9
2.
39
1.
51
3.0
18.0
1.0
 
Compound (15), 1H-NMR (300 MHz, CDCl3) 
0102030405060708090100110120130140150160
16
1.
27
15
1.
30
14
9.
19
83
.9
3
81
.4
8
28
.5
8
14
.9
4
 
Compound (15), 13C-NMR (75 MHz, CDCl3) 
 177
0.01.02.03.04.05.06.07.08.09.0
7.
26
7.
08
3.
98
1.0
1.0
3.4
 
Compound (16), 1H-NMR (300 MHz, CDCl3) 
0102030405060708090100110120130140150160170180190
17
2.
45
13
6.
35
13
0.
98
13
0.
77
12
8.
78
95
.0
3
77
.2
6
37
.3
6
 
Compound (16), 13C-NMR (75 MHz, CDCl3) 
 178 
0.01.02.03.04.05.06.07.08.09.0
7.
96
4.
16
1.0
3.2
 
Compound (17), 1H-NMR (300 MHz, CDCl3) 
0102030405060708090100110120130140150160170180190
17
2.
97
13
3.
74
13
0.
69
12
6.
12
93
.6
3
38
.4
4
 
Compound (17), 13C-NMR (75 MHz, CDCl3) 
 179
0.01.02.03.04.05.06.07.08.09.0
8.
60
3.
97
3.
86
1.0
3.2
3.1
 
Compound (18), 1H-NMR (300 MHz, DMSO-d6) 
0102030405060708090100110120130140150160170180190
15
8.
14
14
4.
88
13
4.
69
12
6.
78
52
.5
7
36
.7
0
 
Compound (18), 13C-NMR (75 MHz, DMSO-d6) 
 180 
0.01.02.03.04.05.06.07.08.0
7.
23
6.
85
3.
97
3.
92
1.
50
3.0
3.0
1.0
9.3
0.9
 
Compound (19), 1H-NMR (300 MHz, CDCl3) 
0102030405060708090100110120130140150160170180190
15
9.
32
15
2.
65
14
9.
73
13
7.
99
11
3.
33
81
.0
8
52
.3
5
35
.9
9
28
.4
1
 
Compound (19), 13C-NMR (75 MHz, CDCl3) 
 181
0.01.02.03.04.05.06.07.08.09.010.011.012.013.014.0
10
.9
2
7.
18
4.
14
1.
54
3.0
9.2
0.9
1.0
 
Compound (20), 1H-NMR (300 MHz, CDCl3) 
0102030405060708090100110120130140150160170180190
15
9.
73
15
2.
78
13
3.
91
13
2.
84
10
9.
29
81
.5
4
35
.5
8
28
.2
4
 
Compound (20), 13C-NMR (75 MHz, CDCl3) 
 182 
0.01.02.03.04.05.06.07.08.0
7.
63
7.
19
7.
08
3.
97
3.
68
3.
65
3.
63
3.
61
3.
59
2.
62
2.
60
2.
58
1.
49
2.0
5.1
3.0
9.0
0.8
0.9
1.0
 
Compound (21), 1H-NMR (300 MHz, CDCl3) 
0102030405060708090100110120130140150160170180190
17
2.
62
15
8.
95
15
2.
67
13
6.
53
13
3.
79
11
2.
01
80
.9
3
51
.9
5
35
.6
6
34
.6
4
34
.0
5
28
.3
9
 
Compound (21), 13C-NMR (75 MHz, CDCl3) 
 183
 
Compound (21), MS (ESI-TOF, pos. CH2Cl2) 
0.01.02.03.04.05.06.07.08.09.010.0
9.
45
7.
71
7.
69
7.
67
7.
40
7.
16
4.
01
4.
00
3.
69
3.
67
3.
64
3.
62
2.
64
2.
62
2.
60
1.
50
2.0
4.9
5.9
9.1
0.9
0.9
1.0
2.4
 
Compound (22), 1H-NMR (300 MHz, CDCl3) 
 184 
0102030405060708090100110120130140150160170180190
17
2.
68
15
9.
11
15
6.
00
15
2.
76
13
7.
08
13
5.
45
13
4.
26
11
3.
87
11
2.
80
81
.0
0
52
.0
0
35
.7
5
35
.6
9
34
.6
9
34
.0
3
28
.4
2
 
Compound (22), 13C-NMR (75 MHz, CDCl3) 
 
Compound (22), MS (ESI-TOF, pos. CH2Cl2) 
 185
0.01.02.03.04.05.06.07.08.09.010.0
9.
40
9.
38
7.
47
7.
41
7.
18
4.
05
4.
04
4.
02
3.
72
3.
70
3.
68
3.
66
3.
64
2.
66
2.
64
2.
62
1.
52
2.0
5.2
9.2
9.5
2.0
1.0
1.3
1.9
 
Compound (23), 1H-NMR (300 MHz, CDCl3) 
0102030405060708090100110120130140150160170180190
17
2.
61
15
9.
19
15
6.
14
15
6.
02
15
2.
81
13
7.
25
13
5.
84
13
5.
46
13
4.
33
13
3.
79
13
3.
36
12
5.
59
11
4.
59
11
3.
91
11
2.
80
80
.8
7
51
.9
7
35
.7
2
35
.6
7
34
.7
3
34
.0
5
28
.4
1
 
Compound (23), 13C-NMR (75 MHz, CDCl3) 
 186 
 
Compound (23), MS (ESI-TOF, pos. CH2Cl2) 
0.01.02.03.04.05.06.07.08.0
7.
28
7.
27
7.
26
7.
23
7.
23
5.
06
2.
64
2.
62
2.
61
2.
60
2.
57
5.2
2.0
4.2
 
Compound (24), 1H-NMR (300 MHz, CDCl3) 
 187
0102030405060708090100110120130140150160170180190
17
7.
83
17
2.
11
13
5.
83
12
8.
72
12
8.
45
12
8.
36
66
.8
1
29
.0
4
28
.9
9
 
Compound (24), 13C-NMR (75 MHz, CDCl3) 
 
Compound (24), MS (ESI-TOF, pos. CH2Cl2) 
 188 
0.01.02.03.04.05.06.07.08.09.010.0
9.
62
8.
90
7.
81
7.
39
7.
37
7.
36
7.
26
7.
20
5.
05
3.
94
3.
93
3.
60
2.
71
2.
70
2.
57
2.0
3.8
9.2
2.2
5.1
2.9
1.3
0.9
1.8
5.0
 
Compound (25), 1H-NMR (300 MHz, CDCl3) 
0102030405060708090100110120130140150160170180190
17
2.
77
17
2.
69
16
9.
43
15
8.
65
15
6.
02
15
5.
78
13
6.
05
13
5.
84
13
5.
72
13
4.
76
13
4.
02
13
3.
67
13
2.
97
12
8.
68
12
8.
39
12
8.
30
11
4.
95
11
4.
90
11
4.
03
66
.7
8
52
.0
1
35
.9
5
35
.8
6
34
.9
5
33
.9
2
30
.9
4
29
.4
1
 
Compound (25), 13C-NMR (75 MHz, CDCl3) 
 189
 
Compound (25), MS (ESI-TOF, pos. CH2Cl2) 
0.01.02.03.04.05.06.07.08.09.010.0
10
.4
4
10
.4
0
9.
66
9.
62
8.
24
7.
63
7.
52
7.
49
4.
00
3.
95
3.
95
3.
61
3.
45
2.
60
2.
52
0.6
0.6
0.8
1.7
0.7
10.5
6.0
3.0
2.0
0.7
 
Compound (26), 1H-NMR (300 MHz, DMSO-d6) 
 190 
0102030405060708090100110120130140150160170180190200
17
3.
71
17
1.
85
16
9.
02
15
8.
36
15
5.
52
15
5.
37
13
6.
45
13
5.
06
13
4.
55
13
4.
12
13
3.
28
13
2.
72
11
4.
69
11
4.
54
11
4.
11
51
.4
0
35
.2
1
35
.0
8
34
.9
8
34
.4
7
33
.4
9
29
.9
6
28
.7
9
 
Compound (26), 13C-NMR (75 MHz, DMSO-d6) 
 
Compound (26), MS (ESI-TOF, pos. MeOH) 
 191
0.01.02.03.04.05.06.07.0
7.
16
7.
00
6.
95
3.
81
3.
78
3.
33
3.
31
2.
44
2.
42
2.
41
2.
40
2.
38
9.0
6.0
2.1
1.0
1.0
1.0
 
Compound (27), 1H-NMR (300 MHz, D2O) 
0102030405060708090100110120130140150160170180190
18
0.
86
18
0.
13
17
2.
28
15
9.
17
15
5.
23
15
5.
09
13
5.
44
13
5.
08
13
4.
75
13
3.
64
13
2.
67
13
2.
58
11
4.
99
11
4.
40
11
4.
05
37
.4
2
36
.7
4
36
.3
9
35
.7
1
35
.4
9
32
.4
4
31
.9
7
 
Compound (27), 13C-NMR (75 MHz, D2O) 
 192 
 
Compound (27), MS (ESI-TOF, pos. CH2Cl2) 
0.01.02.03.04.05.06.07.08.09.010.011.0
10
.0
9
9.
81
8.
32
7.
64
7.
52
4.
05
4.
02
3.
96
3.
62
3.
46
2.
83
2.
59
0.9
1.0
0.9
0.8
1.5
9.0
3.0
4.0
2.2
2.0
 
Compound (28), 1H-NMR (300 MHz, DMSO-d6) 
 193
0102030405060708090100110120130140150160170180190200
17
6.
59
17
1.
85
15
8.
42
15
5.
49
15
5.
44
15
5.
36
13
6.
03
13
4.
99
13
4.
64
13
4.
51
13
4.
13
13
4.
09
13
3.
36
12
8.
75
12
3.
01
51
.4
4
45
.6
7
35
.5
8
35
.2
3
35
.1
0
34
.5
0
33
.5
2
28
.3
8
 
Compound (28), 13C-NMR (125.6 MHz, DMSO-d6) 
 
Compound (28), MS (ESI-TOF, pos. MeOH) 
 194 
0.01.02.03.04.05.06.07.08.0
7.
57
7.
17
6.
87
4.
04
4.
02
3.
96
1.
52
3.0
6.0
11.3
0.8
0.8
1.0
 
Compound (29), 1H-NMR (300 MHz, CDCl3) 
0102030405060708090100110120130140150160170180
15
9.
15
15
6.
18
15
2.
62
13
7.
19
13
6.
84
13
3.
09
13
1.
66
11
4.
99
11
2.
75
80
.8
4
52
.4
0
35
.9
8
35
.5
7
28
.3
4
 
Compound (29), 13C-NMR (75 MHz, CDCl3) 
 195
 
Compound (29), MS (ESI-TOF, pos. CH2Cl2) 
0.01.02.03.04.05.06.07.08.09.010.0
9.
62
9.
32
7.
58
7.
45
7.
16
4.
04
4.
01
4.
00
3.
90
1.
50
1.0
1.0
1.0
1.0
0.9
9.0
10.3
3.0
 
Compound (30), 1H-NMR (300 MHz, CDCl3) 
 196 
0102030405060708090100110120130140150160170180
15
9.
11
15
6.
15
15
6.
00
15
2.
74
13
7.
16
13
6.
72
13
5.
97
13
3.
41
13
3.
18
13
1.
67
11
5.
06
11
4.
60
11
2.
87
80
.9
5
52
.4
5
36
.1
2
35
.7
6
35
.6
9
28
.4
2
 
Compound (30), 13C-NMR (75 MHz, CDCl3) 
 
Compound (30), MS (ESI-TOF, pos. CH2Cl2) 
 197
0.01.02.03.04.05.06.07.08.09.010.011.0
11
.2
5
10
.0
8
9.
59
8.
60
8.
48
8.
31
8.
15
7.
74
7.
71
7.
70
7.
67
7.
66
4.
03
3.
94
3.
91
3.
88
3.
82
9.3
3.1
1.0
1.0
1.0
1.1
0.8
1.1
3.0
5.1
3.1
 
Compound (31), 1H-NMR (300 MHz, DMSO-d6) 
0102030405060708090100110120130140150160170180190200
16
5.
72
16
3.
18
15
8.
70
15
5.
63
15
5.
31
13
6.
40
13
6.
21
13
5.
01
13
4.
06
13
3.
73
13
3.
38
13
3.
16
13
3.
10
13
2.
22
13
1.
19
12
9.
87
12
9.
72
12
9.
34
12
9.
01
12
8.
57
52
.3
3
51
.8
3
35
.6
0
35
.2
5
35
.0
8
 
Compound (31), 13C-NMR (75 MHz, DMSO-d6) 
 198 
 
Compound (31), MS (ESI-TOF, pos. CH2Cl2) 
0.01.02.03.04.05.06.07.08.09.010.011.0
9.
78
9.
39
9.
28
7.
68
7.
50
7.
46
4.
06
4.
06
3.
99
3.
83
3.
55
9.1
3.0
2.0
0.9
1.1
1.0
3.0
0.8
0.9
1.0
 
Compound (32), 1H-NMR (300 MHz, CDCl3) 
 199
0102030405060708090100110120130140150160170180190200
16
9.
24
16
2.
33
15
9.
26
15
6.
21
15
5.
98
13
6.
78
13
5.
91
13
5.
86
13
3.
55
13
3.
39
13
1.
71
11
5.
17
11
4.
66
52
.8
4
52
.4
4
41
.4
8
36
.1
2
35
.8
0
29
.8
3
 
Compound (32), 13C-NMR (75 MHz, CDCl3) 
 
Compound (32), MS (ESI-TOF, pos. CH2Cl2) 
 200 
0.01.02.03.04.05.06.07.08.09.010.011.012.0
11
.2
0
10
.0
1
9.
67
8.
57
8.
27
8.
25
8.
13
8.
11
7.
74
7.
66
7.
65
7.
63
4.
04
4.
01
3.
94
1.0
1.0
1.0
1.0
1.0
1.0
1.0
9.3
 
Compound (33), 1H-NMR (300 MHz, DMSO-d6) 
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Compound (33), 13C-NMR (125.6 MHz, DMSO-d6) 
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Compound (33), MS (ESI-TOF, pos. DMSO) 
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Compound (34), 1H-NMR (125.6 MHz, DMSO-d6) 
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Compound (34), 13C-NMR (75 MHz, DMSO-d6) 
 
Compound (34), MS (ESI-TOF, pos. DMSO) 
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Compound (36), 1H-NMR (300 MHz, CD3OD) 
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Compound (36), 13C-NMR (75 MHz, CD3OD) 
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Compound (36), MS (ESI-TOF, pos. MeOH) 
0.01.02.03.04.05.06.07.08.0
7.
26
6.
54
6.
48
6.
37
5.
06
4.
33
4.
32
4.
28
4.
28
4.
02
3.
92
3.
76
3.
02
2.
98
2.
68
2.
47
1.
79
1.
37
0.
90
8.4
2.6
6.4
4.4
4.2
16.5
8.9
13.4
35.1
2.2
2.0
 
Compound (37), 1H-NMR (300 MHz, CDCl3) 
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Compound (37), 13C-NMR (75 MHz, CDCl3) 
 
Compound (37), MS (ESI-TOF, pos. CH2Cl2) 
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Compound (38), 1H-NMR (300 MHz, DMSO-d6) 
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Compound (38), 13C-NMR (75 MHz, DMSO-d6) 
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Compound (38), MS (ESI-TOF, pos. CH2Cl2) 
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Compound (39), 1H-NMR (300 MHz, DMSO-d6) 
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Compound (39), 13C-NMR (125.6 MHz, DMSO-d6) 
 
Compound (39), MS (ESI-TOF, pos. CH2Cl2) 
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Compound (40), 1H-NMR (500 MHz, DMSO-d6) 
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Compound (40), 13C-NMR (125.6 MHz, DMSO-d6) 
 
Compound (40), MS (ESI-TOF, pos. CH2Cl2, free base) 
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6.5 Data of Fluorescence Titration Experiments 
No. 1  
DNA: (dGdC)10-(dGdC)10 ligand: Dimer A 
C Fl-DNA: 1.0×10-6 M Cligand: 8.0×10-5 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA) 
fluorescence 
emission 
relative 
emission 
difference 
0 500 1.00E-06 0.00E+00 0.00 949.593 0.000 
10 510 1.00E-06 1.57E-06 1.57 831.428 118.165 
20 520 1.00E-06 3.08E-06 3.08 737.502 212.091 
30 530 1.00E-06 4.53E-06 4.53 651.990 297.603 
40 540 1.00E-06 5.93E-06 5.93 583.291 366.302 
50 550 1.00E-06 7.27E-06 7.27 522.218 427.375 
60 560 1.00E-06 8.57E-06 8.57 461.330 488.263 
70 570 1.00E-06 9.82E-06 9.82 408.851 540.742 
80 580 1.00E-06 1.10E-05 11.03 363.267 586.326 
90 590 1.00E-06 1.22E-05 12.20 331.192 618.401 
100 600 1.00E-06 1.33E-05 13.33 299.662 649.931 
110 610 1.00E-06 1.44E-05 14.43 275.918 673.675 
120 620 1.00E-06 1.55E-05 15.48 262.613 686.980 
130 630 1.00E-06 1.65E-05 16.51 257.894 691.699 
140 640 1.00E-06 1.75E-05 17.50 262.355 687.238 
150 650 1.00E-06 1.85E-05 18.46 262.054 687.539 
160 660 1.00E-06 1.94E-05 19.39 256.188 693.405 
 
The graphical representation of the titration curve: 
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Ka(M-1): 1.4×106 Statistical error: 23% 
Stoichiometry: 11:1 (ligand : DNA duplex) 
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No. 2   
 
DNA: (dAdT)10-(dAdT)10 ligand: Dimer A 
C Fl-DNA: 1.0×10-6 M Cligand: 8.0×10-5 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1.00E-06 0.00E+00 0.00 925.456 0.000 
10 510 1.00E-06 1.57E-06 1.57 794.207 131.249 
20 520 1.00E-06 3.08E-06 3.08 674.742 250.714 
30 530 1.00E-06 4.53E-06 4.53 587.920 337.536 
40 540 1.00E-06 5.93E-06 5.93 518.475 406.981 
50 550 1.00E-06 7.27E-06 7.27 452.032 473.424 
60 560 1.00E-06 8.57E-06 8.57 394.860 530.596 
70 570 1.00E-06 9.82E-06 9.82 341.693 583.763 
80 580 1.00E-06 1.10E-05 11.03 292.004 633.452 
90 590 1.00E-06 1.22E-05 12.20 256.903 668.553 
100 600 1.00E-06 1.33E-05 13.33 223.876 701.580 
110 610 1.00E-06 1.44E-05 14.43 206.986 718.470 
115 615 1.00E-06 1.50E-05 14.96 204.389 721.067 
120 620 1.00E-06 1.55E-05 15.48 202.434 723.022 
125 625 1.00E-06 1.60E-05 16.00 201.526 723.930 
 
 
The graphical representation of the titration curve: 
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Ka(M-1): 5.6×105 Statistical error: 24% 
Stoichiometry: 10:1 (ligand : DNA duplex) 
 213
No. 3   
RNA: A20 - U20 ligand: Dimer A 
C Fl-RNA: 1.0×10-6 M Cligand: 8.0×10-5 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-RNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-RNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1.00E-06 0.00E+00 0.00 958.694 0.000 
20 520 1.00E-06 3.08E-06 3.08 829.468 129.226 
40 540 1.00E-06 5.93E-06 5.93 717.284 241.410 
60 560 1.00E-06 8.57E-06 8.57 617.211 341.483 
80 580 1.00E-06 1.10E-05 11.03 537.631 421.063 
100 600 1.00E-06 1.33E-05 13.33 464.814 493.880 
120 620 1.00E-06 1.55E-05 15.48 411.713 546.981 
140 640 1.00E-06 1.75E-05 17.50 363.283 595.411 
160 660 1.00E-06 1.94E-05 19.39 325.696 632.998 
180 680 1.00E-06 2.12E-05 21.18 291.066 667.628 
200 700 1.00E-06 2.29E-05 22.86 259.087 699.607 
220 720 1.00E-06 2.44E-05 24.44 230.478 728.216 
240 740 1.00E-06 2.59E-05 25.95 203.367 755.327 
260 760 1.00E-06 2.74E-05 27.37 181.231 777.463 
280 780 1.00E-06 2.87E-05 28.72 156.363 802.331 
300 800 1.00E-06 3.00E-05 30.00 136.883 821.811 
320 820 1.00E-06 3.12E-05 31.22 118.741 839.953 
340 840 1.00E-06 3.24E-05 32.38 104.630 854.064 
360 860 1.00E-06 3.35E-05 33.49 92.595 866.099 
 
The graphical representation of the titration curve: 
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Ka (M-1): 1.7×105 Statistical error: 22% 
Stoichiometry: 23:1 (ligand : RNA duplex) 
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No. 4   
DNA: (dGdC)10-(dGdC)10 ligand: Dimer B 
C Fl-DNA: 1.0×10-6 M Cligand: 8.0×10-5 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1.00E-06 0.00E+00 0.00 949.710 0.000 
20 520 1.00E-06 3.08E-06 3.08 778.854 170.856 
40 540 1.00E-06 5.93E-06 5.93 616.658 333.052 
60 560 1.00E-06 8.57E-06 8.57 517.894 431.816 
80 580 1.00E-06 1.10E-05 11.03 424.846 524.864 
100 600 1.00E-06 1.33E-05 13.33 357.429 592.281 
120 620 1.00E-06 1.55E-05 15.48 329.447 620.263 
130 630 1.00E-06 1.65E-05 16.51 320.008 629.702 
140 640 1.00E-06 1.75E-05 17.50 317.345 632.365 
150 650 1.00E-06 1.85E-05 18.46 324.119 625.591 
160 660 1.00E-06 1.94E-05 19.39 320.564 629.146 
170 670 1.00E-06 2.03E-05 20.30 319.457 630.253 
180 680 1.00E-06 2.12E-05 21.18 318.920 630.790 
190 690 1.00E-06 2.20E-05 22.03 316.749 632.961 
200 700 1.00E-06 2.29E-05 22.86 315.587 634.123 
210 710 1.00E-06 2.37E-05 23.66 313.229 636.481 
220 720 1.00E-06 2.44E-05 24.44 311.044 638.666 
230 730 1.00E-06 2.52E-05 25.21 310.403 639.307 
240 740 1.00E-06 2.59E-05 25.95 310.022 639.688 
250 750 1.00E-06 2.67E-05 26.67 309.447 640.263 
 
The graphical representation of the titration curve: 
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Ka (M-1): 4.7×106 Statistical error: 22% 
Stoichiometry: 12:1 (ligand : DNA duplex) 
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No. 5     
DNA: (dAdT)10-(dAdT)10 ligand: Dimer B 
C Fl-DNA: 1.0×10-6 M Cligand: 8.0×10-5 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1.00E-06 0.00E+00 0.00 971.039 0.000 
10 510 1.00E-06 1.57E-06 1.57 865.253 105.786 
20 520 1.00E-06 3.08E-06 3.08 767.641 203.398 
30 530 1.00E-06 4.53E-06 4.53 693.458 277.581 
40 540 1.00E-06 5.93E-06 5.93 618.422 352.617 
50 550 1.00E-06 7.27E-06 7.27 555.051 415.988 
60 560 1.00E-06 8.57E-06 8.57 491.890 479.149 
70 570 1.00E-06 9.82E-06 9.82 431.115 539.924 
80 580 1.00E-06 1.10E-05 11.03 382.591 588.448 
90 590 1.00E-06 1.22E-05 12.20 341.238 629.801 
100 600 1.00E-06 1.33E-05 13.33 299.599 671.440 
110 610 1.00E-06 1.44E-05 14.43 266.419 704.620 
120 620 1.00E-06 1.55E-05 15.48 239.771 731.268 
130 630 1.00E-06 1.65E-05 16.51 215.138 755.901 
140 640 1.00E-06 1.75E-05 17.50 200.450 770.589 
150 650 1.00E-06 1.85E-05 18.46 189.764 781.275 
160 660 1.00E-06 1.94E-05 19.39 187.012 784.027 
170 670 1.00E-06 2.03E-05 20.30 186.284 784.755 
180 680 1.00E-06 2.12E-05 21.18 182.127 788.912 
190 690 1.00E-06 2.20E-05 22.03 176.928 794.111 
200 700 1.00E-06 2.29E-05 22.86 176.477 794.562 
210 710 1.00E-06 2.37E-05 23.66 170.802 800.237 
220 720 1.00E-06 2.44E-05 24.44 167.719 803.320 
The graphical representation of the titration curve: 
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Ka (M-1): 2.3×106 Statistical error: 24% 
Stoichiometry: 14:1 (ligand : DNA duplex) 
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No. 6   
 
RNA: A20 - U20 ligand: Dimer B 
C Fl-RNA: 1.0×10-6 M Cligand: 8.0×10-5 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-RNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-RNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1.00E-06 0.00E+00 0.00 972.917 0.000 
20 520 1.00E-06 3.08E-06 3.08 819.784 153.133 
40 540 1.00E-06 5.93E-06 5.93 670.850 302.067 
60 560 1.00E-06 8.57E-06 8.57 540.366 432.551 
80 580 1.00E-06 1.10E-05 11.03 446.862 526.055 
100 600 1.00E-06 1.33E-05 13.33 360.843 612.074 
120 620 1.00E-06 1.55E-05 15.48 302.185 670.732 
140 640 1.00E-06 1.75E-05 17.50 262.228 710.689 
160 660 1.00E-06 1.94E-05 19.39 231.650 741.267 
180 680 1.00E-06 2.12E-05 21.18 201.064 771.853 
200 700 1.00E-06 2.29E-05 22.86 181.781 791.136 
220 720 1.00E-06 2.44E-05 24.44 168.780 804.137 
240 740 1.00E-06 2.59E-05 25.95 156.866 816.051 
440 940 1.00E-06 3.74E-05 37.45 134.000 838.917 
 
 
 
The graphical representation of the titration curve: 
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Ka (M-1): 7.8×105 Statistical error: 8% 
Stoichiometry: 15:1 (ligand : RNA duplex) 
 217
No. 7   
 
DNA: (dGdC)10-(dGdC)10 ligand: Monomer A 
C Fl-DNA: 1.0×10-6 M Cligand: 8.0×10-5 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1.00E-06 0.00E+00 0.00 946.783 0.000 
10 510 1.00E-06 1.57E-06 1.57 814.736 132.047 
20 520 1.00E-06 3.08E-06 3.08 714.245 232.538 
30 530 1.00E-06 4.53E-06 4.53 617.485 329.298 
40 540 1.00E-06 5.93E-06 5.93 530.833 415.950 
50 550 1.00E-06 7.27E-06 7.27 440.949 505.834 
60 560 1.00E-06 8.57E-06 8.57 379.707 567.076 
70 570 1.00E-06 9.82E-06 9.82 326.911 619.872 
80 580 1.00E-06 1.10E-05 11.03 278.120 668.663 
90 590 1.00E-06 1.22E-05 12.20 253.654 693.129 
100 600 1.00E-06 1.33E-05 13.33 250.177 696.606 
110 610 1.00E-06 1.44E-05 14.43 249.707 697.076 
120 620 1.00E-06 1.55E-05 15.48 256.094 690.689 
130 630 1.00E-06 1.65E-05 16.51 251.687 695.096 
140 640 1.00E-06 1.75E-05 17.50 249.429 697.354 
150 650 1.00E-06 1.85E-05 18.46 250.551 696.232 
160 660 1.00E-06 1.94E-05 19.39 252.372 694.411 
170 670 1.00E-06 2.03E-05 20.30 250.749 696.034 
180 680 1.00E-06 2.12E-05 21.18 251.621 695.162 
 
The graphical representation of the titration curve: 
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Ka (M-1): 7.7×106 Statistical error: 25% 
Stoichiometry: 10:1 (ligand : DNA duplex) 
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No. 8  
DNA: (dAdT)10-(dAdT)10 ligand: Monomer A 
C Fl-DNA: 1.0×10-6 M Cligand: 8.0×10-5 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1.00E-06 0.00E+00 0.00 975.099 0.000 
30 530 1.00E-06 4.53E-06 4.53 837.054 138.045 
60 560 1.00E-06 8.57E-06 8.57 729.216 245.883 
90 590 1.00E-06 1.22E-05 12.20 615.945 359.154 
120 620 1.00E-06 1.55E-05 15.48 527.273 447.826 
150 650 1.00E-06 1.85E-05 18.46 446.865 528.234 
180 680 1.00E-06 2.12E-05 21.18 379.797 595.302 
210 710 1.00E-06 2.37E-05 23.66 318.825 656.274 
240 740 1.00E-06 2.59E-05 25.95 266.625 708.474 
270 770 1.00E-06 2.81E-05 28.05 223.813 751.286 
300 800 1.00E-06 3.00E-05 30.00 189.313 785.786 
330 830 1.00E-06 3.18E-05 31.81 164.178 810.921 
360 860 1.00E-06 3.35E-05 33.49 149.853 825.246 
390 890 1.00E-06 3.51E-05 35.06 145.363 829.736 
400 900 1.00E-06 3.56E-05 35.56 145.389 829.710 
410 910 1.00E-06 3.60E-05 36.04 143.221 831.878 
420 920 1.00E-06 3.65E-05 36.52 141.815 833.284 
430 930 1.00E-06 3.70E-05 36.99 140.727 834.372 
440 940 1.00E-06 3.74E-05 37.45 141.689 833.410 
450 950 1.00E-06 3.79E-05 37.89 141.185 833.914 
460 960 1.00E-06 3.83E-05 38.33 142.059 833.040 
 
The graphical representation of the titration curve: 
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Ka (M-1): 2.9×106 Statistical error: 20% 
Stoichiometry: 30:1 (ligand : DNA duplex) 
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No. 9  
 
 
RNA: A20 - U20 ligand:Monomer A 
C Fl-RNA: 1.0×10-6 M Cligand: 8.0×10-5 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-RNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-RNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1.00E-06 0.00E+00 0.00 990.965 0.000 
10 510 1.00E-06 1.57E-06 1.57 841.446 149.519 
20 520 1.00E-06 3.08E-06 3.08 696.212 294.753 
30 530 1.00E-06 4.53E-06 4.53 560.258 430.707 
40 540 1.00E-06 5.93E-06 5.93 443.353 547.612 
50 550 1.00E-06 7.27E-06 7.27 353.329 637.636 
60 560 1.00E-06 8.57E-06 8.57 280.664 710.301 
70 570 1.00E-06 9.82E-06 9.82 216.196 774.769 
80 580 1.00E-06 1.10E-05 11.03 156.910 834.055 
90 590 1.00E-06 1.22E-05 12.20 117.296 873.669 
100 600 1.00E-06 1.33E-05 13.33 97.756 893.209 
110 610 1.00E-06 1.44E-05 14.43 98.893 892.072 
120 620 1.00E-06 1.55E-05 15.48 96.666 894.300 
130 630 1.00E-06 1.65E-05 16.51 97.800 893.165 
140 640 1.00E-06 1.75E-05 17.50 96.779 894.186 
 
 
The graphical representation of the titration curve: 
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Ka (M-1): 3.1×106 Statistical error: 24% 
Stoichiometry: 10:1 (ligand : RNA duplex) 
 220 
No. 10   
 
DNA: (dGdC)10-(dGdC)10 ligand: Monomer B 
C Fl-DNA: 1.0×10-6 M Cligand: 8.0×10-5 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1.00E-06 0.00E+00 0.00 971.194 0.000 
20 520 1.00E-06 3.08E-06 3.08 866.438 104.756 
40 540 1.00E-06 5.93E-06 5.93 777.464 193.730 
60 560 1.00E-06 8.57E-06 8.57 700.128 271.066 
80 580 1.00E-06 1.10E-05 11.03 625.464 345.730 
100 600 1.00E-06 1.33E-05 13.33 557.955 413.239 
120 620 1.00E-06 1.55E-05 15.48 506.162 465.032 
140 640 1.00E-06 1.75E-05 17.50 439.298 531.896 
160 660 1.00E-06 1.94E-05 19.39 394.260 576.934 
180 680 1.00E-06 2.12E-05 21.18 357.982 613.212 
200 700 1.00E-06 2.29E-05 22.86 322.142 649.052 
220 720 1.00E-06 2.44E-05 24.44 301.887 669.307 
240 740 1.00E-06 2.59E-05 25.95 278.301 692.893 
260 760 1.00E-06 2.74E-05 27.37 259.983 711.211 
280 780 1.00E-06 2.87E-05 28.72 246.148 725.046 
300 800 1.00E-06 3.00E-05 30.00 241.306 729.888 
320 820 1.00E-06 3.12E-05 31.22 235.147 736.047 
350 850 1.00E-06 3.29E-05 32.94 236.417 734.777 
 
The graphical representation of the titration curve: 
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Ka (M-1): 1.4×106 Statistical error: 24% 
Stoichiometry: 18:1 (ligand : DNA duplex) 
 221
No. 11     
 
DNA: (dAdT)10-(dAdT)10 ligand: Monomer B 
C Fl-DNA: 1.0×10-6 M Cligand: 8.0×10-5 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1.00E-06 0.00E+00 0.00 955.704 0.000 
10 510 1.00E-06 1.57E-06 1.57 853.336 102.368 
20 520 1.00E-06 3.08E-06 3.08 740.908 214.796 
30 530 1.00E-06 4.53E-06 4.53 641.592 314.112 
40 540 1.00E-06 5.93E-06 5.93 553.095 402.609 
50 550 1.00E-06 7.27E-06 7.27 471.362 484.342 
60 560 1.00E-06 8.57E-06 8.57 394.624 561.080 
70 570 1.00E-06 9.82E-06 9.82 326.730 628.974 
80 580 1.00E-06 1.10E-05 11.03 268.800 686.904 
90 590 1.00E-06 1.22E-05 12.20 225.635 730.069 
100 600 1.00E-06 1.33E-05 13.33 189.943 765.761 
110 610 1.00E-06 1.44E-05 14.43 172.917 782.787 
120 620 1.00E-06 1.55E-05 15.48 169.347 786.357 
130 630 1.00E-06 1.65E-05 16.51 169.501 786.203 
140 640 1.00E-06 1.75E-05 17.50 169.240 786.464 
150 650 1.00E-06 1.85E-05 18.46 168.360 787.344 
160 660 1.00E-06 1.94E-05 19.39 166.567 789.137 
 
The graphical representation of the titration curve: 
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Ka (M-1): 7.3×106 Statistical error: 23% 
Stoichiometry: 12:1 (ligand : DNA duplex) 
 222 
No. 12  
 
RNA: A20 - U20 ligand: Monomer B 
C Fl-RNA: 1.0×10-6 M Cligand: 8.0×10-5 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-RNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-RNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1.00E-06 0.00E+00 0.00 990.261 0.000 
20 520 1.00E-06 3.08E-06 3.08 850.433 139.828 
40 540 1.00E-06 5.93E-06 5.93 731.555 258.706 
60 560 1.00E-06 8.57E-06 8.57 624.199 366.062 
80 580 1.00E-06 1.10E-05 11.03 530.081 460.180 
100 600 1.00E-06 1.33E-05 13.33 448.252 542.009 
120 620 1.00E-06 1.55E-05 15.48 369.936 620.325 
140 640 1.00E-06 1.75E-05 17.50 310.435 679.826 
160 660 1.00E-06 1.94E-05 19.39 265.009 725.252 
180 680 1.00E-06 2.12E-05 21.18 225.636 764.625 
200 700 1.00E-06 2.29E-05 22.86 190.482 799.779 
220 720 1.00E-06 2.44E-05 24.44 155.389 834.872 
240 740 1.00E-06 2.59E-05 25.95 125.593 864.668 
260 760 1.00E-06 2.74E-05 27.37 101.429 888.832 
280 780 1.00E-06 2.87E-05 28.72 85.465 904.796 
300 800 1.00E-06 3.00E-05 30.00 80.380 909.881 
 
 
 
The graphical representation of the titration curve: 
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Ka (M-1): 3.5×105 Statistical error: 18% 
Stoichiometry: 23:1 (ligand : RNA duplex) 
 223
No. 13   
 
DNA: (dAdT)10-(dAdT)10 ligand: DAPI 
C Fl-DNA: 1.0×10-6 M Cligand: 8.0×10-5 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1.00E-06 0.00E+00 0.00 961.732 0.000 
30 530 1.00E-06 4.53E-06 4.53 827.569 134.163 
60 560 1.00E-06 8.57E-06 8.57 765.166 196.566 
90 590 1.00E-06 1.22E-05 12.20 726.731 235.001 
120 620 1.00E-06 1.55E-05 15.48 702.082 259.650 
150 650 1.00E-06 1.85E-05 18.46 683.181 278.551 
180 680 1.00E-06 2.12E-05 21.18 668.295 293.437 
210 710 1.00E-06 2.37E-05 23.66 657.486 304.246 
240 740 1.00E-06 2.59E-05 25.95 647.424 314.308 
270 770 1.00E-06 2.81E-05 28.05 637.434 324.298 
300 800 1.00E-06 3.00E-05 30.00 627.880 333.852 
330 830 1.00E-06 3.18E-05 31.81 619.633 342.099 
360 860 1.00E-06 3.35E-05 33.49 617.277 344.455 
390 890 1.00E-06 3.51E-05 35.06 611.276 350.456 
420 920 1.00E-06 3.65E-05 36.52 606.931 354.801 
450 950 1.00E-06 3.79E-05 37.89 598.620 363.112 
 
 
The graphical representation of the titration curve: 
 
0
100
200
300
400
0 10 20 30 40
eqs. DAPI
Δ I
nt
en
sit
y
 
 
Ka (M-1): 1.3×105 Statistical error: 8% 
Stoichiometry: 6:1 (ligand : DNA duplex) 
 224 
No. 14     
 
DNA: (dGdC)10-(dGdC)10 ligand: DAPI 
C Fl-DNA: 1.0×10-6 M Cligand: 8.0×10-5 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1.00E-06 0.00E+00 0.00 971.995 0.000 
20 520 1.00E-06 3.08E-06 3.08 875.248 96.747 
40 540 1.00E-06 5.93E-06 5.93 759.842 212.153 
60 560 1.00E-06 8.57E-06 8.57 675.297 296.698 
80 580 1.00E-06 1.10E-05 11.03 629.443 342.552 
100 600 1.00E-06 1.33E-05 13.33 602.010 369.985 
120 620 1.00E-06 1.55E-05 15.48 572.139 399.856 
140 640 1.00E-06 1.75E-05 17.50 541.918 430.077 
160 660 1.00E-06 1.94E-05 19.39 515.188 456.807 
180 680 1.00E-06 2.12E-05 21.18 491.459 480.536 
200 700 1.00E-06 2.29E-05 22.86 469.924 502.071 
220 720 1.00E-06 2.44E-05 24.44 452.059 519.936 
240 740 1.00E-06 2.59E-05 25.95 433.206 538.789 
260 760 1.00E-06 2.74E-05 27.37 418.240 553.755 
280 780 1.00E-06 2.87E-05 28.72 404.873 567.122 
300 800 1.00E-06 3.00E-05 30.00 388.897 583.098 
320 820 1.00E-06 3.12E-05 31.22 374.986 597.009 
 
The graphical representation of the titration curve: 
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Ka (M-1): 6.4×104 Statistical error: 10% 
Stoichiometry: 7:1 (ligand : DNA duplex) 
 225
No. 15   
 
DNA: 12bp ligand:Dimer A 
C Fl-DNA: 1.0×10-6 M Cligand: 8.0×10-5 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 600 1.00E-06 0.00E+00 0.00 655.304 0.000 
10 610 1.00E-06 1.31E-06 1.31 606.718 48.586 
20 620 1.00E-06 2.58E-06 2.58 523.006 132.298 
30 630 1.00E-06 3.81E-06 3.81 458.052 197.252 
40 640 1.00E-06 5.00E-06 5.00 394.692 260.612 
50 650 1.00E-06 6.15E-06 6.15 340.985 314.319 
60 660 1.00E-06 7.27E-06 7.27 289.865 365.439 
70 670 1.00E-06 8.36E-06 8.36 252.903 402.401 
80 680 1.00E-06 9.41E-06 9.41 215.504 439.800 
90 690 1.00E-06 1.04E-05 10.43 188.365 466.939 
100 700 1.00E-06 1.14E-05 11.43 171.676 483.628 
120 720 1.00E-06 1.33E-05 13.33 160.222 495.082 
140 740 1.00E-06 1.51E-05 15.14 143.268 512.036 
190 790 1.00E-06 1.92E-05 19.24 136.412 518.892 
290 890 1.00E-06 2.61E-05 26.07 131.366 523.938 
 
 
 
The graphical representation of the titration curve: 
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Ka (M-1): 5.7×106 Statistical error: 31% 
Stoichiometry: 10:1 (ligand : DNA duplex) 
 226 
No. 16   
  
DNA: dG12 - dC12 ligand: Dimer A 
C Fl-DNA: 1.0×10-6 M Cligand: 8.0×10-5 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 600 1.00E-06 0.00E+00 0.00 954.423 0.000 
10 610 1.00E-06 1.31E-06 1.31 776.482 177.941 
20 620 1.00E-06 2.58E-06 2.58 586.611 367.812 
30 630 1.00E-06 3.81E-06 3.81 406.507 547.916 
40 640 1.00E-06 5.00E-06 5.00 256.409 698.014 
50 650 1.00E-06 6.15E-06 6.15 237.001 717.422 
60 660 1.00E-06 7.27E-06 7.27 223.390 731.033 
70 670 1.00E-06 8.36E-06 8.36 207.867 746.556 
80 680 1.00E-06 9.41E-06 9.41 178.098 776.325 
90 690 1.00E-06 1.04E-05 10.43 160.259 794.164 
100 700 1.00E-06 1.14E-05 11.43 170.186 784.237 
110 710 1.00E-06 1.24E-05 12.39 169.011 785.412 
120 720 1.00E-06 1.33E-05 13.33 176.853 777.570 
140 740 1.00E-06 1.51E-05 15.14 182.285 772.138 
 
 
 
The graphical representation of the titration curve: 
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Ka (M-1): 7.3×106 Statistical error: 30% 
Stoichiometry: 5:1 (ligand : DNA duplex) 
 227
No. 17  
  
DNA: dA12 - dT12 ligand: Dimer A 
C Fl-DNA: 1.0×10-6 M Cligand: 8.0×10-5 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1.00E-06 0.00E+00 0.00 974.076 0.000 
10 510 1.00E-06 1.57E-06 1.57 812.433 161.643 
20 520 1.00E-06 3.08E-06 3.08 652.077 321.999 
30 530 1.00E-06 4.53E-06 4.53 492.002 482.074 
40 540 1.00E-06 5.93E-06 5.93 343.562 630.514 
50 550 1.00E-06 7.27E-06 7.27 207.209 766.867 
60 560 1.00E-06 8.57E-06 8.57 88.262 885.815 
70 570 1.00E-06 9.82E-06 9.82 57.280 916.796 
80 580 1.00E-06 1.10E-05 11.03 51.379 922.697 
90 590 1.00E-06 1.22E-05 12.20 51.686 922.391 
100 600 1.00E-06 1.33E-05 13.33 49.591 924.485 
110 610 1.00E-06 1.44E-05 14.43 49.667 924.409 
120 620 1.00E-06 1.55E-05 15.48 51.027 923.049 
 
 
The graphical representation of the titration curve: 
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Ka (M-1): 5.9×107 Statistical error: 32% 
Stoichiometry: 9:1 (ligand : DNA duplex) 
 
 228 
No. 18  
RNA: A12 - U12 ligand:Dimer A 
C Fl-RNA: 1.0×10-6 M Cligand:8.0×10-5 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-RNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-RNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1.00E-06 0.00E+00 0.00 990.392 0.000 
50 550 1.00E-06 7.27E-06 7.27 829.021 161.371 
100 600 1.00E-06 1.33E-05 13.33 673.483 316.909 
150 650 1.00E-06 1.85E-05 18.46 553.519 436.873 
200 700 1.00E-06 2.29E-05 22.86 465.485 524.907 
250 750 1.00E-06 2.67E-05 26.67 367.562 622.830 
300 800 1.00E-06 3.00E-05 30.00 289.238 701.154 
350 850 1.00E-06 3.29E-05 32.94 230.708 759.684 
400 900 1.00E-06 3.56E-05 35.56 177.903 812.489 
450 950 1.00E-06 3.79E-05 37.89 124.019 866.373 
500 1000 1.00E-06 4.00E-05 40.00 85.176 905.216 
550 1050 1.00E-06 4.19E-05 41.90 60.406 929.986 
600 1100 1.00E-06 4.36E-05 43.64 54.223 936.169 
650 1150 1.00E-06 4.52E-05 45.22 49.260 941.132 
700 1200 1.00E-06 4.67E-05 46.67 45.092 945.300 
750 1250 1.00E-06 4.80E-05 48.00 42.585 947.808 
800 1300 1.00E-06 4.92E-05 49.23 41.328 949.064 
850 1350 1.00E-06 5.04E-05 50.37 40.496 949.897 
900 1400 1.00E-06 5.14E-05 51.43 40.133 950.259 
950 1450 1.00E-06 5.24E-05 52.41 40.106 950.286 
1000 1500 1.00E-06 5.33E-05 53.33 39.868 950.524 
 
The graphical representation of the titration curve: 
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Ka (M-1): 1.4×107 Statistical error: 22% 
Stoichiometry: 41:1 (ligand : RNA duplex) 
 229
No. 19   
 
DNA: 12bp ligand: Dimer B 
C Fl-DNA: 1.0×10-6 M Cligand: 8.0×10-5 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1.00E-06 0.00E+00 0.00 993.386 0.000 
30 530 1.00E-06 4.53E-06 4.53 819.469 173.917 
60 560 1.00E-06 8.57E-06 8.57 655.619 337.767 
90 590 1.00E-06 1.22E-05 12.20 525.585 467.801 
120 620 1.00E-06 1.55E-05 15.48 415.356 578.030 
150 650 1.00E-06 1.85E-05 18.46 313.734 679.652 
180 680 1.00E-06 2.12E-05 21.18 261.756 731.630 
210 710 1.00E-06 2.37E-05 23.66 210.000 783.386 
240 740 1.00E-06 2.59E-05 25.95 182.942 810.444 
270 770 1.00E-06 2.81E-05 28.05 156.889 836.497 
 
 
The graphical representation of the titration curve: 
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Ka (M-1): 9.0×105 Statistical error: 31% 
Stoichiometry: 23:1 (ligand : DNA duplex) 
 230 
No. 20 
   
DNA: dG12 - dC12 ligand: Dimer B 
C Fl-DNA: 1.0×10-6 M Cligand: 8.0×10-5 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1.00E-06 0.00E+00 0.00 965.612 0.000 
10 510 1.00E-06 1.57E-06 1.57 874.984 90.628 
20 520 1.00E-06 3.08E-06 3.08 759.987 205.625 
30 530 1.00E-06 4.53E-06 4.53 642.687 322.925 
40 540 1.00E-06 5.93E-06 5.93 532.342 433.270 
50 550 1.00E-06 7.27E-06 7.27 426.087 539.525 
60 560 1.00E-06 8.57E-06 8.57 379.592 586.020 
70 570 1.00E-06 9.82E-06 9.82 324.709 640.903 
80 580 1.00E-06 1.10E-05 11.03 268.498 697.114 
90 590 1.00E-06 1.22E-05 12.20 280.086 685.526 
100 600 1.00E-06 1.33E-05 13.33 258.116 707.496 
110 610 1.00E-06 1.44E-05 14.43 278.379 687.233 
120 620 1.00E-06 1.55E-05 15.48 244.575 721.037 
130 630 1.00E-06 1.65E-05 16.51 279.222 686.390 
140 640 1.00E-06 1.75E-05 17.50 233.615 731.997 
 
 
 
The graphical representation of the titration curve: 
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Ka (M-1): 5.0×105 Statistical error: 39% 
Stoichiometry: 7:1 (ligand : DNA duplex) 
 231
No. 21   
 
DNA: dA12 - dT12 ligand: Dimer B 
C Fl-DNA: 1.0×10-6 M Cligand: 8.0×10-5 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1.00E-06 0.00E+00 0.00 962.251 0.000 
10 510 1.00E-06 1.57E-06 1.57 824.662 137.589 
20 520 1.00E-06 3.08E-06 3.08 694.820 267.431 
30 530 1.00E-06 4.53E-06 4.53 577.412 384.839 
40 540 1.00E-06 5.93E-06 5.93 458.328 503.923 
50 550 1.00E-06 7.27E-06 7.27 346.368 615.883 
60 560 1.00E-06 8.57E-06 8.57 230.712 731.539 
70 570 1.00E-06 9.82E-06 9.82 145.046 817.205 
80 580 1.00E-06 1.10E-05 11.03 84.452 877.799 
90 590 1.00E-06 1.22E-05 12.20 56.905 905.346 
100 600 1.00E-06 1.33E-05 13.33 48.556 913.695 
 
 
The graphical representation of the titration curve: 
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Ka (M-1): 1.4×107 Statistical error: 32% 
Stoichiometry: 11:1 (ligand : DNA duplex) 
 
 232 
No. 22   
RNA: A12 - U12 ligand: Dimer B 
C Fl-RNA: 1.0×10-6 M Cligand: 8.0×10-5 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-RNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-RNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1.00E-06 0.00E+00 0.00 967.153 0.000 
20 520 1.00E-06 3.08E-06 3.08 728.904 238.249 
40 540 1.00E-06 5.93E-06 5.93 524.965 442.188 
60 560 1.00E-06 8.57E-06 8.57 379.322 587.831 
80 580 1.00E-06 1.10E-05 11.03 258.929 708.224 
100 600 1.00E-06 1.33E-05 13.33 164.929 802.224 
120 620 1.00E-06 1.55E-05 15.48 98.002 869.152 
140 640 1.00E-06 1.75E-05 17.50 61.615 905.538 
160 660 1.00E-06 1.94E-05 19.39 51.720 915.433 
180 680 1.00E-06 2.12E-05 21.18 46.840 920.313 
200 700 1.00E-06 2.29E-05 22.86 45.187 921.966 
220 720 1.00E-06 2.44E-05 24.44 44.435 922.718 
240 740 1.00E-06 2.59E-05 25.95 44.369 922.784 
260 760 1.00E-06 2.74E-05 27.37 42.534 924.619 
280 780 1.00E-06 2.87E-05 28.72 42.354 924.799 
300 800 1.00E-06 3.00E-05 30.00 42.265 924.888 
 
The graphical representation of the titration curve: 
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Ka (M-1): 3.2×106 Statistical error: 24% 
Stoichiometry: 13:1 (ligand : RNA duplex) 
 233
No. 23  
 
DNA: 12bp ligand: Monomer A 
C Fl-DNA: 1.0×10-6 M Cligand: 8.0×10-5 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1.00E-06 0.00E+00 0.00 985.099 0.000 
10 510 1.00E-06 1.57E-06 1.57 699.322 285.777 
20 520 1.00E-06 3.08E-06 3.08 479.238 505.861 
30 530 1.00E-06 4.53E-06 4.53 311.182 673.917 
40 540 1.00E-06 5.93E-06 5.93 225.161 759.938 
50 550 1.00E-06 7.27E-06 7.27 187.505 797.594 
60 560 1.00E-06 8.57E-06 8.57 190.787 794.312 
70 570 1.00E-06 9.82E-06 9.82 188.019 797.080 
80 580 1.00E-06 1.10E-05 11.03 182.124 802.975 
90 590 1.00E-06 1.22E-05 12.20 189.448 795.651 
 
 
The graphical representation of the titration curve: 
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Ka (M-1): 6.3×106 Statistical error: 19% 
Stoichiometry: 4:1 (ligand : DNA duplex) 
 
 234 
No. 24   
DNA: dG12 - dC12 ligand: Monomer A 
C Fl-DNA: 1.0×10-6 M Cligand: 8.0×10-5 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1.00E-06 0.00E+00 0.00 925.198 0.000 
20 520 1.00E-06 3.08E-06 3.08 789.670 135.528 
40 540 1.00E-06 5.93E-06 5.93 650.964 274.234 
60 560 1.00E-06 8.57E-06 8.57 515.556 409.642 
80 580 1.00E-06 1.10E-05 11.03 397.976 527.222 
100 600 1.00E-06 1.33E-05 13.33 322.161 603.037 
110 610 1.00E-06 1.44E-05 14.43 285.308 639.890 
120 620 1.00E-06 1.55E-05 15.48 263.301 661.897 
130 630 1.00E-06 1.65E-05 16.51 254.056 671.142 
140 640 1.00E-06 1.75E-05 17.50 247.701 677.497 
150 650 1.00E-06 1.85E-05 18.46 246.782 678.416 
160 660 1.00E-06 1.94E-05 19.39 244.249 680.949 
170 670 1.00E-06 2.03E-05 20.30 242.472 682.726 
180 680 1.00E-06 2.12E-05 21.18 242.098 683.100 
190 690 1.00E-06 2.20E-05 22.03 242.038 683.160 
200 700 1.00E-06 2.29E-05 22.86 240.973 684.225 
210 710 1.00E-06 2.37E-05 23.66 239.670 685.528 
220 720 1.00E-06 2.44E-05 24.44 235.588 689.610 
230 730 1.00E-06 2.52E-05 25.21 235.181 690.017 
240 740 1.00E-06 2.59E-05 25.95 234.229 690.969 
250 750 1.00E-06 2.67E-05 26.67 233.020 692.178 
260 760 1.00E-06 2.74E-05 27.37 232.119 693.079 
The graphical representation of the titration curve: 
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Ka (M-1): 1.0×107 Statistical error: 15% 
Stoichiometry: 14:1 (ligand : DNA duplex) 
 235
No. 25  
DNA: dA12 - dT12 ligand: Monomer A 
C Fl-DNA: 1.0×10-6 M Cligand: 8.0×10-5 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1.00E-06 0.00E+00 0.00 908.497 0.000 
20 520 1.00E-06 3.08E-06 3.08 788.643 119.854 
40 540 1.00E-06 5.93E-06 5.93 663.141 245.356 
60 560 1.00E-06 8.57E-06 8.57 546.477 362.020 
80 580 1.00E-06 1.10E-05 11.03 434.517 473.980 
100 600 1.00E-06 1.33E-05 13.33 336.194 572.303 
120 620 1.00E-06 1.55E-05 15.48 239.764 668.733 
140 640 1.00E-06 1.75E-05 17.50 169.526 738.971 
150 650 1.00E-06 1.85E-05 18.46 138.114 770.383 
160 660 1.00E-06 1.94E-05 19.39 122.026 786.471 
170 670 1.00E-06 2.03E-05 20.30 118.493 790.004 
180 680 1.00E-06 2.12E-05 21.18 113.922 794.575 
190 690 1.00E-06 2.20E-05 22.03 103.352 805.145 
200 700 1.00E-06 2.29E-05 22.86 111.101 797.396 
210 710 1.00E-06 2.37E-05 23.66 107.721 800.776 
220 720 1.00E-06 2.44E-05 24.44 97.238 811.259 
230 730 1.00E-06 2.52E-05 25.21 97.917 810.580 
240 740 1.00E-06 2.59E-05 25.95 99.426 809.071 
250 750 1.00E-06 2.67E-05 26.67 98.254 810.243 
260 760 1.00E-06 2.74E-05 27.37 99.136 809.361 
270 770 1.00E-06 2.81E-05 28.05 99.034 809.463 
280 780 1.00E-06 2.87E-05 28.72 98.384 810.113 
290 790 1.00E-06 2.94E-05 29.37 97.997 810.501 
300 800 1.00E-06 3.00E-05 30.00 97.715 810.782 
310 810 1.00E-06 3.06E-05 30.62 94.295 814.202 
320 820 1.00E-06 3.12E-05 31.22 96.485 812.012 
330 830 1.00E-06 3.18E-05 31.81 96.872 811.625 
340 840 1.00E-06 3.24E-05 32.38 98.323 810.174 
350 850 1.00E-06 3.29E-05 32.94 98.147 810.350 
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Ka (M-1): 1.5×107 
Statistical error: 20% 
Stoichiometry:18:1 (ligand : DNA duplex) 
 236 
No. 26   
 
RNA: A12 - U12 ligand: Monomer A 
C Fl-RNA: 1.0×10-6 M Cligand: 3.0×10-5 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-RNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-RNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1.00E-06 0.00E+00 0.00 990.043 0.000 
20 520 1.00E-06 1.15E-06 1.15 550.600 439.443 
30 530 1.00E-06 1.70E-06 1.70 344.020 646.023 
40 540 1.00E-06 2.22E-06 2.22 168.313 821.730 
50 550 1.00E-06 2.73E-06 2.73 62.711 927.332 
60 560 1.00E-06 3.21E-06 3.21 41.609 948.434 
70 570 1.00E-06 3.68E-06 3.68 38.353 951.690 
80 580 1.00E-06 4.14E-06 4.14 38.028 952.015 
90 590 1.00E-06 4.58E-06 4.58 36.817 953.226 
100 600 1.00E-06 5.00E-06 5.00 36.625 953.418 
110 610 1.00E-06 5.41E-06 5.41 36.042 954.002 
120 620 1.00E-06 5.81E-06 5.81 36.660 953.383 
130 630 1.00E-06 6.19E-06 6.19 37.149 952.894 
 
 
The graphical representation of the titration curve: 
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Ka (M-1): 9.5×107 Statistical error: 10% 
Stoichiometry: 3:1 (ligand : RNA duplex) 
 237
No. 27   
DNA: 12bp ligand: Monomer B 
C Fl-DNA: 1.0×10-6 M Cligand: 2.0×10-4 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1.00E-06 0.00E+00 0.00 973.432 0.000 
50 550 1.00E-06 1.82E-05 18.18 761.589 211.843 
100 600 1.00E-06 3.33E-05 33.33 624.288 349.144 
150 650 1.00E-06 4.62E-05 46.15 515.081 458.351 
200 700 1.00E-06 5.71E-05 57.14 436.762 536.670 
250 750 1.00E-06 6.67E-05 66.67 371.481 601.951 
300 800 1.00E-06 7.50E-05 75.00 312.425 661.007 
350 850 1.00E-06 8.24E-05 82.35 268.365 705.067 
360 860 1.00E-06 8.37E-05 83.72 261.259 712.173 
370 870 1.00E-06 8.51E-05 85.06 261.970 711.462 
380 880 1.00E-06 8.64E-05 86.36 255.968 717.464 
390 890 1.00E-06 8.76E-05 87.64 251.192 722.240 
400 900 1.00E-06 8.89E-05 88.89 245.855 727.577 
410 910 1.00E-06 9.01E-05 90.11 238.934 734.498 
420 920 1.00E-06 9.13E-05 91.30 236.088 737.344 
430 930 1.00E-06 9.25E-05 92.47 236.111 737.321 
440 940 1.00E-06 9.36E-05 93.62 228.254 745.178 
450 950 1.00E-06 9.47E-05 94.74 223.387 750.045 
470 970 1.00E-06 9.69E-05 96.91 216.858 756.574 
480 980 1.00E-06 9.80E-05 97.96 215.503 757.929 
490 990 1.00E-06 9.90E-05 98.99 209.337 764.095 
500 1000 1.00E-06 1.00E-04 100.00 211.468 761.964 
The graphical representation of the titration curve: 
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Ka (M-1): 7.4×104 Statistical error: 24% 
Stoichiometry: 78:1 (ligand : DNA duplex) 
 238 
No. 28   
DNA: dG12 - dC12 ligand: Monomer B 
C Fl-DNA: 1.0×10-6 M Cligand:2.0×10-4 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference
0 500 1.00E-06 0.00E+00 0.00 966.924 0.000 
100 600 1.00E-06 3.33E-05 33.33 595.020 371.904 
150 650 1.00E-06 4.62E-05 46.15 397.774 569.150 
200 700 1.00E-06 5.71E-05 57.14 288.558 678.366 
250 750 1.00E-06 6.67E-05 66.67 227.560 739.364 
300 800 1.00E-06 7.50E-05 75.00 217.558 749.366 
310 810 1.00E-06 7.65E-05 76.54 217.758 749.166 
320 820 1.00E-06 7.80E-05 78.05 215.895 751.029 
330 830 1.00E-06 7.95E-05 79.52 212.124 754.800 
340 840 1.00E-06 8.10E-05 80.95 211.883 755.041 
350 850 1.00E-06 8.24E-05 82.35 210.790 756.134 
360 860 1.00E-06 8.37E-05 83.72 208.105 758.819 
370 870 1.00E-06 8.51E-05 85.06 206.506 760.418 
380 880 1.00E-06 8.64E-05 86.36 205.921 761.003 
390 890 1.00E-06 8.76E-05 87.64 205.884 761.040 
400 900 1.00E-06 8.89E-05 88.89 205.842 761.082 
410 910 1.00E-06 9.01E-05 90.11 207.037 759.887 
420 920 1.00E-06 9.13E-05 91.30 208.410 758.514 
430 930 1.00E-06 9.25E-05 92.47 204.173 762.751 
440 940 1.00E-06 9.36E-05 93.62 209.494 757.430 
450 950 1.00E-06 9.47E-05 94.74 204.110 762.814 
460 960 1.00E-06 9.58E-05 95.83 204.173 762.751 
470 970 1.00E-06 9.69E-05 96.91 196.429 770.495 
480 980 1.00E-06 9.80E-05 97.96 200.558 766.366 
490 990 1.00E-06 9.90E-05 98.99 204.286 762.638 
500 1000 1.00E-06 1.00E-04 100.00 203.544 763.380 
 
 
 
 
 
 
Ka (M-1): 2.3×106 
Statistical error: 35% 
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Stoichiometry: 61:1 (ligand : DNA duplex) 
 239
No. 29  
DNA: dA12 - dT12 ligand: Monomer B 
C Fl-DNA: 1.0×10-6 M Cligand: 2.0×10-4 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1.00E-06 0.00E+00 0.00 995.614 0.000 
50 500 1.00E-06 2.00E-05 20.00 764.818 230.796 
100 600 1.00E-06 3.33E-05 33.33 606.873 388.741 
150 650 1.00E-06 4.62E-05 46.15 453.895 541.719 
200 700 1.00E-06 5.71E-05 57.14 326.412 669.202 
250 750 1.00E-06 6.67E-05 66.67 239.462 756.152 
260 760 1.00E-06 6.84E-05 68.42 228.106 767.508 
270 770 1.00E-06 7.01E-05 70.13 217.244 778.370 
280 780 1.00E-06 7.18E-05 71.79 208.150 787.464 
290 790 1.00E-06 7.34E-05 73.42 199.596 796.018 
300 800 1.00E-06 7.50E-05 75.00 190.042 805.572 
310 810 1.00E-06 7.65E-05 76.54 182.788 812.826 
320 820 1.00E-06 7.80E-05 78.05 171.815 823.799 
330 830 1.00E-06 7.95E-05 79.52 163.862 831.752 
340 840 1.00E-06 8.10E-05 80.95 155.950 839.664 
350 850 1.00E-06 8.24E-05 82.35 148.730 846.884 
360 860 1.00E-06 8.37E-05 83.72 141.277 854.337 
370 870 1.00E-06 8.51E-05 85.06 130.416 865.198 
380 880 1.00E-06 8.64E-05 86.36 123.049 872.565 
390 890 1.00E-06 8.76E-05 87.64 116.545 879.069 
400 900 1.00E-06 8.89E-05 88.89 108.489 887.125 
 
The graphical representation of the titration curve: 
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Ka (M-1): 1.3×104 Statistical error: 28% 
Stoichiometry: 67:1 (ligand : DNA duplex) 
 240 
No. 30 
   
RNA: A12 - U12 ligand: Monomer B 
C Fl-RNA: 1.0×10-6 M Cligand: 2.0×10-4 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-RNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-RNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1.00E-06 0.00E+00 0.00 965.792 0.000 
50 550 1.00E-06 1.82E-05 18.18 777.454 188.338 
100 600 1.00E-06 3.33E-05 33.33 626.285 339.507 
150 650 1.00E-06 4.62E-05 46.15 494.046 471.746 
200 700 1.00E-06 5.71E-05 57.14 376.835 588.957 
250 750 1.00E-06 6.67E-05 66.67 285.638 680.154 
300 800 1.00E-06 7.50E-05 75.00 216.190 749.602 
350 850 1.00E-06 8.24E-05 82.35 159.159 806.633 
400 900 1.00E-06 8.89E-05 88.89 113.996 851.796 
450 950 1.00E-06 9.47E-05 94.74 73.991 891.801 
500 1000 1.00E-06 1.00E-04 100.00 56.335 909.457 
550 1050 1.00E-06 1.05E-04 104.76 45.890 919.902 
600 1100 1.00E-06 1.09E-04 109.09 39.150 926.642 
650 1150 1.00E-06 1.13E-04 113.04 35.356 930.436 
700 1200 1.00E-06 1.17E-04 116.67 35.254 930.538 
950 1450 1.00E-06 1.31E-04 131.03 35.056 930.736 
 
The graphical representation of the titration curve: 
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Ka (M-1): 1.2×106 Statistical error: 25% 
Stoichiometry: 90:1 (ligand : RNA duplex) 
 241
No. 31   
 
DNA: 12bp ligand: Dimer A 
C Fl-DNA: 1.0×10-6 M Cligand: 8.0×10-5 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water:MeOH=1:1. pH=7.10  
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1.00E-06 0.00E+00 0.00 921.506 0.000 
10 510 1.00E-06 1.57E-06 1.57 761.361 160.145 
20 520 1.00E-06 3.08E-06 3.08 598.650 322.856 
30 530 1.00E-06 4.53E-06 4.53 456.943 464.563 
40 540 1.00E-06 5.93E-06 5.93 315.409 606.097 
50 550 1.00E-06 7.27E-06 7.27 185.170 736.336 
60 560 1.00E-06 8.57E-06 8.57 86.044 835.462 
70 570 1.00E-06 9.82E-06 9.82 47.018 874.488 
80 580 1.00E-06 1.10E-05 11.03 39.077 882.429 
180 680 1.00E-06 2.12E-05 21.18 34.492 887.014 
380 880 1.00E-06 3.45E-05 34.55 37.343 884.163 
 
 
 
The graphical representation of the titration curve: 
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Ka (M-1): 3.5×107 Statistical error: 15% 
Stoichiometry: 9:1 (ligand : DNA duplex) 
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No. 32    
 
DNA: dG12 - dC12 ligand: Dimer A 
C Fl-DNA: 1.0×10-6 M Cligand: 8.0×10-5 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water:MeOH=1:1. pH=7.10  
 
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1.00E-06 0.00E+00 0.00 942.958 0.000 
10 510 1.00E-06 1.57E-06 1.57 415.784 527.174 
20 520 1.00E-06 3.08E-06 3.08 184.274 758.684 
30 530 1.00E-06 4.53E-06 4.53 173.644 769.314 
50 550 1.00E-06 7.27E-06 7.27 162.660 780.298 
100 600 1.00E-06 1.33E-05 13.33 147.895 795.063 
150 650 1.00E-06 1.85E-05 18.46 138.573 804.385 
250 750 1.00E-06 2.67E-05 26.67 134.797 808.161 
350 850 1.00E-06 3.29E-05 32.94 133.638 809.320 
 
 
The graphical representation of the titration curve: 
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Ka (M-1): 1.5×107 Statistical error: 17% 
Stoichiometry: 4:1 (ligand : DNA duplex) 
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No. 33   
 
DNA: dA12 - dT12 ligand: Dimer A 
C Fl-DNA: 1.0×10-6 M Cligand: 8.0×10-5 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water:MeOH=1:1. pH=7.10  
 
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1.00E-06 0.00E+00 0.00 642.419 0.000 
10 510 1.00E-06 1.57E-06 1.57 550.903 91.516 
20 520 1.00E-06 3.08E-06 3.08 458.856 183.563 
30 530 1.00E-06 4.53E-06 4.53 372.752 269.667 
40 540 1.00E-06 5.93E-06 5.93 293.381 349.038 
50 550 1.00E-06 7.27E-06 7.27 219.934 422.485 
60 560 1.00E-06 8.57E-06 8.57 156.191 486.228 
70 570 1.00E-06 9.82E-06 9.82 111.028 531.391 
80 580 1.00E-06 1.10E-05 11.03 85.822 556.597 
90 590 1.00E-06 1.22E-05 12.20 74.087 568.332 
100 600 1.00E-06 1.33E-05 13.33 63.872 578.547 
120 620 1.00E-06 1.55E-05 15.48 55.839 586.580 
140 640 1.00E-06 1.75E-05 17.50 50.535 591.885 
200 700 1.00E-06 2.29E-05 22.86 45.975 596.444 
300 800 1.00E-06 3.00E-05 30.00 44.304 598.115 
400 900 1.00E-06 3.56E-05 35.56 41.971 600.448 
 
 
The graphical representation of the titration curve: 
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Ka (M-1): 5.9×106 Statistical error: 4% 
Stoichiometry: 10:1 (ligand : DNA duplex) 
 244 
No. 34   
RNA: A12 - U12 ligand: Dimer A 
C Fl-RNA: 1.0×10-6 M Cligand: 8.0×10-5 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water:MeOH=1:1. pH=7.10  
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-RNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-RNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1.00E-06 0.00E+00 0.00 987.605 0.000 
10 510 1.00E-06 1.57E-06 1.57 640.782 346.823 
20 520 1.00E-06 3.08E-06 3.08 314.397 673.208 
30 530 1.00E-06 4.53E-06 4.53 82.842 904.763 
40 540 1.00E-06 5.93E-06 5.93 52.749 934.856 
50 550 1.00E-06 7.27E-06 7.27 46.569 941.036 
60 560 1.00E-06 8.57E-06 8.57 42.079 945.526 
70 570 1.00E-06 9.82E-06 9.82 39.146 948.460 
80 580 1.00E-06 1.10E-05 11.03 35.697 951.908 
90 590 1.00E-06 1.22E-05 12.20 35.870 951.735 
100 600 1.00E-06 1.33E-05 13.33 35.661 951.945 
110 610 1.00E-06 1.44E-05 14.43 35.186 952.419 
120 620 1.00E-06 1.55E-05 15.48 35.078 952.527 
130 630 1.00E-06 1.65E-05 16.51 35.093 952.512 
140 640 1.00E-06 1.75E-05 17.50 34.923 952.682 
150 650 1.00E-06 1.85E-05 18.46 34.806 952.799 
160 660 1.00E-06 1.94E-05 19.39 34.796 952.809 
260 760 1.00E-06 2.74E-05 27.37 36.069 951.536 
460 960 1.00E-06 3.83E-05 38.33 37.326 950.279 
 
The graphical representation of the titration curve: 
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Ka (M-1): 9.0×107 Statistical error: 44% 
Stoichiometry: 5:1 (ligand : RNA duplex) 
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No. 35   
 
DNA: 12bp ligand:Dimer B 
C Fl-DNA: 1.0×10-6 M Cligand: 8.0×10-5 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water:MeOH=1:1. pH=7.10  
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 700 1.00E-06 0.00E+00 0.00 990.402 0.000 
10 710 1.00E-06 1.13E-06 1.13 884.177 106.225 
20 720 1.00E-06 2.22E-06 2.22 788.420 201.982 
30 730 1.00E-06 3.29E-06 3.29 697.102 293.300 
40 740 1.00E-06 4.32E-06 4.32 599.476 390.926 
50 750 1.00E-06 5.33E-06 5.33 524.655 465.747 
60 760 1.00E-06 6.32E-06 6.32 446.420 543.982 
70 770 1.00E-06 7.27E-06 7.27 379.815 610.587 
80 780 1.00E-06 8.21E-06 8.21 307.211 683.191 
90 790 1.00E-06 9.11E-06 9.11 241.044 749.358 
100 800 1.00E-06 1.00E-05 10.00 181.034 809.368 
110 810 1.00E-06 1.09E-05 10.86 123.950 866.452 
120 820 1.00E-06 1.17E-05 11.71 86.992 903.410 
130 830 1.00E-06 1.25E-05 12.53 76.031 914.371 
140 840 1.00E-06 1.33E-05 13.33 71.863 918.539 
200 900 1.00E-06 1.78E-05 17.78 58.687 931.715 
 
 
The graphical representation of the titration curve: 
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Ka (M-1): 9.1×106 Statistical error: 31% 
Stoichiometry: 11:1 (ligand : DNA duplex) 
 246 
No.36    
 
DNA: dG12 - dC12 ligand:Dimer B 
C Fl-DNA: 1.0×10-6 M Cligand: 8.0×10-5 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water:MeOH=1:1. pH=7.10  
 
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1.00E-06 0.00E+00 0.00 971.136 0.000 
10 510 1.00E-06 1.57E-06 1.57 520.990 450.146 
20 520 1.00E-06 3.08E-06 3.08 320.757 650.379 
30 530 1.00E-06 4.53E-06 4.53 232.646 738.490 
40 540 1.00E-06 5.93E-06 5.93 228.492 742.644 
50 550 1.00E-06 7.27E-06 7.27 228.449 742.687 
100 600 1.00E-06 1.33E-05 13.33 208.234 762.902 
150 650 1.00E-06 1.85E-05 18.46 183.976 787.160 
200 700 1.00E-06 2.29E-05 22.86 182.528 788.608 
250 750 1.00E-06 2.67E-05 26.67 176.003 795.133 
350 850 1.00E-06 3.29E-05 32.94 168.733 802.403 
450 950 1.00E-06 3.79E-05 37.89 92.000 879.136 
 
 
The graphical representation of the titration curve: 
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Ka (M-1): 3.1×106 Statistical error: 9% 
Stoichiometry: 4:1 (ligand : DNA duplex) 
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No. 37   
 
DNA: dA12 - dT12 ligand: Dimer B 
C Fl-DNA: 1.0×10-6 M Cligand: 8.0×10-5 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water:MeOH=1:1. pH=7.10  
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1.00E-06 0.00E+00 0.00 601.653 0.000 
10 510 1.00E-06 1.57E-06 1.57 533.641 68.012 
20 520 1.00E-06 3.08E-06 3.08 468.894 132.759 
30 530 1.00E-06 4.53E-06 4.53 402.270 199.383 
40 540 1.00E-06 5.93E-06 5.93 341.023 260.630 
50 550 1.00E-06 7.27E-06 7.27 279.913 321.740 
60 560 1.00E-06 8.57E-06 8.57 220.484 381.169 
70 570 1.00E-06 9.82E-06 9.82 167.673 433.980 
80 580 1.00E-06 1.10E-05 11.03 120.300 481.353 
90 590 1.00E-06 1.22E-05 12.20 90.251 511.402 
100 600 1.00E-06 1.33E-05 13.33 75.511 526.142 
130 630 1.00E-06 1.65E-05 16.51 61.430 540.223 
170 670 1.00E-06 2.03E-05 20.30 56.605 545.048 
220 720 1.00E-06 2.44E-05 24.44 50.291 551.362 
320 820 1.00E-06 3.12E-05 31.22 48.852 552.801 
420 920 1.00E-06 3.65E-05 36.52 46.946 554.707 
 
 
The graphical representation of the titration curve: 
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Ka (M-1): 1.0×107 Statistical error: 18% 
Stoichiometry: 12:1 (ligand : DNA duplex) 
 248 
No. 38   
 
RNA: A12 - U12 ligand: Dimer B 
C Fl-RNA: 1.0×10-6 M Cligand: 8.0×10-5 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water:MeOH=1:1. pH=7.10  
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-RNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-RNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1.00E-06 0.00E+00 0.00 571.400 0.000 
10 510 1.00E-06 1.57E-06 1.57 435.928 135.472 
20 520 1.00E-06 3.08E-06 3.08 294.467 276.933 
30 530 1.00E-06 4.53E-06 4.53 184.184 387.216 
40 540 1.00E-06 5.93E-06 5.93 78.894 492.506 
50 550 1.00E-06 7.27E-06 7.27 40.107 531.293 
60 560 1.00E-06 8.57E-06 8.57 32.903 538.497 
70 570 1.00E-06 9.82E-06 9.82 29.098 542.302 
80 580 1.00E-06 1.10E-05 11.03 27.076 544.324 
90 590 1.00E-06 1.22E-05 12.20 25.457 545.943 
100 600 1.00E-06 1.33E-05 13.33 24.583 546.817 
110 610 1.00E-06 1.44E-05 14.43 23.277 548.123 
120 620 1.00E-06 1.55E-05 15.48 22.480 548.920 
130 630 1.00E-06 1.65E-05 16.51 21.992 549.408 
140 640 1.00E-06 1.75E-05 17.50 21.092 550.308 
150 650 1.00E-06 1.85E-05 18.46 21.019 550.381 
160 660 1.00E-06 1.94E-05 19.39 20.919 550.481 
260 760 1.00E-06 2.74E-05 27.37 19.462 551.938 
460 960 1.00E-06 3.83E-05 38.33 18.132 553.268 
 
The graphical representation of the titration curve: 
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Ka (M-1): 1.2×107 Statistical error: 11% 
Stoichiometry: 6:1 (ligand : RNA duplex) 
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No. 39 
 
DNA: (dGdC)10-(dGdC)10 ligand: Dimer C 
C Fl-DNA: 1.0×10-6 M Cligand: 1.0×10-3 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
   
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1,00E-06 0,00E+00 0,00 941,984 0,000 
0,5 500,5 1,00E-06 9,99E-07 1,00 909,391 32,593 
1 501 1,00E-06 2,00E-06 2,00 888,886 53,098 
2 502 1,00E-06 3,98E-06 3,98 829,280 112,704 
3 503 1,00E-06 5,96E-06 5,96 773,019 168,965 
5 505 1,00E-06 9,90E-06 9,90 680,197 261,787 
7,5 507,5 1,00E-06 1,48E-05 14,78 569,613 372,371 
10 510 1,00E-06 1,96E-05 19,61 469,962 472,022 
12,5 512,5 1,00E-06 2,44E-05 24,39 402,901 539,083 
15 515 1,00E-06 2,91E-05 29,13 350,799 591,185 
17,5 517,5 1,00E-06 3,38E-05 33,82 321,183 620,801 
20 520 1,00E-06 3,85E-05 38,46 303,755 638,229 
22,5 522,5 1,00E-06 4,31E-05 43,06 292,366 649,618 
25 525 1,00E-06 4,76E-05 47,62 284,672 657,312 
27,5 527,5 1,00E-06 5,21E-05 52,13 280,287 661,697 
30 530 1,00E-06 5,66E-05 56,60 275,396 666,588 
 
 
The graphical representation of the titration curve: 
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Ka (M-1): 6.4×105 Statistical error: 7% 
Stoichiometry: 24:1 (ligand : DNA duplex) 
 250 
No. 40   
 
DNA: (dAdT)10-(dAdT)10 ligand: Dimer C 
C Fl-DNA: 1.0×10-6 M Cligand: 1.0×10-3 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1,00E-06 0,00E+00 0,00 958,483 0,000 
0,5 500,5 1,00E-06 9,99E-07 1,00 895,226 63,257 
1 501 1,00E-06 2,00E-06 2,00 846,628 111,855 
2 502 1,00E-06 3,98E-06 3,98 759,608 198,875 
3 503 1,00E-06 5,96E-06 5,96 662,939 295,544 
4 504 1,00E-06 7,94E-06 7,94 569,301 389,182 
5 505 1,00E-06 9,90E-06 9,90 474,045 484,438 
6 506 1,00E-06 1,19E-05 11,86 392,419 566,064 
7 507 1,00E-06 1,38E-05 13,81 305,811 652,672 
8 508 1,00E-06 1,57E-05 15,75 260,859 697,624 
9 509 1,00E-06 1,77E-05 17,68 253,294 705,189 
10 510 1,00E-06 1,96E-05 19,61 251,317 707,166 
11 511 1,00E-06 2,15E-05 21,53 247,511 710,972 
12 512 1,00E-06 2,34E-05 23,44 245,246 713,237 
 
 
The graphical representation of the titration curve: 
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Ka (M-1): 1.2×107 Statistical error: 38% 
Stoichiometry: 14:1 (ligand : DNA duplex) 
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No. 41   
DNA: dG20 – dC20 ligand: Dimer C 
C Fl-DNA: 1.0×10-6 M Cligand: 1.0×10-3 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1,00E-06 0,00E+00 0,00 915,958 0,000 
2 502 1,00E-06 3,98E-06 3,98 727,691 188,267 
4 504 1,00E-06 7,94E-06 7,94 551,551 364,407 
6 506 1,00E-06 1,19E-05 11,86 391,042 524,916 
8 508 1,00E-06 1,57E-05 15,75 275,093 640,865 
9 509 1,00E-06 1,77E-05 17,68 259,845 656,113 
10 510 1,00E-06 1,96E-05 19,61 254,962 660,996 
11 511 1,00E-06 2,15E-05 21,53 259,774 656,184 
12 512 1,00E-06 2,34E-05 23,44 258,026 657,932 
13 513 1,00E-06 2,53E-05 25,34 255,832 660,126 
14 514 1,00E-06 2,72E-05 27,24 256,478 659,480 
15 515 1,00E-06 2,91E-05 29,13 258,763 657,195 
16 516 1,00E-06 3,10E-05 31,01 259,201 656,757 
17 517 1,00E-06 3,29E-05 32,88 254,710 661,248 
18 518 1,00E-06 3,47E-05 34,75 256,168 659,790 
19 519 1,00E-06 3,66E-05 36,61 257,085 658,873 
20 520 1,00E-06 3,85E-05 38,46 256,151 659,807 
21 521 1,00E-06 4,03E-05 40,31 254,894 661,064 
22 522 1,00E-06 4,21E-05 42,15 256,690 659,268 
23 523 1,00E-06 4,40E-05 43,98 258,456 657,502 
24 524 1,00E-06 4,58E-05 45,80 254,213 661,745 
25 525 1,00E-06 4,76E-05 47,62 255,758 660,200 
26 526 1,00E-06 4,94E-05 49,43 257,028 658,930 
 
The graphical representation of the titration curve: 
 
 
 
 
 
Ka (M-1): 3.7×107 
Statistical error: 36% 
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Stoichiometry: 15:1 (ligand : DNA duplex) 
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No. 42  
 
DNA: dA20 – dT20 ligand: Dimer C 
C Fl-DNA: 1.0×10-6 M Cligand: 1.0×10-3 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1,00E-06 0,00E+00 0,00 930,973 0,000 
0,5 500,5 1,00E-06 9,99E-07 1,00 841,182 89,791 
1 501 1,00E-06 2,00E-06 2,00 782,963 148,010 
2 502 1,00E-06 3,98E-06 3,98 697,248 233,725 
3 503 1,00E-06 5,96E-06 5,96 619,976 310,997 
4 504 1,00E-06 7,94E-06 7,94 549,519 381,454 
5 505 1,00E-06 9,90E-06 9,90 483,944 447,029 
6 506 1,00E-06 1,19E-05 11,86 420,489 510,484 
7 507 1,00E-06 1,38E-05 13,81 362,890 568,083 
8 508 1,00E-06 1,57E-05 15,75 317,535 613,438 
9 509 1,00E-06 1,77E-05 17,68 311,759 619,214 
10 510 1,00E-06 1,96E-05 19,61 308,075 622,898 
11 511 1,00E-06 2,15E-05 21,53 306,880 624,093 
12 512 1,00E-06 2,34E-05 23,44 305,993 624,980 
 
 
 
The graphical representation of the titration curve: 
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Ka (M-1): 4.8×105 Statistical error: 30% 
Stoichiometry: 10:1 (ligand : DNA duplex) 
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No. 43    
  
DNA: dG20 – dC20 ligand: Dimer A 
C Fl-DNA: 1.0×10-6 M Cligand: 1.0×10-3 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1,00E-06 0,00E+00 0,00 922,915 0,000 
1 501 1,00E-06 2,00E-06 2,00 850,863 72,052 
2 502 1,00E-06 3,98E-06 3,98 782,334 140,581 
3 503 1,00E-06 5,96E-06 5,96 698,580 224,335 
4 504 1,00E-06 7,94E-06 7,94 624,102 298,813 
5 505 1,00E-06 9,90E-06 9,90 547,250 375,665 
6 506 1,00E-06 1,19E-05 11,86 473,250 449,665 
7 507 1,00E-06 1,38E-05 13,81 410,381 512,534 
8 508 1,00E-06 1,57E-05 15,75 344,697 578,218 
9 509 1,00E-06 1,77E-05 17,68 275,626 647,289 
10 510 1,00E-06 1,96E-05 19,61 209,654 713,261 
11 511 1,00E-06 2,15E-05 21,53 144,537 778,378 
12 512 1,00E-06 2,34E-05 23,44 86,501 836,414 
13 513 1,00E-06 2,53E-05 25,34 33,939 888,977 
14 514 1,00E-06 2,72E-05 27,24 5,760 917,155 
15 515 1,00E-06 2,91E-05 29,13 -24,320 947,235 
16 516 1,00E-06 3,10E-05 31,01 -36,809 959,724 
17 517 1,00E-06 3,29E-05 32,88 -41,192 964,107 
 
The graphical representation of the titration curve: 
 
0
200
400
600
800
1000
0 5 10 15 20 25 30 35
eqs. Dimer A
Δ I
nt
en
si
ty
 
 
Ka (M-1): 1.5×106 Statistical error: 29% 
Stoichiometry: 28:1 (ligand : DNA duplex) 
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No. 44   
 
DNA: dA20 – dT20 ligand: Dimer A 
C Fl-DNA: 1.0×10-6 M Cligand: 1.0×10-3 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1,00E-06 0,00E+00 0,00 942,711 0,000 
3 503 1,00E-06 5,96E-06 5,96 810,444 132,267 
6 506 1,00E-06 1,19E-05 11,86 686,535 256,176 
9 509 1,00E-06 1,77E-05 17,68 566,693 376,018 
12 512 1,00E-06 2,34E-05 23,44 478,960 463,751 
15 515 1,00E-06 2,91E-05 29,13 411,811 530,900 
18 518 1,00E-06 3,47E-05 34,75 359,993 582,718 
21 521 1,00E-06 4,03E-05 40,31 350,031 592,680 
22 522 1,00E-06 4,21E-05 42,15 344,547 598,164 
23 523 1,00E-06 4,40E-05 43,98 339,170 603,541 
24 524 1,00E-06 4,58E-05 45,80 338,140 604,571 
 
 
The graphical representation of the titration curve: 
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Ka (M-1): 1.1×106 Statistical error: 27% 
Stoichiometry: 29:1 (ligand : DNA duplex) 
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No. 45   
 
DNA: (dGdC)10-(dGdC)10 ligand: Dimer C 
C Fl-DNA: 1.0×10-6 M Cligand: 1.0×10-3 M 
Buffer: 20 mM sodium phosphate in water. pH=7.0  
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1,00E-06 0,00E+00 0,00 939,491 0,000 
5 505 1,00E-06 9,90E-06 9,90 853,061 86,430 
10 510 1,00E-06 1,96E-05 19,61 762,060 177,431 
15 515 1,00E-06 2,91E-05 29,13 669,814 269,677 
20 520 1,00E-06 3,85E-05 38,46 583,142 356,349 
25 525 1,00E-06 4,76E-05 47,62 521,369 418,122 
30 530 1,00E-06 5,66E-05 56,60 482,640 456,851 
35 535 1,00E-06 6,54E-05 65,42 459,709 479,782 
40 540 1,00E-06 7,41E-05 74,07 452,516 486,975 
42,5 542,5 1,00E-06 7,83E-05 78,34 448,074 491,417 
45 545 1,00E-06 8,26E-05 82,57 444,155 495,336 
47,5 547,5 1,00E-06 8,68E-05 86,76 439,513 499,978 
50 550 1,00E-06 9,09E-05 90,91 436,254 503,237 
52,5 552,5 1,00E-06 9,50E-05 95,02 434,729 504,762 
55 555 1,00E-06 9,91E-05 99,10 431,043 508,448 
57,5 557,5 1,00E-06 1,03E-04 103,14 430,981 508,510 
60 560 1,00E-06 1,07E-04 107,14 426,651 512,840 
 
 
The graphical representation of the titration curve: 
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Ka (M-1): 1.0×106 Statistical error: 21% 
Stoichiometry: 55:1 (ligand : DNA duplex) 
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No. 46  
 
DNA: (dAdT)10-(dAdT)10 ligand:Dimer C 
C Fl-DNA: 1.0×10-6 M Cligand:1.0×10-3 M 
Buffer: 20 mM sodium phosphate in water. pH=7.0 
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1,00E-06 0,00E+00 0,00 950,256 0,000 
2,5 502,5 1,00E-06 4,98E-06 4,98 863,299 86,957 
5 505 1,00E-06 9,90E-06 9,90 780,418 169,838 
7,5 507,5 1,00E-06 1,48E-05 14,78 700,261 249,995 
10 510 1,00E-06 1,96E-05 19,61 617,382 332,874 
12,5 512,5 1,00E-06 2,44E-05 24,39 530,579 419,677 
15 515 1,00E-06 2,91E-05 29,13 446,275 503,981 
17,5 517,5 1,00E-06 3,38E-05 33,82 364,694 585,562 
20 520 1,00E-06 3,85E-05 38,46 300,578 649,678 
22,5 522,5 1,00E-06 4,31E-05 43,06 279,761 670,495 
25 525 1,00E-06 4,76E-05 47,62 273,907 676,349 
27,5 527,5 1,00E-06 5,21E-05 52,13 271,502 678,754 
30 530 1,00E-06 5,66E-05 56,60 270,629 679,627 
32,5 532,5 1,00E-06 6,10E-05 61,03 270,577 679,679 
 
 
The graphical representation of the titration curve: 
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Ka (M-1): 2.3×107 Statistical error: 36% 
Stoichiometry: 39:1 (ligand : DNA duplex) 
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No. 47  
DNA: dG20 – dC20 ligand: Dimer C 
C Fl-DNA: 1.0×10-6 M Cligand: 1.0×10-3 M 
Buffer: 20 mM sodium phosphate in water. pH=7.0 
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1,00E-06 0,00E+00 0,00 899,617 0,000 
3 503 1,00E-06 5,96E-06 5,96 802,254 97,363 
6 506 1,00E-06 1,19E-05 11,86 705,420 194,197 
9 509 1,00E-06 1,77E-05 17,68 606,690 292,927 
12 512 1,00E-06 2,34E-05 23,44 507,604 392,013 
15 515 1,00E-06 2,91E-05 29,13 411,284 488,333 
18 518 1,00E-06 3,47E-05 34,75 329,164 570,453 
21 521 1,00E-06 4,03E-05 40,31 309,410 590,207 
21,5 521,5 1,00E-06 4,12E-05 41,23 306,236 593,381 
22 522 1,00E-06 4,21E-05 42,15 305,409 594,208 
22,5 522,5 1,00E-06 4,31E-05 43,06 303,777 595,840 
23 523 1,00E-06 4,40E-05 43,98 301,990 597,627 
23,5 523,5 1,00E-06 4,49E-05 44,89 301,788 597,829 
24 524 1,00E-06 4,58E-05 45,80 301,195 598,422 
24,5 524,5 1,00E-06 4,67E-05 46,71 301,013 598,604 
25 525 1,00E-06 4,76E-05 47,62 300,996 598,621 
25,5 525,5 1,00E-06 4,85E-05 48,53 299,015 600,602 
26 526 1,00E-06 4,94E-05 49,43 298,165 601,452 
26.5 527 1,00E-06 5,03E-05 50,33 297,889 601,728 
27 527 1,00E-06 5,12E-05 51,23 297,025 602,592 
 
The graphical representation of the titration curve: 
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Ka (M-1): 1.8×107 Statistical error: 29% 
Stoichiometry: 36:1 (ligand : DNA duplex) 
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No. 48   
 
DNA: dA20 – dT20 ligand: Dimer C 
C Fl-DNA: 1.0×10-6 M Cligand: 1.0×10-3 M 
Buffer: 20 mM sodium phosphate in water. pH=7.0 
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1,00E-06 0,00E+00 0,00 956,611 0,000 
5 505 1,00E-06 9,90E-06 9,90 775,239 181,372 
10 510 1,00E-06 1,96E-05 19,61 642,802 313,809 
12,5 512,5 1,00E-06 2,44E-05 24,39 568,077 388,534 
15 515 1,00E-06 2,91E-05 29,13 503,647 452,964 
17,5 517,5 1,00E-06 3,38E-05 33,82 456,350 500,261 
20 520 1,00E-06 3,85E-05 38,46 426,613 529,998 
22,5 522,5 1,00E-06 4,31E-05 43,06 416,946 539,665 
25 525 1,00E-06 4,76E-05 47,62 416,411 540,200 
27,5 527,5 1,00E-06 5,21E-05 52,13 415,822 540,789 
30 530 1,00E-06 5,66E-05 56,60 415,066 541,545 
32,5 532,5 1,00E-06 6,10E-05 61,03 414,826 541,785 
35 535 1,00E-06 6,54E-05 65,42 413,456 543,155 
37,5 537,5 1,00E-06 6,98E-05 69,77 413,023 543,588 
40 540 1,00E-06 7,41E-05 74,07 412,889 543,722 
 
 
The graphical representation of the titration curve: 
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Ka (M-1): 2.3×106 Statistical error: 24% 
Stoichiometry: 33:1 (ligand : DNA duplex) 
 259
No. 49     
 
DNA: (dGdC)10-(dGdC)10 ligand: Bridge C 
C Fl-DNA: 1.0×10-6 M Cligand: 1.0×10-3 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1,00E-06 0,00E+00 0,00 977,227 0,000 
4 504 1,00E-06 3,97E-05 39,68 823,880 153,347 
8 508 1,00E-06 7,87E-05 78,74 696,288 280,939 
12 512 1,00E-06 1,17E-04 117,19 567,138 410,089 
16 516 1,00E-06 1,55E-04 155,04 443,959 533,268 
20 520 1,00E-06 1,92E-04 192,31 319,858 657,369 
24 524 1,00E-06 2,29E-04 229,01 253,281 723,946 
28 528 1,00E-06 2,65E-04 265,15 231,255 745,972 
32 532 1,00E-06 3,01E-04 300,75 219,604 757,623 
36 536 1,00E-06 3,36E-04 335,82 211,642 765,585 
40 540 1,00E-06 3,70E-04 370,37 207,310 769,917 
44 544 1,00E-06 4,04E-04 404,41 204,162 773,065 
48 548 1,00E-06 4,38E-04 437,96 200,964 776,263 
52 552 1,00E-06 4,71E-04 471,01 199,607 777,620 
56 556 1,00E-06 5,04E-04 503,60 198,205 779,022 
60 560 1,00E-06 5,36E-04 535,71 197,545 779,682 
 
 
The graphical representation of the titration curve: 
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Ka (M-1): 1.1×105 Statistical error: 23% 
Stoichiometry: 192:1 (ligand : DNA duplex) 
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No. 50  
DNA: (dAdT)10-(dAdT)10 ligand: Bridge C 
C Fl-DNA: 1.0×10-6 M Cligand:1.0×10-3 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1,00E-06 0,00E+00 0,00 974,078 0,000 
2 502 1,00E-06 1,99E-05 19,92 848,392 125,686 
4 504 1,00E-06 3,97E-05 39,68 758,247 215,831 
6 506 1,00E-06 5,93E-05 59,29 681,675 292,403 
8 508 1,00E-06 7,87E-05 78,74 608,944 365,134 
10 510 1,00E-06 9,80E-05 98,04 543,547 430,531 
12 512 1,00E-06 1,17E-04 117,19 483,850 490,228 
14 514 1,00E-06 1,36E-04 136,19 428,770 545,308 
16 516 1,00E-06 1,55E-04 155,04 381,154 592,924 
18 518 1,00E-06 1,74E-04 173,75 338,076 636,002 
20 520 1,00E-06 1,92E-04 192,31 300,678 673,400 
22 522 1,00E-06 2,11E-04 210,73 269,031 705,047 
24 524 1,00E-06 2,29E-04 229,01 244,634 729,444 
26 526 1,00E-06 2,47E-04 247,15 229,413 744,665 
28 528 1,00E-06 2,65E-04 265,15 219,604 754,474 
30 530 1,00E-06 2,83E-04 283,02 212,639 761,439 
32 532 1,00E-06 3,01E-04 300,75 207,230 766,848 
34 534 1,00E-06 3,18E-04 318,35 203,408 770,670 
36 536 1,00E-06 3,36E-04 335,82 199,628 774,450 
38 538 1,00E-06 3,53E-04 353,16 197,564 776,514 
40 540 1,00E-06 3,70E-04 370,37 195,611 778,467 
 
The graphical representation of the titration curve: 
0
200
400
600
800
0 100 200 300 400
eqs. Bridge C
Δ I
nt
en
si
ty
 
Ka (M-1): 3.3×104 Statistical error: 10% 
Stoichiometry: 136:1 (ligand : DNA duplex) 
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No. 51   
DNA: dA20 – dT20 ligand: Bridge C 
C Fl-DNA: 1.0×10-6 M Cligand: 1.0×10-3 M 
Buffer: 2 mM HEPES and 150 mM NaCl in water. pH=7.10  
 
Addition 
ligand 
(μL) 
Total 
volume 
(μL) 
CFl-DNA 
(mol/L) 
C ligand 
(mol/L) 
ratio 
(Cligand/CFl-DNA)
fluorescence 
emission 
relative 
emission 
difference 
0 500 1,00E-06 0,00E+00 0,00 979,989 0,000 
1 501 1,00E-06 9,98E-06 9,98 862,642 117,347 
2 502 1,00E-06 1,99E-05 19,92 765,093 214,896 
3 503 1,00E-06 2,98E-05 29,82 687,395 292,594 
4 504 1,00E-06 3,97E-05 39,68 626,406 353,583 
5 505 1,00E-06 4,95E-05 49,50 565,118 414,871 
6 506 1,00E-06 5,93E-05 59,29 516,967 463,022 
7 507 1,00E-06 6,90E-05 69,03 468,876 511,113 
8 508 1,00E-06 7,87E-05 78,74 421,313 558,676 
9 509 1,00E-06 8,84E-05 88,41 383,594 596,395 
10 510 1,00E-06 9,80E-05 98,04 348,515 631,474 
11 511 1,00E-06 1,08E-04 107,63 315,701 664,288 
12 512 1,00E-06 1,17E-04 117,19 289,539 690,450 
13 513 1,00E-06 1,27E-04 126,71 268,614 711,375 
14 514 1,00E-06 1,36E-04 136,19 255,163 724,826 
15 515 1,00E-06 1,46E-04 145,63 245,978 734,011 
16 516 1,00E-06 1,55E-04 155,04 238,075 741,914 
17 517 1,00E-06 1,64E-04 164,41 232,880 747,109 
18 518 1,00E-06 1,74E-04 173,75 226,340 753,649 
19 519 1,00E-06 1,83E-04 183,04 218,450 761,539 
20 520 1,00E-06 1,92E-04 192,31 215,257 764,732 
 
The graphical representation of the titration curve: 
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Ka (M-1): 3.8×104 Statistical error: 7% 
Stoichiometry: 60:1 (ligand : DNA duplex) 
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Abbreviations 
 
 
A adenine 
Å Ångstrom 
abs. absolute 
Arg arginine 
Bn benzyl 
Boc tert-butyloxycarbonyl 
Boc2O di-tert-butyldicarbonate 
C cytosine 
CD circular dichroism 
DAPI 4',6-diamidino-2-phenylindole 
DCC N,N'-dicyclohexylcarbodiimide 
DCM dichloromethane 
DIEA N,N-diisopropylethylamine 
DMAP 4-(N,N-dimethylamino)pyridine 
DMF N,N-dimethylformamide 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
EDC 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride 
eq. equivalent 
ESI electrospray ionization 
Et3N triethylamine 
EtBr ethidium bromide 
G guanine 
HATU 2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate 
HBTU O-benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate 
  
 263
HCTU 2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium 
hexafluorophosphate 
Hepes  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
His histidine 
HOBt hydroxybenzotriazole 
Hz Hertz 
ICD induced circular dichroism 
ITC isothermal titration calorimetry 
M moles per liter 
mM millimoles per liter 
µM micromoles per liter 
Me methyl 
neg. negative 
nm nanometer 
NMR nuclear magnetic resonance 
PNA peptide nucleic acid 
pos. positive 
ppm parts per million 
Rf retention value 
RNA ribonucleic acid 
r.t. room temperature 
T thymine 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
U uracil 
UV ultraviolet 
Vis  visible 
Z benzyloxycarbonyl 
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